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Cancer is a leading cause of death, being responsible for over 9.6 million deaths worldwide in 
2018. Photodynamic therapy (PDT) is an alternative cancer treatment with FDA approval. It is 
based on the use of photosensitisers (PS) such as protoporphyrin IX (PpIX), which are activated 
through light and produce singlet oxygen when irradiated, leading to tumour ablation. Highly 
controlled light dosimetry and rapid drug uptake maximizes the PDT effect while protecting 
surrounding tissue from damage. However, it is limited by inefficient drug accumulation in 
target tissue, light scattering, variable oxygen gradients, and high toxicity. Carbon dots (CDs) 
are carbon-based fluorescent nanoparticles that have gained attention due to their interesting 
photophysical properties, low toxicity, tuneable surface functionality and adaptable synthesis 
making them ideal candidates for drug delivery, bioimaging, and theragnostics applications. 
CDs have been previously used for PDT as PS carriers and have shown great success in 
improving treatment efficiency. However, to date, no comparison between conjugates with 
different drug loading strategies has been made to determine the best-performing methodology. 
This research aimed to produce PpIX-loaded conjugates capable of an enhanced PDT effect. 
Conjugates should be water-dispersible and produce singlet oxygen, demonstrating enhanced 
photoluminescence, fast intracellular uptake, low dark toxicity, and high light toxicity. In this 
work, carbon dot (CD) and protoporphyrin IX (PpIX) conjugates were fabricated using 
microwave-assisted pyrolysis. PpIX loading was carried out using the one-pot reaction method 
of host-guest encapsulation (PpIX@CD) and previously established amide crosslinking 
(soluble fraction PpIX-CD and insoluble fraction (PpIX-CD)p). Characterization showed 
conjugates have a loading efficiency of 34–48%, with similar singlet oxygen production and 
surface chemistry to PpIX. PpIX-containing CDs showed a 2.2 to 3.7-fold decrease in dark 
toxicity. PpIX-CD and PpIX@CD showed equivalent light-induced toxicity to PpIX in C8161 
human melanoma cell monolayers at concentrations >1 μg/ml, leading to a 3.2 to 4.1-fold 
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increase in photo-toxicity index (PI). The less soluble fraction of cross-linked conjugates 
(PpIX-CD)p did not show significant difference from PpIX. Confocal light scanning 
microscopy demonstrated rapid intracellular uptake and accumulation of conjugates. In vitro 
PDT evaluation of conjugates was continued using multicellular cancer spheroids (MCTS). 
Spheroids showed increased resistance to conjugate toxicity and PDT effect. Light doses were 
adjusted to 2.5 – 10 J/cm2, which caused significant cell death without photobleaching the 
samples. Parameter screening confirmed light doses >5 J/cm2 and concentrations >5 μg/mL 
were the most effective, greatly decreasing in cell viability and total dsDNA content. Light 
fractionation, also known as sequential light exposure, was shown to greatly increase cell 
membrane damage and slightly lower dsDNA content in comparison to single light treatments. 
Light sheet fluorescence microscopy (LSFM) was used to observe PDT-induced 
morphological changes to spheroids, showing ablation and significant damage throughout their 
structures. Finally, computer-assisted analysis (AnaSP) was used to extract morphometric data 
from spheroid images taken with widefield microscopy. Morphological parameters were then 
used to reduce variability between spheroids by monitoring sphericity and area during their 
growth. Spheroids subjected to various PDT combinations showed parameters like convexity, 
solidity, and sphericity had low usefulness for differentiating sample viability. Conversely, 
area and volume showed better results, being able to predict spheroid PDT response in various 
conditions. In summary, this work showed the importance of selecting loading strategies for 
drug delivery applications. CDs were shown to be highly useful and effective carriers for PpIX, 
demonstrating an enhanced PDT effect through advantageous intracellular localization and 
decreased cytotoxicity. Furthermore, the use of cancer spheroids and morphometric parameter 
acquisition demonstrated how multiple treatment parameters can be simultaneously screened 




Aguilar Cosme, JR., Bryant, HE., and Claeyssens, F. Carbon dot-protoporphyrin IX 
conjugates for improved drug delivery and bioimaging. PLoS ONE 14,7 (2019)  
Liu, G., Zhao, P., Liu, N., Yoshino, F., Qin, H., Zou, Y., Shi, S., Amano, T., Aguilar Cosme, 
JR., Nagano, Y., Tamiaki, H., and Komatsu, N. Photosensitizer and anticancer drug-loaded 
















4-morpholinoethanesulfonic acid (MES) 
4′,6-diamidino-2-phenylindole (DAPI) 
5-aminolevulenic acid (5-ALA) 
Adsorption, distribution, metabolism, and 
excretion (ADME) 
Amide crosslinked CDs (low solubility) 
((PpIX-CD)p) 
Amide crosslinked CDs (PpIX-CD) 
amine functionalized silica nanoparticles 
(ASNPs) 
ANAlyse SPheroids (AnaSP) 
Antimicrobial photodynamic therapy (A-PDT)  
Antimicrobial photothermal therapy (A-PTT) 
Arbitrary unit (A.U.) 
Arginyl-Glycyl-Aspartic acid (RGD) 
Aspirin-coated CDs (FACDs) 
Atom transfer radical polymerization (ATRP) 
B-cell lymphoma 2 (Bcl-2) 
Biotin-decorated CD (B-CD) 
Blood-brain barrier (BBB) 
Body weight (BW) 
Carbon dots (CDs) 
Carbon nanotubes (CNTs) 
Carbon nitride (C3N4) 
CD-based nanosphere (CDNS) 
Chick chorioallantoic membrane (CAM) 
Chlorin e6 (Ce6) 
Cisplatin (IV) (PtIV) 
Citric acid (CA) 
Citric acid-based CDs (CA-EDA) 
Cancer stem-like cell (CSC) 
Cancer tissue-originated organoids (CTOS) 
Computed tomography (CT) 
Computed tomography (CT) 
Confocal laser scanning microscopy (CLSM) 
Copper (CuII) 
Cresyl violet (CV) 
Degrees Celsius (°C) 
Dicyclohexylcarbodiimide (DCC) 
Differential interference contrast (DIC) 
Diketopyrrolopyrrole (DPP) 
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Dimethylmaleic acid (DMMA) 
Doxorubicin (DOX) 
dsDNA (dual-stranded DNA) 
Dulbecco’s Modified Eagle’s Medium 
(DMEM) 
Eicosapentaenoic acid (EPA) 
Enhanced permeability and retention (EPR) 
Ethylenediamine (EDA) 
Excitation wavelength (λex) 
Foetal bovine serum (FBS) 
Fibroblast growth factor (FGF) 
Fluence (J/cm2) 
Fluorescence resonance energy transfer 
(FRET) 
Fluorine-doped CDs (F-CDs) 
Folic acid (FA) 
Fourier-transform infrared spectroscopy 
(FTIR) 
Graphene quantum dots (GQDs) 
High-throughput screening (HTS) 
Hollow CDs (HCDs) 
Host-guest embedded CDs (PpIX@CD) 
Hours post-fertilisation (hpf) 
Human hepatocellular carcinoma cell line 
(HUH7) 
Human melanoma cell line (C8161) 
Human osteosarcoma cell line (U2OS) 
Human ovarian adenocarcinoma cell line (NCI-
ADR-RES) 
hyaluronate (HA) 
Hydroxylphenyl triphenylporphyrin (TPP) 
Hyperbranched poly(amido amine) (HPAP) 
Irradiance or power output (W/cm2) 
Joule (J) 
Lactate dehydrogenase (LDH) 
Lanthanides (Ln) 
Lauryl betaine (BS-12) 
Length of Major Diameter Through Centroid 
(LMajorDTC) 
Length of Minimum Diameter Through 
Centroid (LMinDTC) 
Lethal concentrations (LC50) 
Light microscopy (LM) 
Light sheet fluorescence microscopy (LSFM) 
Light treatment (LT) 
m‐phenylenediamine (mPD) 
Magnetic iron (III) oxide (Fe3O4) 
Magnetic resonance imaging (MRI) 
Manganese (II) phthalocyanine (Mn-Pc) 
Mass spectrometry (MS) 
Mesenchymal stem cells (MSCs) 









Mitogen-activated protein kinases (MAPK) 
Molecular weight cut-off MWCO 
Monomethoxypolyethylene glycol (mPEG) 




Nanoscale MOFs (NMOFs) 
Near-infrared (NIR) 
Neodymium (Nd+3) 
Nile blue (NB) 
Nitric oxide (NO) 
Nitrogen-doped CDs (N-CDs) 
Nuclear factor kappa-light-chain-enhancer of 
activated B cells (NF-κB) 
o‐phenylenediamine (oPD) 
Oxaliplatin (IV) (Oxa(IV)) 
P‐phenylenediamine (pPD) 
Phenalenone (PH) 
Phosphate buffered saline (PBS) 
Photo-toxicity index (PI) 
Photodynamic diagnosis (PDD) 
Photodynamic therapy (PDT) 
Photoluminescence (PL) 
Photon upconversion (UC) 
Photosensitisers (PS) 
Photosensitizer fluorescence detection (PFD) 
Photosensitizers (PS) 
Photothermal therapy (PTT) 
PicoGreen (PG) 
Plasmid SOX9 (pSOX9) 
Poly(allyamine) (PAH) 
Poly(ethylene) glycol (PEG) 
Polycyclic aromatic hydrocarbons (PAH) 
Polyethylene glycol diacrylate (PEGDA) 
Polyethyleneimine (PEI) 
Polyethyleneimine average molecular weight 
25 kDa (PEI25k) 
Positron emission tomography (PET) 
Protoporphyrin IX (PpIX) 
Prussian blue (PB) 
Reactive oxygen species (ROS) 
Reconstruction and Visualization from a Single 
Projection (ReViSP) 
Resazurin reduction (RR) 
Rotations per minute (rpm) 
Scanning electron microscopy (SEM) 
Standard error of the mean (SEM) 
Short interfering RNA Tumour Necrosis Factor 
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alpha (siTnf) 
Singlet oxygen (1O2) 
Short interfering RNA (siRNA) 
Standard deviation (SD) 
Succinic acid (SA) 
Sucrose (S) 
Sucrose-based CDs (S-EDA) 
Sulfosuccinimidyl 4-(N-maleimidomethyl) 
Cyclohexane-1-carboxylate (sulfo-SMCC) 
Surface plasmon resonance (SPR) 
Temozolomide (TMZ) 
Tetracycline (TC) 
Tetraplatinated porphyrin complex (PtPor) 
Thermogravimetric analysis (TGA) 
Thermogravimetric analysis (TGA) 
Three-dimensional (3D) 
TNF-related apoptosis-inducing ligand 
(TRAIL) 
Total light exposure (He) 
Transmission electron microscopy (TEM) 
Triphenylphosphonium (TPP) 
triplet oxygen (3O2) 
Tumour necrosis factor receptor (TNFR) 




U.S. Food and Drug Administration (FDA) 
Ultraviolet (UV) 
Ultraviolet-Visible (UV-Vis) 
Tn-doped CDs (UCDs) 
Upconverting nanoparticles (UCNPs) 
Vascular endothelial growth factor (VEGF) 
Watt (W) 
Weight/weight ratio (w/w) 
X-ray photoelectron spectroscopy (XPS) 
X-ray photoelectron spectroscopy (XPS) 
Ytterbium (Yb+3) 
Zeolitic imidazolate frameworks (ZIFs) 








List of figures 
Chapter 1 
1.1 Timeline of improvements in CD synthesis and modification. 
1.2 Nanodiamonds have a core-shell geometrical structure with many available surface groups. 
They can be used without modifications (bottom left) or functionalised to improve 
biocompatibility and other properties (bottom right).   
1.3 GQDs are obtained from the cleavage of graphite or carbon black and treated with heat to 
remove oxide from the surface. 
1.4 Upconversion nanoparticles can convert near-infrared light into visible light. These crystals 
are often composed of fluorides such as NaYF4 or oxides like Gd2O3. 
1.5 Cell damage from nanoparticles is multifaceted and occurs simultaneously in various sites. 
Damage can alter membrane integrity, changes in cytoskeleton, production of reactive 
oxygen species, and inflammation. 
1.6 The anti-inflammatory properties of aspirin were maintained after CD synthesis. 
Concentrations up to 100 μg/ml were not shown to cause observable in vitro and in vivo 
toxicity. 
1.7 Cell cycle homeostasis is impacted by CDs at different stages depending on charge.  
1.8 CDs can be doped with various compounds during synthesis, influencing photophysical 
properties as surface chemistry is altered.  
1.9 CDs can be passivated with molecules such as eicosapentaenoic acid (EPA) or 
ethylenediamine (EDA). Passivation can impact circulation lifetime and colloidal stability.   
1.10 ZW800 increases CD absorption in the NIR region after amide crosslinking (A). CD-
ZW800 particles were mainly cleared through kidneys, resulting in rapid urinary excretion 
(B).  
1.11 Histological evaluation of various tissues excised from mice treated with 20 mg/kg BW 
produced by nitric acid oxidation showed no observable morphology change or 
genotoxicity.  
1.12 NIR fluorescence at 655 nm was observed in mice after an intravenous CD injection 
(0.2 mL, 1000 μg mL) (a). Ex vivo imaging of tumours at various timepoints show gradual 
uptake until 3 hours post injection (b). Kidneys were the only other organ which showed 
similar signal strength (c).   
1.13 CD accumulation in wild-type (N2) nematodes can be observed with confocal imaging. 
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From left to right, images were taken with differential interference contrast (DIC), 
fluorescence (λex = 405 nm) and a merged image.  
1.14 Zebrafish embryos incubated with 2.5 mg/ml CDs show uptake at 3 hours post-
fertilisation (hpf) (A). Fluorescence gradually decreases at various timepoints, being 
observable until 60 hpf (F).  
1.15 Ex ovo CAM assay can also be achieved by cracking fertilised eggs and placing the 
embryos in plastic containers. The appearance of the membrane can be seen on embryonic 
development day (EDD) 5 and is shown with black arrows on days 7 and 8. CAM assay 
has a maximum of 17 days for development before termination. 
1.16 Multicellular tumour spheroids can replicate some in vivo cancer parameters such as 
hypoxia, diffusion, and ECM formation. Cell phenotype, protein expression, and drug 
response are more like in vivo tumours.  
1.17 Cancer stem cell (CSC)-derived organoids. Organoids can be obtained from cancerous 
tissue after excising samples, digesting them to form single-cell suspensions, and 
suspending cells in an appropriate medium. Cancer tissue-originated spheroids (CTOS) are 
prepared through incomplete cell dissociation. Clusters of cells are suspended and rapidly 
form CTOS. It is currently unclear how interchangeable CTOS and CSC organoid results 
are between each other. 
1.18 Discovery and development of new drugs is a multistep process with huge experimental 
and regulatory hurdles. Many drugs show positive results prior to clinical trials but fail due 
to unexpected side effects before Phase III.  
1.19 Ciproflaxin-loaded CDs showed controlled release over a period of 24 hrs. S. cerevisiae 
showed quick uptake and no toxicity from Ciproflaxin release.  
1.20 CDs were shown to be capable of substantial photothermal conversion, increasing 
temperature over 30° in a 1-minute timescale. Heat generation was used to destroy E. coli 
in exponential and stationary phases.  
1.21 CDs crosslinked with heparin were shown to efficiently bind doxorubicin and were 
capable of controlled intracellular release triggered by low pH in tumour 
microenvironment.  
1.22 CD charge can be influenced through passivation to introduce additional amine groups. 
Nitrogen-containing compounds can also be used as carbon sources for CD formation.  
1.23 FA-mediated uptake and targeting has been shown to be effective in treatments against 
cancer. DOX release is significantly improved after carrier internalization. 
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1.24 Phosphorus and nitrogen-doped hollow carbon dots entered cells through endocytosis 
and showed efficient doxorubicin release near nuclei. 
1.25 CDs@ZIF-8 show similar photoluminescence and surface chemistry, indicating 
complexation. TEM images show ZIF morphology is not affected by CD/DOX loading.  
1.26 Schematic showing immune response to PDT. Irradiation causes PS excitation and 
producing ROS such as singlet oxygen (1O2). Continuous 1O2 production leads to cell 
damage and eventual death, inciting an immune response in the affected area.  
1.27 Schematic representation of EDC/NHS crosslinking. Compound 1, containing 
carboxylic acid, is prepared for binding as an amine-reactive ester is formed. The 
intermediate o-acylisourea is protected from hydrolysis by NHS/Sulfo-NHS. Conjugation 
with a stable primary amine group leads to the formation of an amide bond. 
1.28 Host-guest encapsulation of Nile Blue (NB) and Zinc phthalocyanine (ZnPc) within 
CDs changes optical properties, enhancing emissions in red and NIR regions.  
1.29 Ce6 was conjugated with CDs and covered with hyaluronic acid to improve 
dispersibility in water and improve tissue penetration. NIR excitation enabled transdermal 
PS activation.  
1.30 Schematic representation of CD and NO photodonor linking. Nitric oxide can be 
produced in environments with low partial oxygen pressure.  
1.31 Alternate strategies for PDT in hypoxic environments can make use of other 
nanomaterials, such as carbon nitride. Water-splitting produced sufficient oxygen in 
hypoxic regions for effective PDT with PpIX.  
1.32 Photoactivation with an 808 nm NIR laser of copper-doped CDs can produce a 
simultaneous PDT and PTT effect.  
1.33 Gene delivery typically makes use of a vector or carrier to aid cellular uptake while 
avoiding degradation.  
1.34 Fluorescence imaging was used to monitor real-time siRNA uptake in human 
mesenchymal stem cells. While fluorescein-labelled siRNA was used, this system could be 
utilised with only CD-SMCC fluorescence.  
1.35 ATRP was used to graft zwitterionic polymers onto CDs, functioning as multicolour 
imaging probes with high DNA condensation efficiency. Outer layers protected DNA from 
degradation and nonspecific interactions. Transfection efficiency was improved 13 to 28-
fold in comparison to lipofectamine 2000. 
1.36 siRNA-loaded CDs showed fast complexation, retention, and effective gene silencing 
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in mosquito larvae compared to chitosan and silica-complexed siRNA.  
1.37 Fluorine-doped CDs showed improved gene delivery efficiency compared to undoped 
CDs (UCDs) and the gold standard lipofectamine 2000.  
1.38 CD photoluminescence is excitation-dependent and increased with PEG1500N 
passivation. Multicolour PL can be observed after excitation at various wavelengths using 
a ban-pass filter. Adapted from  
1.39 N-O doped CDs show strong NIR absorption due to the presence of pyrrolic and 
graphitic residues on surface edges. IR imaging and PPT were shown to be effective using 
an 808 nm laser at the absorption maxima.  
1.40 CDs are versatile and can be doped with complexed iron ions before synthesis. In vitro 




2.1 Schematic detailing PDT mechanism. Reactive oxygen species produced by 
photosensitizers lead to cell death and eventual tumour ablation. 
2.2 Porphyrins and phthalocyanines are well-known PS families. The abundance of pyrrole 
groups and facile modification has led to many the formation of numerous derivatives and 
conjugates.  
2.3 CD synthesis is highly versatile. Fabrication of samples can be top-down: produced 
from a pre-existing structure such as carbon allotropes, or bottom-up: based on the 
pyrolysis of organic compounds. 
2.4 CD conjugates were synthesised with two distinct loading strategies. Host-guest 
encapsulated (PPIX@CD) samples were produced in a one-pot reaction. CA-EDA CDs 
were used to produce amide bond-linked (PPIX-CD and (PpIX-CD)p) conjugates. S-EDA 
CDs were embedded with PpIX in a one-pot encapsulation step. 
2.5 Samples produced through domestic microwave synthesis. CD samples obtained by 
domestic microwave-assisted pyrolysis of sucrose and PEG-400. The colour change can 
be observed from the precursor solution (left) to CD solutions. Char formation after 
carbonization can be seen at the bottom of the beaker (right). 
2.6 Microwave reactor synthesis setup. Precursor solution is placed within vessel with 
metal-reinforced cap (left). The solution is pyrolysed with the Discover SP microwave 
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reactor setup (middle) and recovered after cooling (right). 
2.7 PpIX@CD samples change according to wt%. Lower percentages such as 0.5 and 1% 
(a) showing decreased aggregate formation compared to 2% (b). 
2.8 Freeze-dried PpIX@CD conjugates. A noticeable colour change can be seen as PpIX 
wt% increases. 
2.9 Crosslinked conjugates are separated by centrifugation. The solution gradually 
separated into two fractions: PpIX-CD and (PpIX-CD)p. 
2.10 Schematic detailing newly synthesized PpIX-loaded conjugates. 
2.11 Dialysis was repeated to remove contaminants. The process was repeated until no 
colour change could be observed. 
2.12 Dialysis significantly changes end product quality. The repetition of this process 
successfully removed most contaminants from the suspension and prevented sample 
rehydration after freeze-drying. 
2.13 Sequential rounds of freeze-drying ensured complete removal of residual water. 
CDs were recovered and stored to prevent rehydration due to ambient moisture. 
2.14 PpIX conjugates show variable dispersibility in water. After initial addition to 
solution, PpIX@CD and (PpIX-CD)p remained suspended and remained as such until 
mixed. PpIX-CD readily formed a slightly reddish suspension without observable 
precipitation. 
2.15 Comparison of emission at 300 and 400 nm excitation with various molecules 
used for passivation. EDA-coated CDs demonstrated significantly higher 
photoluminescence at both 300 and 400 nm excitation compared to PEG and PEI.  
2.16 Fluorescence spectra of synthesized CD samples from various carbon sources 
using excitation wavelengths ranging from 300-500 nm. PEG-coated samples showed 
drastically reduced photoluminescence in comparison to amine-rich PEI and EDA.   
2.17 Fluorescence spectra of conjugates separated by CD subtype. 
2.18 Drug loading in conjugates was calculated using a PpIX calibration curve. The 
curve was based on PpIX fluorescence at the absorbance maximum (λmax = 405 nm). 
Conjugates were diluted and compared to estimate PpIX content. 
2.19 Fluorescence spectra of PpIX host-guest encapsulated conjugates. All samples 
show fluorescence corresponding to the characteristic emission bands. PpIX loading 
efficiency was calculated as previously detailed. 
2.20 Absorbance spectra of PpIX, PpIX-CD, (PpIX-CD)p and PpIX@CD in water. 
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2.21 FT-IR spectra comparing surface chemistry of CA-EDA samples. The 
characteristic amine band (N-H) does not appear in PpIX-CD, indicating complete 
crosslinking using EDC/NHS. 
2.22 FT-IR spectra comparing surface chemistry of S-EDA sample PpIX@CD. Amine 
groups are available as PpIX was noncovalently bound through host-guest chemistry.  
2.23 Full FT-IR spectra of CA-EDA and S-EDA conjugates. 
2.24 FT-IR spectra comparing surface chemistry of PpIX host-guest encapsulated 
samples. 
2.25 CDs form small aggregates in water suspension. TEM images of CDs at 690× (a) 
and 68,000× (b). CDs form small aggregates (<200 nm) at higher concentration (a). 
Individual particles can be seen after diluting stock solutions and sonicating samples (b). 
2.26 CD-PS conjugates show decreased aggregation in water. TEM images of 
conjugates at 30,000× (A) and 68,000× (B). Conjugates show irregular morphology and 
less aggregation in comparison to PpIX (30,000× and 18,500×). 
2.27 PpIX-loaded CDs can form aggregates depending on synthesis conditions. 
PpIX@CD formed some separate porous nanoparticles, seen at 49,000× (right). PpIX-CD 
aggregates caused by dimerization could be seen at 49,000× (right). 
2.28 PpIX@CD self-assembles at higher concentrations. TEM images of PpIX@CD 
show tendril-like structures forming from aggregates, with individual particles becoming 
clearer at higher magnifications. 
2.29 (PpIX-CD)p rapidly forms large aggregates in water. TEM image at 18,500X, 
individual particles can be observed around the edges of the aggregate. 
2.30 Singlet oxygen yield of conjugates in DMF. Corrected initial amplitude of lifetime 
generated singlet oxygen against the power of a 355 nm Nd:YAG laser to calculate 
singlet oxygen yield of each sample. Phenalenone was used as a control for 95% 
production. 
2.31 Drug loading increases CD thermal stability. TGA demonstrates CDs decompose 
at lower temperatures compared to PpIX and its conjugates. 
2.32 TGA of CDs and drug loaded conjugates. Conjugates show slight variation from 




3.1 Schematic detailing conjugates used for in vitro PDT. PpIX-CD and (PpIX-CD)p were 
fabricated through amide crosslinking. The latter corresponds to the insoluble (precipitate) 
fraction separated from PpIX-CD after centrifugation. PpIX@CD was obtained using a 
one-pot reaction. 
3.2 CDs and PpIX have significantly different effects on metabolic activity due to dark 
toxicity. PpIX shows a sharp drop in viability after 10 μg/ml (a). In comparison, CD 
cytocompatibility can be clearly seen, with cells maintaining high metabolic activity 
(>80%) at ultrahigh concentrations of 100 μg/ml (b). All samples were compared to the 
negative control to determine differences at each concentration. (N=3, n=3) 
3.3 Conjugates show significantly improved biocompatibility in comparison to PpIX. The 
improvement was observed regardless of crosslinking strategy. PpIX@CD was slightly 
more toxic than PpIX-CD or (PpIX-CD)p at lower concentrations (<5 μg/ml). Each 
conjugate was compared to the positive control PpIX. (N=3, n=3)  
3.4 CDs and conjugates have lower dark toxicity than PpIX. PpIX-CD and PpIX@CD 
show similar trends with increasing concentrations. (PpIX-CD)p appears to be the most 
biocompatible conjugate, closely mirroring CA-EDA until around 50 μg/ml. (N=3, n=3) 
3.5 PpIX-adjusted concentrations show improved biocompatibility in conjugates. 
Samples demonstrated decreased dark toxicity after changing values to %PpIX (μg/ml). 
Conjugates showed a similar drop in metabolic activity to PpIX until 4 – 5 μg/ml.  
3.6 Heatmap indicating variation in phototoxicity. The position of the LED spot was 
adjusted to cover most of the 96 well plate. Wells on the top right corner show a reduced 
PDT effect due to insufficient light exposure. Outer rows and columns were not used as 
media evaporation causes variance in cell growth.  
3.7 Phototoxicity varies according to total light exposure duration. A 2-fold increase in 
light exposure duration leads to increased variability at higher conjugate concentrations. 
Each conjugate was compared to the positive control PpIX. (N=3, n=3)  
3.8 Light-activated toxicity of CA-EDA conjugates (3-minute light exposure, 24-hour post 
light). (PpIX-CD) showed markedly diminished PDT efficiency in comparison to other 
samples. PpIX-CD and PpIX@CD showed equal performance to PpIX at concentrations 
>1 μg/ml (p <0.05). (N=3, n=3) 
3.9 Light-activated toxicity of CA-EDA conjugates varies after PDT. 3 minutes of light 
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exposure reduces metabolic activity by over 75% after 24 hours of treatment, but slowly 
recovers over a 72-hour period. (N=3, n=3) 
3.10 PpIX-CD and PpIX@CD show similar PDT efficiency to PpIX at concentrations 
>1 μg/ml. In contrast, (PpIX-CD)p shows a constant difference at all timepoints with 
concentrations >1 μg/ml. Each comparison was made between the control (PpIX) and 
conjugates. (N=3, n=3)  
3.11 CD-PS conjugates can be used as probes for fluorescence imaging. CSLM images 
of U2-OS osteosarcoma. PpIX-CD and PpIX@CD have similar emissions to both CDs and 
PpIX, while (PpIX-CD)p has greatly decreased fluorescence emission. Conjugates appear 
to aggregate near the nuclei. 
3.12 CD-PS conjugates show non-specific intracellular localisation. CSLM of conjugates 
show accumulation in the perinuclear area and cytosol. However, particles do not penetrate 
within the nucleus, which can be seen through the various z-slices. Lower z-slices (left) do 
not show brightness with DAPI staining while CD and PpIX fluorescence is high. 
Conversely, higher z-slices (right) clearly show cell nuclei with no overlapping signal from 
488 or 543 nm. 
 
Chapter 4 
4.1 In vivo mouse models are the current gold standard for cancer drug testing. Typically, 
there are two distinct approaches: human xenografts make use of cancer cell lines, while 
syngeneic models use allografts from immortalised mouse cancerous tissue. 
4.2 3D cell culture models improve the relevance of in vitro drug evaluation. Cancer 
spheroids can replicate relevant morphophysiological characteristics of in vivo tumours 
like hypoxia and increased drug resistance. They have also been widely used in high-
throughput screening and are easily produced with inexpensive reagents. Nonetheless, their 
single cell line lineage and inability of long-term culture limit their usefulness in 
comparison of organoids. 
4.3 Schematic detailing conjugates used for in vitro PDT. PpIX-CD and (PpIX-CD)p were 
fabricated through amide crosslinking. The latter corresponds to the insoluble (precipitate) 
fraction separated from PpIX-CD after centrifugation. PpIX@CD was obtained using a 
one-pot reaction. 
4.4 Spheroid growth kinetics based on initial seeding density. Diameter was measured using 
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images taken with an AE2000 inverted light microscope and ImageJ. Growth reached a 
slowed after spheroids passed 600 µm. 
4.5 Progression of spheroid growth after initial aggregation. Spheroids reach a maximum 
diameter (~600 μm) and maintain their morphology until decaying. 
4.6 Multicellular tumour spheroids react differently to PDT. Spheroids were selected for 
use in PDT after reaching ~450 μm (A). Prolonged exposure to environmental stress in 
addition to conjugate dark toxicity caused slight damage to the outer cell layer (B). PDT 
caused significantly more damage, resulting in large seen as debris surrounding the 
spheroid (C). Debris can be removed to reveal the spheroid (D).  
4.7 LDH release varies according to sample type and dose (μg/ml). PpIX-adjusted values 
show samples have similar dark toxicity in spheroids. Each sample was compared to the 
positive control PpIX. (N=3, n=6) 
4.8 Total dsDNA concentration shows less variability between samples and 
concentrations. PpIX-adjusted concentrations show similar behaviour to LDH release, 
with no significant difference between conjugates and PpIX. Each sample was compared 
to the positive control PpIX. (N=3, n=6) 
4.9 Effect of prolonged exposure to environmental stress on spheroid viability. Spheroids 
showed no significant difference in LDH release and total DNA content after a 2-hour 
period outside the incubator. Each sample was compared to spheroids left within incubation 
conditions. (n=3, N=3) 
4.10 PDT-induced phototoxicity in spheroids after 24 hrs (PpIX-CD 5 μg/ml, 5 J/cm2, 
1LT). Cell debris precipitates to the bottom of the well, obscuring the spheroid. Removal must be done with 
care to avoid spheroid disruption. 
4.11 Light fractionation improves PDT outcome. Fractionated treatments (2LT) showed 
significant differences from single treatments (1LT) at concentrations >5 μg/ml. Higher 
irradiance and drug concentration significantly increased damage to spheroids regardless 
of sample type. (N=3, n=6) 
4.12 Fractionation of light exposure increases PDT effectiveness. Treatments with 1LT 
show slightly decreased damage to spheroids in comparison to 2LT, even with lower 
fluence in each repeat exposure. (N=3, n=6) 
4.13 PpIX-adjusted values show similar behaviour between PpIX and conjugates. This 
trend can be seen in LDH release and total DNA content in samples treated with single 
(top) and double (bottom) light treatments. (N=3, n=6) 
4.14 Heatmap of all treatment combinations. Values correspond to % viability (LDH 
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release) or %dsDNA (DNA quantification). Treatments with best outcomes are shown in 
green.  
4.15 Schematic of 405 nm laser setup. The laser was controlled through software (a) and 
directed towards the spheroids using a mirror (b).  
4.16 PDT effect does not scale with high irradiance. The increase of irradiance does not 
lead to significantly different treatment outcomes in multicellular tumour spheroids using 
a 405 nm laser (25 and 100 J/cm2). (N=3, n=6) 
4.17 Conjugate uptake in spheroids at 1 μg/ml. Drug uptake with 1 μg/ml is an insufficient 
dose for PDT as uptake is limited to outer spheroid layers. 
4.18 Conjugate uptake in spheroids at 5 μg/ml Drug uptake and signal emission are 
significantly improved after increasing dose to 5 μg/ml. PpIX@CD shows signs of 
aggregation or quenching. 
4.19 Conjugate uptake in spheroids at 10 μg/ml. PpIX-based emissions with 10 μg/ml 
show drug uptake throughout the spheroid diameter and within the hypoxic core.  
4.20 Sample rotation within LSFM permits more detailed evaluation of spheroid 
morphology. Live (green) and dead(red) cells can be seen throughout the spheroid at all 
angles (top). PDT damage can be seen in some samples, with spheroids showing sloughing 
and loss of sphericity after treatment (bottom). Image at 0° corresponds to the point of view 
seen with light microscopy.  
4.21 Live LSFM imaging of spheroid treated with lysis buffer. Images were separated by 
channel (calcein-AM, ethidium homodimer-1, and the merged image). 
4.22 Spheroids show directional ablation after PDT. Post-PDT morphology varies 
according to viewing angle, with parts of spheroids becoming ablated due to significant 
cell death. 
4.23 Drug dose increases damage to spheroids. Increased drug doses destabilise spheroid 
morphology and cause ongoing cell death after 24 hours of PDT. 
4.24 Spheroids showed prolonged response to phototoxicity. Continuous cell death could 
be observed up to 48 hours after the final light treatment. Initial damage was similar to that 
found in 1LT (top) and continued to reduce spheroid size while increasing cell death 
(bottom). 
4.25 3LT causes significant PDT damage compared to 1LT and 2LT. Live imaging of 
3LT PDT (24 hrs) shows significantly increased cell death and localised damage on the top 
section of the spheroid. Outer layers begin to detach after sequential light treatments. 
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4.26 Standard C8161 melanoma spheroid imaged using SEM. Slight damage visible in 
the top right corner due to manipulation during fixation. 
4.27 PDT-induced damage is visible using SEM. In comparison to the previously shown 
untreated spheroid (Fig. 4.25), treated spheroids show a significantly reduced size and loss 
of sphericity. PDT caused sloughing of outer layers as damage increased due to fractionated 
light treatments, indicated with arrows for all samples.  
4.28 Cancer spheroid microscopy for evaluating PDT damage. Fractionated light 
treatments significantly alter spheroid morphology, greatly reducing their size.  
 
Chapter 5 
5.1 Automated parameter acquisition using multicellular tumour spheroids. Spheroids 
were cultured, pre-screened, and treated with various PDT combinations. Image acquisition 
was done using widefield microscopy and automatic segmentation with AnaSP led to 
parameter extraction. Finally, morphometric parameters were compared with in vitro 
assays. 
5.2 – Spheroid growth and morphology depends on agarose coating quality. Spheroids 
initially may show irregular morphology as cells begin to aggregate in Day 1. Steady 
growth eventually leads to a more spherical shape with no irregularities by Day 3. Defects 
in the agarose coating or incubation conditions led to irregular morphology. 
5.3 Automatic segmentation reduces variability during image pre-processing. Manual 
segmentation results for area, perimeter, and volume showed high variation after multiple 
segmentation attempts with the same image. 
5.4 Parameter extraction improves as debris is cleared from the well. Automatic 
segmentation depends on initial binary conversion and accuracy decreases as more opaque 
objects are present in the foreground alongside spheroids. 
5.5 Group variability was lowered with spheroid pre-screening. Area values from extracted 
morphological data did not show significant variability between spheroid and treatment 
groups. (N=3, n=6). 
5.6 Variability in spheroid morphology at 24 hours post-PDT. Greater variations in colours 
indicate which parameters can be used to distinguish treatments known to cause 
significantly different damage to spheroids, such as 5 μg 1LT versus 10 μg 3LT. 
5.7 PpIX and PpIX-CD show similar reductions to viability and area with equivalent 
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treatment conditions (a, b). Light fractionated treatments caused very similar effects 
regardless of drug dosages (c). 
5.8 Spheroid area can be used to predict viability and DNA content. Each point on the 
graph corresponds to an independent repeat; the same spheroid was monitored through 
imaging (parameter acquisition) and biological assays (LDH release and total dsDNA 
content).  (N=3, n=6) 
5.9 Spheroid curvature is not linked to viability. Morphological parameters based on 
spheroid curvature (sphericity) and diameter (LMinDTC) showed significant variability 
compared to area or volume.  
5.10 Variations in surface roughness based on different models for 3D projection: (a) 
roughness and (b) mixed from Zeiss ZEN 2014 software. Data such as total fluorescence 
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Chapter 1 – Literature review: Carbon dot conjugates for biomedical and 
biomaging applications 
Introduction 
Nanomaterials in biomedical applications 
Carbon-based nanomaterials have unique photophysical properties which have been used in 
research for a wide variety of biomedical applications including drug delivery, bioimaging, and 
sensing. Carbon dots (CDs), also known as C-dots and carbon quantum dots, are quasispherical 
fluorescent nanoparticles which have received continuous attention and research interest since 
their serendipitous discovery during the purification of single-walled carbon nanotubes in 2004 
[1]. The term “carbon dot” has also been used to describe several different types of particles 
such as carbon nanoparticles, amorphous carbon dots, and polymer dots.  
In general, CDs have key characteristics such as excellent biocompatibility, tuneable 
photoluminescence, photostability, and facile surface group modification that make them ideal 
candidates for several applications [2]. Moreover, synthesis routes for CDs are highly adaptable 
and inexpensive, leading to greater control over several photophysical characteristics through 
mechanisms like surface passivation, which is the process by which reactive surfaces are coated 
to prevent changes. CDs typically are passivated with compounds such as branched polymers 
or glycerol, which maintain photoluminescence and prevent surface oxidation [3]. However, 
there are contradictory reports regarding key properties such as photoblinking, [4] photon 
upconversion, [5] pH-dependent photoluminescence, and size-dependent photoluminescence 




Fig. 1.1 – Timeline of improvements in CD synthesis and modification. Reprinted from Yao 
et al. (2019) with permission from Elsevier [8]. 
Carbon nanotubes (CNTs) 
Currently there are many competing technologies within the field of nanoparticle conjugates 
for biomedical applications, particularly from the same carbon allotrope family. Carbon 
nanotubes (CNTs) are one of the most widely known nanomaterials and have been exhaustively 
investigated for biomedical applications. Though they have excellent electrical, mechanical, 
and chemical properties, they have been continuously limited in their use due to ongoing 
concerns regarding toxicity. CNTs have been shown to be cytotoxic mainly because of their 
shape and length, which pierce cells. This can lead to abnormalities in phagocytosis, which is 
commonly observed in cancer and malignant lymphoid cells [9,10]. Additionally, metal 
catalyst impurities have been investigated as important factors in toxicity [11]. 
Nanodiamonds (NDs) 
Nanodiamonds exhibit very similar properties to carbon dots with intrinsic photoluminescence 
and excellent biocompatibility. However, they have a crystalline structure and synthesis 
conditions are limited as conventional methods require high pressure and temperature for initial 
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growth or require additional solvents (Fig. 1.2) [12].  Furthermore, they suffer from poor 
colloidal stability in water unless coated with PEG or a similar polymer and tend to aggregate 
non-specifically with other biomolecules [13]. However, this is a common problem for all 
nanoparticles which are used as colloidal dispersions. 
 
Fig. 1.2 – Nanodiamonds have a core-shell geometrical structure with many available surface 
groups. They can be used without modifications (bottom left) or functionalised to improve 
biocompatibility and other properties (bottom right).  Adapted from Zhao et al. (2004) 
through the Creative Commons CC BY license [14]. 
Graphene quantum dots (GQDs) 
Graphene quantum dots have also seen increased research interest thanks to their intriguing 
optoelectronic properties. This zero-dimensional luminescent material is formed by small (3-
20 nm) fragments of graphene that exhibit high photoluminescence while maintaining 
biocompatibility and semiconducting behaviour (Fig. 1.3). However, GQDs typically suffer 




Fig. 1.3 – GQDs are obtained from the cleavage of graphite or carbon black and treated with 
heat to remove oxide from the surface. Reprinted from Sun et al. (2017) through the Creative 
Commons CC BY license [16]. 
 
Inorganic nanoparticles 
Inorganic nanoparticles have also been shown to have suitable properties to act as both carriers 
and contrast agents. Semiconductor quantum dots have excellent photoluminescence and have 
been widely explored for use in similar biomedical applications to CDs. Despite their high 
performance due to their excellent photophysical properties, many have raised concerns about 
possible toxicity and side effects caused by heavy metals such as cadmium, selenium, 
tellurium, and lead [17]. Metallic nanoparticles have shown great versatility due to their strong 
optical properties and high magnetic susceptibility. They can be subdivided into four categories 
based on their composition: metallic, bimetallic (also known as alloy), metal oxide, and 
magnetic nanoparticles. However, they suffer from instability in physiological environments, 
size and shape-dependent toxicity, and impurities present as a result of their synthesis [18].  
Upconverting nanoparticles (UCNPs) 
Nanoparticles containing uncommon elements open up many possibilities due to their 
intriguing optical properties such as photon upconversion (UC). This phenomenon is based on 
the conversion of higher wavelength (lower energy) light to lower wavelength (higher energy) 
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light as a result of their unusually high absorption cross section [19]. Upconverting 
nanoparticles are made up of a crystalline matrix in which lanthanide ions are embedded (Fig. 
1.4). Although they are excellent candidates for bioimaging and light-based therapeutics, they 
are limited as their excitation maximum (980 nm) overlaps with water and is relatively low in 
brightness [20]. Nonetheless, all these materials have shown varying degrees of success in 
biomedical and bioimaging applications due to their innate properties like high surface area 
and photoluminescence [21]. 
 
Fig. 1.4 – Upconversion nanoparticles can convert near-infrared light into visible light. These 






(Lower wavelength, higher energy
Near infrared light















Carbon dots (CDs) 
Initially, CDs were thought to be an alternative to semiconductor quantum dots because of their 
high photostability, tuneable emission spectra, and low toxicity. However, the extreme 
variability of photoluminescence and toxicity has somewhat limited the application of CDs in 
several fields [22]. Furthermore, the prediction of CD photophysical characteristics remains a 
great challenge due to their complex chemical structure; the relationship between contributions 
of bulk and surface-derived effects on these properties has not been completely understood [8]. 
In recent years, there has been much progress in regards with the general properties and 
application of CDs which has been succinctly summarized in several review articles [23–25]. 
This review will focus on describing the recent progress of CDs in biomedical applications as 
nanoparticle-drug conjugates, focusing on the many variations in synthesis, modifications, 
crosslinking, and drug delivery strategies. 
Evaluation of in vitro and in vivo toxicity 
Biocompatibility is one of the most important properties for biomedical applications. However, 
it should be noted that the concept of “biocompatible” has been in constant change since its 
introduction and is often thought to be the opposite of cytotoxicity. Williams (2008) proposed 
that biocompatibility is the ability of a system or material to perform intended function without 
causing localised or systemic damage in vivo [26]. In contrast, cytotoxicity generally refers to 
a broad range of effects that lead to accidental (necrosis) and regulated (apoptosis) cell death. 
These differ according to the mechanism by which cell death occurs; typically regulated cell 
death is the end result of multiple signalling pathways and a combination of multiple events 
within cells (Fig. 1.5) [27]. 
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Fig. 1.5 – Cell damage from nanoparticles is multifaceted and occurs simultaneously in 
various sites. Damage can occur within the membrane (1), cytoskeleton (2), DNA (3) , 
mitochondria (4), lysosomes (5), production of reactive oxygen species (6), and through the 
expression of pro-inflammatory components (7) . Reprinted from Sukhanova et al. (2018) 
through the Creative Commons CC BY license [28].   
 
The evaluation of toxicity of carbon nanomaterials has proven to be difficult as their behaviour 
is highly variable depending on factors like surface chemistry, dispersion properties, 
hydrophilicity, and particle size. The toxicity of nanoparticles is the combination of a multitude 
of effects which determine how these materials interact with cells. Nanoparticle-mediated 
toxicity has been linked to several stress-related cellular events caused by the alteration of 
homeostasis. 
In particular, the physiochemical properties of particles have been shown to be crucial in 
determining cytotoxicity in vitro, and include surface charge [29], size, shape [30], and 
elemental composition [31]. Furthermore, nanoparticles can arrest the cell cycle by disrupting 
the cell-division cycle. As cells cannot repair the damage that is caused, they can become 
necrotic or apoptotic, which continuously supresses proliferation [32]. Extensive testing is a 
key step in understanding the mechanism of cellular toxicity in any nanomaterial. 
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Determination of cytotoxicity is essential for nanomaterial development  
There is a wide variety of protocols used to determine cytotoxicity, from simpler cell viability 
assays like live/dead staining, metabolic activity, membrane damage, or total DNA content, up 
to more complex immunoassays for detecting various biomolecules as markers for alterations 
in key cellular pathways [33]. The model used for evaluating toxicity greatly impacts the 
quality and relevance of obtained data. These can be either in vitro, which includes cell 
monolayers and various 3D cell culture models, or in vivo models like rats, mice, chick 
chorioallantoic membrane.  
Panessa-Warren et al. (2006) suggest a combination of in vitro and in vivo assays is the ideal 
method to maintain the balance of cost-benefit in cytotoxicity evaluation. In particular, the use 
of immortalized cell lines with high passages or brief exposure times may not reflect 
physiological conditions and should be used alongside another more complex model to obtain 
complementary data [34]. Additionally, Moore et al. (2019) showed nanoparticle-cell 
interactions are affected by the administration method – as particles can be in a concentrated 
solution, pre-mixed, or mixed in situ [35]. Therefore, cytocompatibility results should be 
compared only after a careful observation of the experimental design that was utilised. 
The general consensus across several studies is that CDs generally possess a very low toxicity, 
mainly as a result of their hydrophilicity [36]. CDs have previously shown widely varied results 
related to a multitude of experimental factors such as cell line used, synthesis route, chemical 
modifications, and incubation times. LD50 values for cell viability are extremely variable, 
ranging from 15.625 μg/ml to 10 mg/ml in cell monolayers (Table A2.1, Chapter 2 Annex). 
Therefore, CD-based conjugates can be greatly affected by the variability seen in 
cytocompatibility, indicating the need for extensive toxicological evaluation prior to their use. 
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In vitro (cytocompatibility) 
CDs show low cytotoxicity though high dose range is variable 
A key factor in the evaluation of cytotoxicity is determining what concentration is considered 
as a “high dose” – this can be particularly difficult as this varies according to each application 
and author. Tao et al. (2012) showed a comparison of in vitro and in vivo accumulation of 
graphite or carbon nanotube-derived CDs and determined no appreciable toxicity even at 
“ultrahigh” concentrations of 0.5 mg/ml. These CDs are highly hydrophilic possibly due 
exceptionally high oxygen content (55%) and many carbonyl and hydroxyl surface groups, 
which makes them similar to hydrophilic carbon clusters [37]. Similarly, Huang et al. (2014) 
did not observe significant changes in cell viability of cultured AD-923 cells with extremely 
high concentrations of up to 2 mg/ml with histidine-derived CDs. [38]   
 
Fig. 1.6 – The anti-inflammatory properties of aspirin were maintained after CD synthesis. 
Concentrations up to 100 μg/ml were not shown to cause observable in vitro and in vivo 
toxicity. Reprinted with permission from Xu et al. (2016) [39]. Copyright (2016) American 
Chemical Society. 
 
In comparison, Jiang et al. (2015) used a lower range of 0 – 50 μg/ml to test the CD toxicity 
with MCF-7 cells and observed >95% viability in all concentrations up to 50 μg/ml, noting that 
samples showed “excellent biocompatibility” [40]. Likewise, Xu et al. (2016) determined 
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aspirin-based CDs do not cause significant cell death in RAW264.7 cells at concentrations up 
to 100 μg/ml [39]. These results highlight excellent CD cytocompatibility but suggest there are 
more factors involved in predicting CD-based cellular toxicity. It is possible that the synthesis 
protocol leads to specific surface chemistry which improve cytocompatibility, as seen in Fig. 
1.6. These variations in lethal concentrations (LC50) are likely caused by variations in 
synthesis conditions, reagents, and sample processing.  
Cytotoxicity evaluation depends on various assays 
Cell viability and proliferation assays are also varied across the literature, with most 
evaluations being carried out using the MTT assay. However, other assays such as MTS, 
resazurin reduction, CCK-8 or CellTiter96 have been used to evaluate CD cytotoxicity. Ray et 
al. (2009) combined MTT and Trypan blue assays to determine the cytotoxicity of 2 – 6 nm 
CDs obtained by nitric acid oxidation of carbon soot and found minimal cell death at 
concentrations under 1 mg/ml [41]. Cui et al. (2015) also showed high cytocompatibility of 
CDs fabricated by the hydrothermal processing of ammonium citrate and ammonium 
hydroxide. Particles were evaluated in concentrations up to 2 mg/ml with CKK-8 and did not 
impact cellular morphology or proliferation [42]. Nanoparticle incubation time for cytotoxicity 
evaluation in cell monolayers is mostly the same across the literature, with most work 
coinciding at 24-hour exposure periods immediately followed by a metabolic activity assay. 
However, the use of longer timescales is useful as it may show additional data regarding 
changes to proliferation after several cell division cycles. Hill et al. (2016) evaluated the 
cytotoxic effect of amine-functionalized CDs over a lengthier timescale of 1 to 7-day exposure 
with live/dead staining and resazurin reduction assays. The reductive metabolism per cell 
(RMPC) was calculated by comparing the total metabolic activity with the number of live cells 
estimated with staining. Amine-coated CDs showed elevated RMPC at 1-hour exposure, with 
significant cell death apparent at concentrations above 250 μg/ml. Lactose-coated CDs showed 
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increased RMPC levels consistently across all time points, which suggest glycans could be 
useful for improving the cytocompatibility of CDs [43]. Yang et al. (2011) evaluated the 
toxicity of CDs synthesized by the hydrothermal treatment of monopotassium phosphate and 
glucose. HepG2 cells did not show appreciable cytotoxicity after incubation with CDs, up to a 
total of 72 hours of exposure [44].  
Variations in cell lines lead to different outcomes for toxicity 
There are reports of variation between in vitro CD toxicity when utilising different cell lines in 
similar experiments. Shereema et al. (2014) showed CDs fabricated by combustion of styrene 
produce highly variable LD50 concentrations between HEK 293 (>250 μg/ml) and A549 
(15.625 μg/ml) cells [45]. Similarly, Yang et al. (2009) fabricated CDs by laser ablation of 13C 
and graphite cement and evaluated toxicity in MCF-7 and HT-29 cells. CDs in vitro were 
shown to decrease around 25% of cell proliferation and viability at concentrations over 50 
μg/ml (HT-29) and 100 μg/ml (MCF-7). HT-29 cells showed decreased mortality in 
comparison to MCF-7. It is possible that cancer cells are capable of higher rates of cellular 
uptake and storage due to the EPR (enhanced permeability and retention) effect [46]. 
Throughout literature there are conflicting results regarding variations between cell lines, 
which indicates that the evaluation of CD cytotoxicity should be thoroughly evaluated with a 
standardized method.  
Synthesis method may affect cytotoxicity as surface chemistry changes 
CD synthesis and carbon sources used in their production could also be a source of variability 
between samples. Vedamalai et al. (2014) synthesized CDs through hydrothermal 
decomposition of o-phenylenediamine and observed cells showed toxicity leading to cell death 
mainly through apoptosis in A549 (~250 μg/ml), MCF-10A and MDA-MB-231 cells (>300 
μg/ml). Additionally, the addition of CDs did not cause significant change in intracellular pH 
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values [47]. Zhang et al. (2013) utilised CCK-8 for evaluating cell viability in both NIH-3T3 
fibroblasts and A549 cells with nanodiamond-derived CDs. They did not observe adverse 
effects in cell morphology and viability up to concentrations of 320 μg/ml in both cell lines. 
Additionally, there was no significant difference in cell viability between NIH-3T3 and A549 
cells at all concentrations regardless of incubation times. Bright field microscopy shows the 
outline of carbon dot aggregates in the cytoplasm, with normal cellular morphology at 50 μg/ml 
[48]. Zhang et al. (2015) showed minimal variation between the toxicity of iodine-doped CDs 
in A549 and 4T1 cancer cell lines [49]. Likewise, Liu et al. (2012) showed CD 
cytocompatibility varies only slightly between HepG2 and COS-7 cells. Additionally, it was 
found that microwave irradiation time greatly affected CD cytotoxicity at concentrations over 
4 μg/ml. It is possible that as synthesis time increases the majority of positively-charged groups 
in polyethyleneimine (PEI) are either destroyed during the passivation or are located within the 
nanoparticle core, thus reducing membrane damage [50]. 
Passivation can greatly increase photoluminescence and cytocompatibility  
Surface passivation has been shown to be an important factor in CD cytocompatibility. 
Havrdova et al. (2016) found surface charge greatly influences soot-derived CD toxicity in 
NIH/3T3 fibroblasts. Polyethylene glycol-coated nanoparticles showed no significant effect on 
cell viability up to a concentration of ~300 μg/ml and began to affect morphology at similar 
concentrations. In comparison, negatively charged pristine CDs were found to disrupt part of 
the cell cycle and decrease proliferation at around 200 μg/ml, while positively charged PEI-
coated CDs caused significant changes to cell viability at concentrations around 100 μg/ml. As 
can be seen in Fig. 1.7, cell cycle homeostasis can be disrupted by CDs at various stages. Flow 
cytometry analysis of cell populations suggest free PEI molecules interact with various 
organelles and intracellular components such as DNA, contributing to increased cell death [51]. 
Likewise, Li et al. (2010) utilised silica spheres as carriers for CD synthesis via nitric acid 
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oxidation and compared the effect of polymer surface passivation on cytotoxicity. CD3 
(particles passivated with PEI-PEG-PEI polymer chains) showed increased binding to cell 
membranes due to its positive zeta potential of +3.35 mV, while non-passivated CDs led to 
decreased cytotoxicity as a result of their negative charge [52]. 
 
Fig. 1.7 – Cell cycle homeostasis is impacted by CDs at different stages depending on 
charge. Reprinted from Havrdova et al. (2016) with permission from Elsevier [51]. 
  
Heteroatom doping improves photoluminescence in CDs 
The introduction of elements other than carbon, hydrogen, and oxygen in CDs has been shown 
to be an adaptable and facile method of increasing photoluminescence. Typically, this is done 
using nitrogen and phosphorous-containing compounds for particle synthesis. The main 
advantage of one-pot synthesis combined with heteroatom doping is the lack of any other 
external additives like passivating agent, alkali, acid, or salt which may be disadvantageous for 
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cytocompatibility and quantum yield, as can be seen in Fig. 1.8. Zhai et al. (2012) showed the 
very low toxicity in N-doped CDs with high quantum yields (30.2%) at unusually high 
concentrations of >10 mg/ml. The additional passivation with amine-rich compounds such as 
4,7,10-trioxa-1,13-tridecanediamine or PEI was not found to significantly impact particle 
toxicity and increased quantum yield. CDs did not have an effect cell morphology even at 2 
mg/ml, with concentrations metabolic activity remaining unchanged at 3 mg/ml (100%) and a 
slight decrease when increased to 6 mg/ml (84%) [53].  Zhou et al. (2014) demonstrated P-
doping of CDs increased photoluminescence and quantum yield in a similar manner to N-
doping by forming more isolated sp2 carbon clusters. P-doped CDs show reduced greatly 
cytocompatibility in HeLa cells (~100 μg/ml) due to this modification [54]. Parvin and Mandal 
(2017) evaluated the toxicity of nitrogen and phosphorous co-doped CDs in RAW264.7 cells. 
PN-CQDs were determined to be highly fluorescent and non-cytotoxic with concentrations up 
to 1 mg/ml not significantly affecting cell metabolism, proliferation, and survival [55]. 
 
 
Fig. 1.8 – CDs can be doped with various compounds during synthesis, influencing 
photophysical properties as surface chemistry is altered. Reprinted from Mohammadinejad et 
al. (2019) through the Creative Commons CC-BY-NC-ND license [56]. 
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Postprocessing samples leads to improved photoluminescence and cytocompatibility 
Interestingly, the separation of CDs via HPLC has revealed the presence of distinct groups of 
more homogeneous particles within a single sample. Vinci et al. (2013) resolved a mixture of 
CDs obtained from graphite nanofibers and found a complex mix of 12 individual fractions. 
They observed highly variable quantum yield (<1 – 7%) plus unique absorption bands and 
emission wavelengths. Furthermore, the toxicological profile of each fraction was evaluated, 
with several fractions showing significantly improved cytocompatibility in comparison to the 
unprocessed mixed CD solution [57].  
In vivo (biocompatibility) 
CDs have continuously shown excellent biocompatibility in vitro with a large variety of cell 
lines. However, there are clear limitations when utilising in vitro studies for toxicological 
screening of compounds. Although conditions such as oxidative stress, pro-inflammatory 
response, and NF-κB (nuclear factor kappa-light-chain-enhancer of activated B cells) 
activation have been linked to particle toxicity in cell culture, the replication of pathogenic 
effects seen in vivo has not yet been achieved. This has led to false positives (e.g. glass 
microfibres) or negatives (e.g. purified single-walled carbon nanotubes) during initial testing 
phases [58]. In vivo evaluation of nanoparticle toxicity with various animal models, including 
mice, rats, and zebrafish, can provide more clinically relevant data. The toxicity assessment 
typically includes haematological analysis, particle clearance, biodistribution, and histological 
evaluation of various tissues. In vivo and ex vivo imaging and other similar techniques can also 
be used to determine particle uptake in organs.  
Fig. 1.9 shows two commonly used compounds for surface passivation, both with amine 
groups. These molecules cover the reactive CD surface and preserve photoluminescence while 
improving uptake. This effect has been found both in vivo and in vitro [51]. Yang et al. (2009) 
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demonstrated accumulation of subcutaneous and intravenous-injected CDs passivated with 
PEG1500N and PPEI-EI in several key organs of DBA/1 mice. Kidneys demonstrated stronger 
fluorescence consistent with the urinary excretion pathway of compounds, while the liver only 
showed low particle accumulation. Although increased hepatic uptake has been previously 
observed in other nanoparticles, PEG passivation may have reduced protein affinity [59]. 
However, contrary to expectations, zeta potential did not significantly change in vivo toxicity 
at the concentrations that were evaluated.  
 
Fig. 1.9 – CDs can be passivated with molecules such as eicosapentaenoic acid (EPA) or 
ethylenediamine (EDA). Passivation can impact circulation lifetime and colloidal stability. 
Reprinted from Dong et al. (2017) through the Creative Commons CC BY license [60]. 
 
Route of administration impacts in vivo efficiency 
The use of different administration routes directly impacts in vivo distribution, clearance, and 
tumour uptake of nanoparticles and has been found to be one of the main factors in determining 
compound toxicity. Furthermore, animal models provide great versatility in the tools used for 
observing nanoparticle accumulation both in vivo and ex vivo. Huang et al. (2013) performed 
 51
a thorough evaluation of the effects of different subcutaneous, intravenous, and intramuscular 
injection of CDs on their in vivo distribution, clearance, and tumour uptake in BALB/c mice. 
CDs were passivated with diamine-terminated oligomeric PEG1500N and crosslinked to ZW800 
(near-infrared dye) through EDC-NHS chemistry to enhance optical properties, which can be 
seen in Fig. 1.10 [61]. Additionally, 64Cu was used for CD radiolabelling to monitor uptake via 
dynamic positron emission tomography (PET) scanning. SCC-7 cells were injected into 
BALB/c mice to promote tumour growth. Blood clearance rates were shown to vary according 
to the administration route, with particle concentration dropping dramatically 1 hour after 
intravenous injection, in comparison to increases with both subcutaneous and intramuscular 
injections. 
 
Fig. 1.10 – ZW800 increases CD absorption in the NIR region after amide crosslinking (A). 
CD-ZW800 particles were mainly cleared through kidneys, resulting in rapid urinary 
excretion (B). Adapted with permission from Huang et al. (2013). Copyright (2013) 
American Chemical Society [61]. 
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It is possible rapid blood clearance could be due to rapid protein adsorption to CDs, leading to 
removal via the reticuloendothelial system. This is a widespread problem with nanoparticle 
suspensions: circulation lifetime is limited due to increased aggregation and clearance. 
Histology and ex vivo fluorescence imaging demonstrated high CD concentrations in kidneys 
compared to the liver in all administration routes. Intramuscular injection showed higher 
particle retention in kidneys followed by subcutaneous and intravenous injection. PET 
scanning confirmed low accumulation of CDs in the reticuloendothelial system, with less than 
1% ID/g radioactivity in all organs measured. Urine clearance was shown to be rapid for all 
samples, repeating the pattern of blood clearance rate. CDs were shown to not accumulate at 
injection sites. Tumours showed significantly higher fluorescence from other tissue at 2, 4, and 
24 hours post injection [61].  However, these results do not accurately reflect CD distribution 
as they were previously conjugated with ZW800, changing pharmacokinetics. 
In vivo nanoparticle distribution can be monitored 
Imaging tools such as CT and PET scanning are key for the study of in vivo distribution and 
retention over longer timescales. Furthermore, rapid renal clearance has been widely reported 
for CDs and other nanoparticles such as semiconductor quantum dots. This is highly desirable 
for imaging applications to decrease signal to noise ratios while reducing background toxicity 
[62]. Zhang et al. (2015) reported the synthesis of iodine-doped CDs for use as X-ray computed 
tomography (CT) contrast agents for Sprague Dawley rats. I-doped CDs were shown to be 
extremely hydrophilic and biocompatible with almost no adverse effects up to 200 μg/ml while 
showing superior X-ray attenuation capacity to commercial contrast agents. In vivo 
biodistribution was studied using rats with an intravenous injection of 40 mg/kg BW. Kidney 
and bladder showed a strong signal 10 minutes post injection, indicating rapid distribution and 
urinary excretion of nanoparticles. Histological analysis of susceptible organs did not reveal 
any obvious abnormalities [49]. Similarly, drug delivery applications benefit from rapid 
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clearance as treatment typically takes place 24 – 72 hours post nanoparticle administration.  
Dosage is also an important factor in drug toxicity in vivo, which has to be carefully evaluated 
to enhance treatment efficiency. In this context, toxicity refers to the dose where deleterious 
effects start occurring.  Wang et al. (2013) performed a systematic evaluation of CD toxicity 
and accumulation in rat and mouse models and did not find significant toxic effects or 
abnormalities in a wide range of concentrations. The high dose values are below the range of 
commercially available fluorescent imaging compounds like FDA-approved indocyanine 
green which has an LD50 of 50 – 80 mg/kg BW in mice. However, it should be noted the 
maximum recommended dose for humans is tenfold lower (5 mg/kg BW, body weight), which 
further reveals discrepancies between animal models and clinical data [63]. Acute toxicity was 
evaluated by comparing body weight and blood sample analysis of BALB/c mice injected with 
5.1 and 51 mg/kg body weight in a 14-day period with no significant toxicological effects or 
mortality. Biochemical and haematological analysis determined no variation in the levels of 
biomolecules such as urea, cholesterol, blood glucose, and albumin. Histological analysis of 
major organs showed similar results to acute toxicity studies, with no apparent lesions or 
damage caused by 20 mg/kg BW. CDs did not show signs of genotoxicity (damage to genes 
by chemical or physical agents) after a single tail injection in low, middle, and high doses (2.04, 
5.01, and 51 mg/kg BW) with 40 mg/kg Cytoxan as a positive control [64]. Fig. 1.11 shows no 
significant differences between control and test tissues excised from mice. 
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Fig. 1.11 – Histological evaluation of various tissues excised from mice treated with 20 
mg/kg BW produced by nitric acid oxidation showed no observable morphology change or 
genotoxicity. Reprinted from Wang et al. (2013) through the Creative Commons CC BY 
license [64]. 
 
CD accumulation does not cause a significant toxic effect  
Nanoparticle accumulation can lead to changes in tissue morphology, function, and expression 
of proteins. Organs with higher particle concentrations can provide insight about the 
adsorption, distribution, metabolism, and excretion (ADME) routes. Animal models can be 
combined with a wide variety of imaging technologies to more accurately determine drug 
concentration at key time points both in vivo and ex vivo. Tao et al. (2012) used carbon 
nanotube-derived CDs in athymic mice to observe in vivo accumulation. CD radiolabelling was 
used to study the pharmacokinetics, comparing blood radioactivity levels after an intravenous 
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injection over a 7-day period and followed a two-compartment model indicating slowed 
distribution within the body. Reticuloendothelial organs showed higher particle accumulation 
in comparison to others after injection, like other nanomaterials previously tested in vivo. 
BALB/c mice did not show BW drop or any obvious toxic side effect from CDs at 
concentrations of 20 mg/kg BW within 90 days of administration. Histological analysis 
demonstrated normal tissue behaviour with no observable lesions in any organ at the highest 
dosage that was evaluated [37].  
These results were like those reported by Yang et al. (2009) as they used CD-1 mice to evaluate 
in vivo toxicity of laser-ablated CDs at 8 and 40 mg/kg BW. Mice exposed to high dosage (40 
mg/kg BW) were used to observe CD uptake and accumulation in several organs. 
Histopathological analyses of liver, spleen, and kidney tissue did not show altered morphology. 
CDs fabricated with 13C were detected using isotope-mass spectrometry analysis and a total 
carbon core-equivalent content of 20 μg in liver and 2 μg in spleen were calculated [46]. Studies 
suggest CDs are highly biocompatible and cause minimal alterations in normal metabolism 
even at concentrations of up to 40 mg/kg BW. Radiolabelling and isotope-mass spectrometry 
analysis determined minimal CD retention in tissue at longer exposure periods. 
Mouse models can be used to study drug distribution and inflammatory response  
In vivo models are also highly useful to study distribution and toxicity in cancer tumours and 
are highly tied to the evaluation of CD-based conjugates for drug delivery. Murine models are 
widely used in cancer research through the use xenografts, chemical induction, or genetic 
engineering and are very advantageous due to rapid disease progression and shorter lifespans. 
He et al. (2015) investigated the in vivo tissue staining and tumour uptake of CDs synthesised 
from the hydrothermal treatment of citric acid (CA) and ethylenediamine (EDA). CDs were 
conjugated with the Arginyl-Glycyl-Aspartic acid (RGD) peptide to target integrin αvβ3 which 
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is highly expressed in new blood vessels and cancerous tissue. They were able to observe 
tumours despite strong tissue autofluorescence at 405 nm. Mice were intravenously injected 
with 8 mg/ml CDs after tumours reached a size of 100 – 120 mm3. Bladder and tumour tissue 
showed high fluorescence indicating rapid uptake after 24 hours, while other organs (including 
liver) showed decreased intensity [65]. These results are consistent with observations from Bao 
et al. (2018), where they observed NIR fluorescence from CDs co-doped with sulphur and 
nitrogen during PTT [66]. Particles passively accumulated in cancerous tissue and kidneys, 
showing high performance with rapid excretion (Fig. 1.12). 
 
 
Fig. 1.12 – NIR fluorescence at 655 nm was observed in mice after an intravenous CD 
injection (0.2 mL, 1000 μg mL) (a). Ex vivo imaging of tumours at various timepoints show 
gradual uptake until 3 hours post injection (b). Kidneys were the only other organ which 
showed similar signal strength (c). Reprinted from Bao et al (2018) through the Creative 
Commons CC BY license [66]. 
 
Zheng et al. (2016) showed a simple one-pot synthesis protocol could produce CDs with near-
infrared absorption and emission using PEG400 and a hydrophobic cyanine dye [2-((E)-2-((E)-
2-chloro-3-((E)-2-(1-(2-hydroxyethyl)-3,3-dimethylindolin-2-ylidene) ethylidene)cyclohex-1-
en-1-yl)vinyl)-1-(2-hydroxyethyl)-3,3-dimethyl-3H-indol-1-ium iodide, CyOH]. CyCDs 
demonstrated increased water dispersibility and preferential uptake in tumours. BALB/c mice 
with CT26-induced tumours were used as a model for CyCD distribution. In vivo fluorescence 
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imaging demonstrated accumulation of CyOH and CyCDs after an intravenous injection of 4 
mg/kg BW. Tumours and kidneys retained higher concentrations of nanoparticles than liver, 
spleen and heart in a period of 48-72 hours. [67] These results reveal preferential CD uptake 
in cancerous tissue regardless of the inclusion of conjugated targeting motif. Furthermore, they 
suggest particles can avoid the reticuloendothelial system for fast renal clearance. 
Nanoparticle-induced oxidative stress can lead to chronic inflammation as particles cannot be 
cleared from tissue. Therefore, the study of inflammatory response to CD administration is 
crucial. Xu et al. (2016) investigated the toxicity, accumulation, and anti-inflammatory 
properties of aspirin-coated CDs (FACDs) in vivo compared with 1% carrageenan-soaked 
polyester sponges implanted Wistar rats. FACDs were evaluated for possible anti-
inflammatory effects by comparing the decreased production of prostaglandins in vivo. FACDs 
and aspirin significantly decreased PGE2 levels in serum indicating an effective anti-
inflammatory effect in tissue. In vivo toxicity was evaluated by haematological analyses, with 
no statistically significant differences on days 1, 3, and 7. Histological analysis of various 
organs showed no abnormalities for all samples at 25 mg/kg BW [39].  
Alternative models for evaluating novel nanomaterials 
Recently there has been work on alternate models aside from mice and rats for the evaluation 
of CD biocompatibility and biodistribution. These models aim to maintain the relevance of 
acquired data while reducing costs and increasing repeatability and high-throughput capacity.  
Nematode 
The nematode (C. elegans) is an attractive in vivo model for toxicological evaluation that 
provide data from an organism with various active systems including digestive, endocrine, 
muscular, neuronal, and reproductive. Thus, they are a model meant to bridge in vitro work 
and mammalian toxicity testing by optimising drug concentrations. Although it has several 
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limitations due to its lower complexity compared murine models, it has consistently predicted 
mammalian LD50 values for a wide variety of compounds [68]. Fig. 1.13 shows nematodes 
readily uptake CDs throughout their bodies with no adverse effects. 
 
Fig. 1.13 – CD accumulation in wild-type (N2) nematodes can be observed with confocal 
imaging. From left to right, images were taken with differential interference contrast (DIC), 
fluorescence (λex = 405 nm) and a merged image. Adapted from Singh et al. (2018) with 
permission from Elsevier [69]. 
 
Singh et al. (2018) reported the cytotoxic evaluation of highly fluorescent and photostable of 
blue (B-CQDs) and green (G-CQDs) particles produced by hydrothermal treatment of beetroot 
extract in nematodes and BALB/c mice. Nematodes were fed using 1.5 mg/ml CDs mixed with 
E. coli OP50 and observed using confocal laser scanning microscopy. Treated specimens 
showed strong fluorescence in the gut and surrounding tissue, indicating systemic absorption 
of nanoparticles [69].  
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Zebrafish 
Zebrafish is a well-known and established animal model due to their great similarity to the 
human toxicological profile, low cost, tissue transparency, and convenient drug delivery to 
embryos and larvae. In particular, zebrafish have great potential for drug delivery and 
toxicology because of variety of toxicological endpoints that can be observed throughout 
embryonic and larval development [70].  
Kang et al. (2015) described an alternate method for the evaluation of CD distribution and 
toxicity in zebrafish. Embryos and larvae showed different biodistribution when exposed to 
CDs by microinjection and soaking. Embryos showed CDs possibly have different tissue 
affinities as they are mainly deposited in the yolk sac, tail, and head, being excreted at around 
60 hours post exposure. There is also a slight accumulation in the dorsal aorta which may 
indicate nanoparticle entry through the circulatory system. Interestingly, CDs can cross the 
blood-ocular barrier and accumulate in the lens but were incapable of crossing the blood-brain 
barrier. The ADME route of CDs was shown to be primarily based on swallowing and skin-
based absorption, followed by transfer through the cardiovascular system and excretion by 
urine or faeces. Zebrafish embryos revealed slight variations in survivability according to the 
administration route at 24- and 48-hours post exposure.  
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Fig. 1.14 – Zebrafish embryos incubated with 2.5 mg/ml CDs show uptake at 3 hours post-
fertilisation (hpf) (A). Fluorescence gradually decreases at various timepoints, being 
observable until 60 hpf (F). Adapted from Kang et al. (2015) through the Creative Commons 
CC BY license [71]. 
 
Fig. 1.14 shows zebrafish embryos subjected to microinjections had a small decrease in 
survival rate, down to 80% at 1.5 mg/ml and 50% at 2.5 mg/ml. In comparison, embryos soaked 
in CDs at 1.5 mg/ml and 2.5 mg/ml were 85% and 55% respectively. Concentrations under 
0.625 mg/ml demonstrated no significant effect on embryo survival rate. Zebrafish larvae 
developed normally and did not have adverse effects at solutions of 1.5 mg/ml [71].  
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Li et al. (2016) demonstrated low quantum yield CDs prepared from carbon nanopowder have 
a strong affinity and retention to zebrafish bones. Intracardiac injection of zebrafish larvae 
showed a strong fluorescence of skeletal structures after only 30 minutes post-injection. 
Furthermore, larvae were able to tolerate CDs and retain fluorescence in tissue until day 8. In 
vivo fluorescence emission was found to be excitation wavelength-dependent, following a 
similar shifting pattern as observed with CDs in an aqueous solution. Skeletal tissue was 
identified with Alizarin red staining for co-localization with CDs showing high affinity and 
specificity with calcified bone. In comparison, non-mineralized tissue such as cartilage was not 
extensively stained. Immunohistochemistry was used to observe fluorescein-labelled CDs in 
calcified cleithrum and ceratobranchial bones. CD binding to mineralized tissue was shown to 
be dependent on bone ossification by modifying retinoic acid levels for larvae [72]. In 
summary, zebrafish have been shown to be a reliable predictive model for the evaluation of 
CD-related pharmacokinetics at longer timescales post fecundation. Nonetheless, there is still 
a wide variability between experimental procedures and standards used in literature.  
Chick chorioallantoic membrane (CAM) assay 
CAM assay is an in vivo model which uses the extraembryonic vasculature and membrane of 
developing chicken eggs. This model has several advantages for high-throughput drug 
screening as it is low-cost, versatile, and reproducible. Furthermore, this model has the 
capability of supporting tumour growth due to its immunodeficiency at early developmental 
stages, which is not possible in murine models [73]. CAM assays have additional adaptability 
by being able to be cultivated outside of the eggshell, in comparison to the traditional use of 
windowing. This approach enables easier performance of xenograft-based studies using 
mammalian stem and cancer cells throughout the various chick developmental stages, which 
can be seen in Fig. 1.15 [74]. Shereema et al. (2015) evaluated the biocompatibility and 
angiogenic effect of styrene soot-based CDs via CAM assay and compared results with in vitro 
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toxicity assays performed with HEK 293 cells. The estimation of total haemoglobin as measure 
of vascular density and angiogenesis after an intravenous injection of 100 μg CDs suggested 
particles have an antiangiogenic effect. The reduction of angiogenic cytokines vascular 
endothelial growth factor (VEGF) and fibroblast growth factor (FGF) and the comparison of 
vascular densities through photomicrographic analysis further proved this reduction of blood 
vessel formation from days 4 to 12. Additionally, there was no observable toxic effects during 
the 14-day incubation period [45].   
  
Fig. 1.15 – Ex ovo CAM assay can also be achieved by cracking fertilised eggs and placing 
the embryos in plastic containers. The appearance of the membrane can be seen on 
embryonic development day (EDD) 5 and is shown with black arrows on days 7 and 8. CAM 
assay has a maximum of 17 days for development before termination. Reprinted from Mangir 
et al. (2019). Copyright (2019) American Chemical Society [75]. 
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Three-dimensional (3D) cell culture models as alternatives for drug studies 
Together, in vitro and vivo models have provided highly useful information regarding CD 
toxicity. However, the comparison of both models has consistently shown negligible 
correlation in results. This demonstrates the need for an evaluation of an in vitro model that 
can be easily validated and compared to in vivo data [76]. 3D-cell culture models have been 
intensely pursued as the next step in drug discovery and are expected to address the 
shortcomings of traditional monolayer cell culture models [77].  
Scaffolds for tissue engineering and cell-derived matrices 
The use of scaffolds for cell culture has proven to be extremely useful to replicate physiological 
conditions. Strategies are typically based on mimicking in vivo cell microenvironment, 
particularly the extracellular matrix. This is achieved using a variety of materials, such as 
hydrogels, porous scaffolds, fibrous scaffolds, or cell-derived materials like alginate or 
decellularized scaffolds [78]. An advantage of scaffolds is the possibility of forming controlled 
structures through a variety of methods such as emulsion templating, electrospinning, or salt 
leaching [79]. Chandra and Singh (2017) showed CDs were nontoxic to cells growing in a 3D 
microgel environment made with 10% (w/v) polyethylene glycol diacrylate (PEGDA) 
(molecular weight: 10 kDa) and 1% (w/v) Irgacure 2959 in PBS. CDs were loaded onto the 
gels at 0.5 mg/ml by dispersing them in CD-PEGDA solution prior to photopolymerization. 
HeLa cells and NIH-3T3 cells showed negligible toxicity at concentrations up to 1 mg/ml 
within the gels. Furthermore, CDs were observed to remain loaded onto microgels for up to 12 
days after formation [80]. In addition to biochemical composition, another advantage of 
scaffolds is the similitude with mechanical properties of target tissue. Mechanical stimuli can 
lead to various responses in cells such as differentiation, migration, and signalling, among 
others [81]. Stiffness vastly differs depending on the type of tissue, and has been linked with 
drug resistance in cancerous tissue [82]. 
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Multicellular tumour spheroids (MCTS) 
MCTS, also known as spheroids, have been widely used in the evaluation of nanoparticle 
toxicity screening due to their similarities to in vivo conditions such as increased drug 
resistance, cell-cell interactions, and hypoxia (Fig. 1.16). They are cellular aggregates from cell 
line monocultures which represent a single type of tissue component [83]. Spheroids can be 
used to study cancer microenvironment due to the presence of hypoxic areas, cell-cell 
interactions, and increased drug resistance [84]. Furthermore, they have been used high-
throughput drug screening [85]. Scialabba et al. (2019) demonstrated MCTS could be used to 
monitor biotin-decorated CD (B-CD) delivery through fluorescence imaging. Comparisons 
between 2D and 3D cell cultures revealed selective uptake through overexpressed biotin 
receptors in MCTS compared to monolayers [86]. Spheroids were shown to be a suitable 
alternative to animal models for the study of nanoparticle penetration across tissue.  
 
Fig. 1.16 – Multicellular tumour spheroids can replicate some in vivo cancer parameters such 
as hypoxia, diffusion, and ECM formation. Cell phenotype, protein expression, and drug 
response are more like in vivo tumours. Reprinted from Langhans (2018) through the 
Creative Commons CC BY license [77]. 
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However, MCTS has inherent variability in morphology between individual samples due to 
differences in growth conditions. Most importantly, this affects diffusion rates across different 
spheroid layers. Both ellipsoidal or irregular spheroids show significantly reduced hypoxic 
areas and varied oxygen distribution, influencing drug resistance. Wang et al. (2017) 
demonstrated a reduction of spheroid size after survivin siRNA silencing and doxorubicin 
(DOX) delivery with amphiphilic CDs (ACD/Sur), with PEI-coated CDs acting as a 
comparison. Confocal microscopy demonstrated particle uptake on the spheroid surface and 
interior and significant size reduction after 48 hours transfection[87]. However, ACD/Sur in 
vitro toxicity was not evaluated using biological assays with spheroids. Instead, the mean 
diameter from each condition was used as an indicator of uptake and gene silencing. CDs 
showed high toxicity compared to the literature, with around 80% viability at 25 μg/ml and 
only 25% viability at 50 μg/ml. This is likely due to the hydrophobic nature of the particle 
combined with the use of polyethyleneimine (PEI) as a passivating agent. Although spheroids 
showed a significant size reduction, it is unclear if it is caused by the action of siRNA or the 
possible toxicity of PEI-coated CDs, which have a zeta potential of +35 mV. 
Organoids 
Although spheroids are a well-known model, they suffer from clear limitations. They are only 
partially representative of physiological parameters due to their single cell lineage and are 
difficult to keep in culture conditions for extended periods of time (>2 weeks). In contrast, 
organoids are a much more complex 3D cell culture model, which essentially function as 
miniature versions of different organs, hence their name. They are capable of accurately 
replicating organ microanatomy, signalling pathways, protein expression, and drug response 
while comprising multiple cell lineages. Organoids are obtained from either single adult stem 
cells, embryonic stem cells, induced pluripotent stem cells, patient tumours, or xenograft 
 66
tumours (Fig. 1.16). Cancer organoids are typically obtained from tissue samples, as shown in 
Fig. 1.17. Additionally. organoids have been shown to be excellent platforms for high 
throughput drug screening in PDT [88]. 
 
Fig. 1.17 – Cancer stem cell (CSC)-derived organoids. Organoids can be obtained from 
cancerous tissue after excising samples, digesting them to form single-cell suspensions, and 
suspending cells in an appropriate medium. Cancer tissue-originated spheroids (CTOS) are 
prepared through incomplete cell dissociation. Clusters of cells are suspended and rapidly 
form CTOS. It is currently unclear how interchangeable CTOS and CSC organoid results are 
between each other. Reprinted from Kondo et al. (2019) through the Creative Commons BY 
license [89]. 
 
However, the cancer organoid model has some significant drawbacks. Their generation is made 
difficult due to logistical and technical challenges, particularly when scaling production. In a 
sense, they are highly affected by the “craftsmanship” of each individual. Special care has to 
be taken during manipulation as tissue rapidly undergoes anoikis, which is a type of 
programmed cell death caused due to loss of adhesion to a surface [90]. The establishment of 
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a reproducible protocol for organoid generation in a laboratory typically requires large amounts 
of resources for validation and optimisation. Access to primary tissue from hospitals is also a 
limiting factor. Finally, the costs for organoid development are much higher than those for 
spheroids [89]. Nonetheless, organoids are still an attractive 3D cell model which has been 
steadily gaining research interest in the field of drug delivery and photodynamic therapy. 
Summary 
In summary, in vitro models should ideally be highly reproducible, resemble in vivo 
physiological conditions, and be adaptable to high-throughput screening (HTS) of compound 
libraries or experimental conditions. In vivo studies have shown all CD samples do not show 
appreciable toxicity and are readily cleared from the body after short periods of time. However, 
further testing is necessary to elucidate the mechanism of CD uptake and retention, both in 
vitro and in vivo. The use of models such as C. elegans, zebrafish, and CAM assay have been 
shown to provide clinically relevant data while reducing costs and complexity associated with 
murine models. Additionally, 3D cell culture models for the evaluation of CD-based toxicity 
have not yet been widely explored. CDs have been shown to have widely varied toxicity in 
vitro, with synthesis conditions possibly contributing the most to this parameter. Therefore, the 
use of CDs in conjugates should consider previous synthesis conditions to maximize efficiency 
and decrease adverse effects. 
Drug delivery with carbon dot conjugates 
Current limitations with drug discovery and development 
Drug development is costly and time-consuming, with approximately 90% of new drugs failing 
to pass clinical trials and subsequently gain FDA approval (Fig. 1.18). Therefore, improvement 
of drug safety is essential in order to overcome the high failure rate in phase I and II studies 
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[91]. There are several key factors in drug toxicity, most notably the poor pharmacokinetics of 
new drugs as over 95% of new potential therapeutic compounds found through drug discovery 
are not found to be suitable for further evaluation. Conventional drug delivery has several 
issues that limit the effectiveness of treatments and use of various compounds clinically. The 
development of new drug delivery approaches has shown drugs can be made safer and more 
effective [92]. The use of natural products, chemical modifications [93], and computational 
methods for drug design and discovery have made great impact in this area [94]. 
 
Fig. 1.18 – Discovery and development of new drugs is a multistep process with huge 
experimental and regulatory hurdles. Many drugs show positive results prior to clinical trials 
but fail due to unexpected side effects before Phase III. Adapted from Hu et al. (2011) 
through the Creative Commons CC BY license [95]. 
 
Nanomaterials as carriers for improving drug delivery 
Drug delivery can be achieved through several different formulations consisting of a carrier 
and cargo. These can be divided into categories such as virus, immunoconjugates, vesicle-
based systems, emulsions, nanoparticles, and polymers, among others [96]. Nanoparticle-drug 
formulations have been widely studied due to the advantages these systems have such as 
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increased solubility, bioavailability, efficacy enhancement, and protection from degradation. 
In particular, nanoparticles can be manufactured and customized for various drug delivery 
applications including controlled drug release [97]. Furthermore, new nanoparticle-drug 
formulations are highly attractive as previously unwanted compounds suffering from low 
solubility, decreased efficiency or specificity, and high toxicity can be evaluated for use in a 
clinical setting [98]. Nanoparticles also benefit from facile addition of other components such 
as PEG to improve circulation lifetime during intravascular administration, as it hinders protein 
adsorption to the conjugate envelope [99]. 
CDs have been widely studied as part of drug delivery systems in the literature due to their 
physiochemical properties like high water solubility, interchangeable surface functional 
groups, photostability, and tuneable fluorescence [100]. For example, fluorescence-based drug 
tracking is able to provide additional insight to therapeutic efficiency, intracellular localization, 
and in vivo distribution, which is not immediately possible with traditional drug carriers. [101]  
Antimicrobial applications 
Nanoparticles have several antimicrobial mechanisms such as the production of reactive 
oxygen species (ROS), destabilization of cell membranes, and interruption of enzyme activity 
or DNA synthesis. Nanoantibiotics are a promising tool for circumventing the problems of 
broad-spectrum antibiotics as they simultaneously act against multiple targets. Furthermore, 
conjugates possess high temperature stability, controlled release, enhanced intracellular 
uptake, and improved solubility. However, the long-term effects are not yet understood as their 
interactions with tissue have yet to be completely detailed [102]. Conjugates have been 
evaluated in both gram positive and negative bacteria. 
A key advantage of nanoparticle-based carriers is their high loading capacity due to their 
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extremely elevated surface area, which can be exploited to achieve high loading ratios while 
maintaining low toxicity with carriers such as CDs, as can be seen in Fig. 1.19. Thakur et al. 
(2014) also showed promising results as ciproflaxin-loaded CDs showed drug loading 
efficiency of >99%, low toxicity in mammalian cells, and pH-dependent controlled release. 
Prolonged exposure to the antibiotic due to sustained release over a period of 24 hours (up to 
18 μM) inhibited the growth of gram-negative bacteria P. aeuroginosa and B. subtilis. [103]. 
 
Fig. 1.19 – Ciproflaxin-loaded CDs showed controlled release over a period of 24 hrs. S. 
cerevisiae showed quick uptake and extremely low toxicity from Ciproflaxin release. 
Adapted from Thakur et al. (2014) through the Creative Commons CC BY license [103].   
 
Yang et al. (2016) demonstrated a 17-fold increase in efficiency against gram-negative S. 
aureus using CDs loaded with lauryl betaine (BS-12), a quaternary ammonium compound. 
This growth inhibition occurred mostly during the first twelve hours of incubation, while free 
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BS-12 did not show significant antimicrobial effect at concentrations lower than 30 μg/ml. 
Likewise, CDs did not show any cytotoxic effect, which indicates there may be a synergistic 
effect between CDs and BS-12 even with a fraction of the concentration [104]. Gogoi and 
Chowdhury (2014) also showed CDs could be used to coat calcium alginate beads (CA-CDs) 
through electrostatic interactions. Tetracycline (TC) and tetracycline associated with β-
cyclodextrin (b-TC) were shown to have higher loading efficiency in CA-CDs in comparison 
to CA hydrogels alone. This system was also shown to be highly adaptable, being capable of 
sustained drug release across a wide range of pH values [105]. Nonetheless, the loading 
capacity between Ciproflaxin, TC, b-TC, and BS-12 was highly variable, ranging from 1 to 17-
fold loading ratios. 
Metal ions improve antimicrobial properties in CDs  
Heteroatom doping has also shown positive results with CDs for antibiotic-based applications. 
Elements such as silver, copper, brass, and gold have been shown to have antimicrobial 
properties, known as the oligodynamic effect [106]. Metal-doped CDs are an emerging 
research area which requires further investigation on the interactions between intrinsic CD 
properties (shape, charge, surface chemistry) and the antimicrobial properties gained through 
doping. Fang et al. (2019) showed silver-carbon nanocomposites could be synthesized through 
a facile one-pot reaction. C-dot/Ag composites demonstrated a significant antibacterial effect 
against E. coli, likely due to the release of silver ions causing cell membrane damage. [107] 
Similarly, Priyadarshini et al. (2017) demonstrated size-dependent toxicity of gold 
nanoparticles and CDs (Au@CD) in Candida albicans at concentrations of 250 – 500 μg/ml. 
CDs were used to stabilize gold nanoparticles after their synthesis, with nucleation being 
controlled through varying the amount of tetrachloroauric acid. In addition to their antifungal 
properties, Au@CDs showed a wide range of properties including surface plasmon resonance 
(SPR) and tuneable fluorescence [108]. Although these nanocomposites have shown high 
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efficiency, there are some concerns regarding long-term toxicity and accumulation, limiting 
their use. 
Antimicrobial photodynamic therapy (A-PDT) and photothermal therapy (A-PTT) 
A-PDT has been explored as a tool for rapid wound healing, taking advantage of rapid uptake 
and cell death. Photodynamic therapy is based on the production of reactive oxygen species 
(ROS) through photoactivation of a sensitizing compound. Kumari et al. (2019) demonstrated 
CDs could be used as crosslinkers for hydrogels along with cytosine-rich ssDNA and 
protoporphyrin IX (PpIX). CDs were used as fluorescence resonance energy transfer (FRET) 
donors for enhanced A-PDT. Interestingly, the ssDNA chain could be modified to adjust FRET 
efficiency and diminish PpIX quenching. The hydrogel showed sustained drug release over a 
period of 10 days, with over 90% of the drug being released before 96 hours [109].  
There have been reports of CDs with intrinsic ROS production which could be used for A- 
PDT. Meziani et al. (2016) evaluated CD visible light-induced microbial toxicity. Interestingly, 
ambient light was sufficient to significantly reduce E. coli growth after a 1-hour exposure time 
while no significant change was seen in the dark [110]. It is possible that highly efficient 
surface passivation is the key for producing particles with higher ROS production, as 
fluorescence emission is based on the presence of emissive excited states after light absorption. 
Jijie et al. (2018) also demonstrated effective A-PDT utilising ampicillin-loaded CDs capable 
of ROS production, with concentration-dependent bacterial killing after irradiation with 260 
nm light (0.3 W, 10/20 min). Ampicillin-CDs inhibited the growth of K12-MG 1655 E. coli at 
14 μg/ml in comparison to 25 μg/ml of free ampicillin. In comparison, conjugates did not show 
toxicity to HeLa cells even at concentrations of up to 200 μg/ml, indicating suitability for 
antimicrobial applications [111].  
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Photothermal therapy (PTT) is a process similar to PDT in which light-sensitive compounds 
transform energy from light into heat, causing cell death as local temperature rises over 30° 
more than standard conditions [113]. This increase can be seen in Fig. 1.20, where temperature 
steadily rises until the laser source is switched off. Similarly, Kang et al. (2018) demonstrated 
A-PTT using CDs loaded with IR825, an infrared dye capable of NIR absorption and heat 
generation. CDs acted as carriers for IR825, which was released in both acidic and basic 
conditions within cells and enabled targeted A-PTT. This led to nearly 100% drug release after 
1 hour of incubation. Approximately 99% of bacteria in a water sample were killed as 
temperature rose 37 °C [114]. 
 
 
Fig. 1.20 – CDs were shown to be capable of substantial photothermal conversion, increasing 
temperature over 30° in a 1-minute timescale. Heat generation was used to destroy E. coli in 
exponential and stationary phases. Belkhala et al. (2019) through the Creative Commons CC 




Chemotherapy has been limited by the inherent drug toxicity and subsequent side effects to 
patients, as there is cytotoxicity in both healthy and diseased tissue. Therefore, drug toxicity 
reduction is one of the main benefits of nanoparticle-drug formulations. Drug solubility has 
always been a key concern as many compounds rapidly aggregate in aqueous media or with 
high serum concentrations. The formation of aggregates commonly leads to false positives in 
enzyme-based assays and negatives in cell-based assays, lowering the effectiveness of early 
screening during drug discovery; improved colloidal stability in serum has been linked to blood 
circulation lifetime in vivo [115]. This has been shown in model systems such as simulated 
intestinal fluid, where 22 out of 29 drugs rapidly formed aggregates and interfered with enzyme 
assays [116]. Therefore, the use of model drugs for in vitro and in vivo evaluation is a crucial 
part of research in the field of nanomedicine. 
Drugs retain activity after loading on CDs 
The preservation of drug activity in adverse physiological conditions is crucial for ensuring 
high treatment efficiency. CDs are highly versatile nanoparticles which can be tailored to have 
specific surface chemistry and photoluminescence, which has been used to potentiate their 
efficiency within drug delivery applications. Recent work has shown various biomolecules can 
be effectively incorporated within CDs and retain their biological activity (Fig. 1.21). Xu et al. 
(2016) demonstrated FA-CDs retained and enhanced the anti-inflammatory effects of aspirin 
in vivo even after pyrolysis. It is likely that the acetyl groups from the aspirin remain on the 
CD surface, which interact with the serine residue of cyclooxygenases 1 and 2, effectively 
blocking oxygenation and avoiding inflammation. Synthesis was adjusted by adding hydrazine 
for increased solubility and dispersion prior to FACD formation [39]. Likewise, Zhang et al. 
(2017) utilised CDs with heparin to increase cellular uptake while maintaining the biological 
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activity and stability of heparin in physiological conditions. The amine-rich CDs and heparin 
outer shell allowed an extremely high DOX loading efficiency (32.3%) through electrostatic 
interactions. CD-Hep-DOX showed an increased anticoagulant effect, decreased haemolysis, 
and steady drug release within acidic vesicles [117]. 
  
Fig. 1.21 – CDs crosslinked with heparin were shown to efficiently bind doxorubicin and 
were capable of controlled intracellular release triggered by low pH in tumour 
microenvironment. Adapted from Zhang et al. (2017) through the Creative Commons CC BY 
license [117]. 
 
Charge-reversible conjugates offer improved pH stability 
Drug loading strategies based on CDs as carriers are varied, ranging from covalent crosslinking 
to electrostatic interactions. Although covalent linking is useful for increasing drug solubility 
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and stability, electrostatic interactions allow conjugates to display new characteristics based on 
charge conversion in various physiological conditions, as can be seen in Fig. 1.22. Feng et al. 
(2016) evaluated in vitro and vivo uptake and toxicity of charge-reversible CDs (CDs–
Pt(IV)@PEG-(PAH/DMMA); CDs were bound with cisplatin (IV) [PtIV] and complexed with 
a combination of dimethylmaleic acid (DMMA) and poly(ethylene) glycol (PEG)-
functionalized poly(allyamine) (PAH) or succinic acid (SA). CDs–Pt(IV)@PEG-(PAH) 
showed variable toxicity in A2780 cells at pH 7.4 (>11.4 μM) in comparison to 6.7 (5.72 μM), 
while CDs–Pt(IV)@PEG-(SA) showed no appreciable toxicity at concentrations up to 11.4 
μM[118].  
 
Fig. 1.22 – CD charge can be influenced through passivation to introduce additional amine 
groups. Nitrogen-containing compounds can also be used as carbon sources for CD 
formation. Reprinted from Mohammadinejad et al. (2019) through the Creative Commons 
CC-BY-NC-ND license [56]. 
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Likewise, Wang et al. (2017) reported the synthesis of amphiphilic CDs (ACDs) from PEI 
capable of forming micelles in water. ACDs showed a low critical micelle concentration value, 
which suggest they can load hydrophobic drugs such as DOX effectively. DOX@ACDs 
showed high drug loading ratios and increased efficiency in vitro. Additionally, the conjugates 
were stable in water at 4 °C for several months [87]. Zeng et al. (2016) demonstrated pH 
dependent DOX release loaded on CDs via electrostatic interactions. DOX loading was 
optimised by varying citric acid and urea ratios to obtain a predominantly carboxylic acid (-
COOH) surface. Conjugates showed a very effective pH response, varying DOX release from 
24.2% (pH 7.4) to 86.5% (pH 5). CD-DOX was shown to be more effective against cancer 
cells (HepG2) in comparison to normal cells (HL-7702) due to the intracellular pH difference 
triggering selective release[119]. 
Release profiles can be adjusted based on pH 
The adaptability of drug release combined with rapid cellular uptake is important to mitigate 
the toxicity of chemotherapy drugs such as doxorubicin (DOX), temozolomide (TMZ), or 
methotrexate (MTX). The possibility of multiple drug release profiles based on pH-sensitive 
systems would limit release in healthy tissue and improve treatment outcomes in patients, 
particularly in compounds with high inherent toxicity. Kong et al. (2018) showed DOX loading 
on CDs using electrostatic interactions, obtaining a 57.5% loading efficiency. Furthermore, the 
conjugates showed faster release rates at pH 5.0 in comparison to 6.8 or 7.2, likely impacted 
by changes in CD zeta potential. CDs-DOX showed greatly increased anti-cancer effect and 
higher apoptosis ratio in comparison to free DOX in vitro, possibly due to higher internalization 
speed of complexed DOX. However, intracellular uptake did not appear to be significantly 
improved through CD complexation after a 4-hour incubation period [120]. Wang et al. (2015) 
demonstrated DOX loading with constant drug release and an equal effect to free DOX at 
concentrations under 320 μg/ml [121]. Variations in loading efficiency and rapid intracellular 
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uptake could also be influenced by CD size and surface chemistry. These results highlight the 
importance of controlled CD synthesis in order to achieve both higher efficiency and increase 
experimental reproducibility. 
Controlled drug release is another key component of an ideal nanoparticle-based drug delivery 
system. Their adaptability makes the use microenvironmental cues for rapid release possible, 
such as the case with pH gradients in the tumour microenvironment. Yang et al. (2016) 
demonstrated DOX could be loaded on CDs using 4-hydrazinobenzoic acid as a linker, which 
formed a pH-sensitive bond capable of cleavage. Conjugates showed improved efficiency in 
vitro and in vivo compared to free DOX [122]. Likewise, Yuan et al. (2017) demonstrated CDs 
loaded with DOX with high loading efficiency and selective release in acidic environments, 
with the highest release at pH 5. CD-DOX conjugates showed rapid accumulation and cell 
death. The ratio of apoptosis to necrosis was higher with conjugates in comparison to free 
DOX. Higher rates of apoptosis are linked to an increased therapeutic efficiency in cancer 
drugs [123]. However, there have been reports of no significant difference in drug release 
between slightly acidic and alkaline environments. Pandey et al. (2013) used CDs separated by 
centrifugation to decorate gold nanorods and load doxorubicin through both covalent and non-
covalent bonding. NIR (near-infrared) irradiation also triggered a burst release of DOX (~60%) 
and no significant differences were observed when pH was adjusted [124]. 
Combining targeting and efficient delivery improves treatments  
There has also been research into crossing the blood-brain barrier (BBB), which represents a 
significant challenge for drug delivery. Limited accumulation and uptake limit the efficiency 
of current treatments, leading to complications in conditions such as glioblastoma. 
Hettiarachchi et al. (2018) demonstrated triple-conjugated CDs (C-DT) based on amide 
crosslinking of transferrin, temozolomide, and epirubicin can efficiently cross the BBB. The 
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efficacy of various combinations of conjugates was tested including dual systems with 
transferrin-temozolomide (C-TT) and transferrin-epirubicin (C-ET), with the triplet system C-
DT exhibiting the highest cytotoxic effect against SJ-GBM2 glioblastoma [125].  
This work was continued as Hettiarachchi et al. (2019) demonstrated a triple-conjugated 
system based on CDs, transferrin, and either epirubicin or temozolomide could increase 
therapeutic efficiency. Non-transferrin drug conjugated CDs did not efficiently reduce cell 
viability due to poor uptake as the nanoparticles were likely ejected by cell membrane drug 
efflux pumps. On the contrary, CD-transferrin-drug conjugates showed a drastic reduction in 
cell viability even at low concentrations. A synergistic effect between both drugs was observed 
at all concentrations that were evaluated. [125] However, the use of various components with 
covalent crosslinking requires a multi-step approach to conjugate fabrication. In particular, 
sequential coupling is less efficient as only approximately half of the available carboxylic acids 
are converted to amide [126]. Therefore, experimental conditions should be thoroughly 
standardised in order to maximize drug loading and minimise conjugate loss after sample 
purification. 
Targeted drug delivery can improve treatment efficiency 
Currently, it is generally accepted that drug diffusion through lipid membrane is the dominant 
process for delivery. Lipinski’s rule of 5 is used to predict pharmacokinetics of unknown 
compounds based on 5 criteria. Ideally, compounds should have a molecular mass <500 
Daltons, <5 hydrogen bond donors (C-O or N-O bonds), <10 oxygen or nitrogen atoms, and a 
partition coefficient <5. However, these considerations can be circumvented through the use 
of carrier-mediated uptake [127].  
Targeted drug delivery using receptor-mediated uptake is a very effective strategy to 
circumvent high compound toxicity and low water solubility. Molecules such as folic acid (FA) 
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have been used to guide conjugates with great efficiency (Fig. 1.23). Although many drugs are 
highly effective against cancer, there is a widespread lack of selectivity towards target tissue. 
Li et al. (2016) also demonstrated delivery across the blood-brain barrier was possible using 
cancer-targeting transferrin decorated CDs. MALDI-TOF mass spectrometry (MS) was used 
to estimate the loading of a single molecule of DOX per transferrin. Although DOX-loaded 
CDs showed higher efficiency in comparison to free DOX, the exact mechanism of cell death 
is not completely understood. [129] Tang et al. (2013) used a carbon dot and folic acid system 
to monitor doxorubicin delivery in vitro by monitoring FRET. The energy transfer between 
CDs and DOX is easily detected and was used to quantify drug release. The direct coupling of 
PEG on the CD surface allowed DOX entrapment through π – π stacking and showed pH-
dependent release. Additionally, real-time monitoring of drug release was achieved in tissue 
(65 - 300 μm thickness) [130]. Mewada et al. (2014) used bovine serum albumin and folic acid 
(FA) to coat CDs for improved DOX delivery. Conjugates showed a high drug loading 
efficiency and pH-dependent release; combined with FA-mediated targeting, they showed 
great potential in therapeutic applications [131].  
 
Fig. 1.23 – FA-mediated uptake and targeting has been shown to be effective in treatments 
against cancer. DOX release is significantly improved after carrier internalization. Zhao et al. 
(2019) through the Creative Commons CC-BY license [128]. 
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Platinum-based cancer drugs are highly effective and currently used clinically in over 50% of 
patients. However, they are limited in efficiency in a similar manner to DOX: side effects due 
to unspecific accumulation in non-target tissue, rapid aggregation, low blood circulation 
lifetime, and drug resistance. Zheng et al. (2014) showed Oxaliplatin (IV) [Oxa(IV)] loading 
on CDs through EDC/NHS crosslinking could efficiently be reduced to Oxa(II) and produce 
significant cell death. Real-time monitoring the fluorescence from the conjugates allowed 
quantification of gradual drug release with low signal-to-noise ratios [132]. Feng et al. (2016) 
also demonstrated the benefits of dual responsive drug delivery systems by combining CDs 
with an RGD targeting ligand, monomethoxypolyethylene glycol (mPEG), and Cisplatin(IV). 
PEGylation ensured the conjugate was protected at neutral pH, while acidic conditions exposed 
the RGD peptide for enhanced tumour targeting capability in cells overexpressing αvβ3.  [133] 
Hollow CDs (HCDs) can be used to increase drug loading ratio 
HCDs have a display a similar amorphous carbon phase to CDs and an internal cavity with 
pores. It has been hypothesized that HCDs be used to increase drug loading efficiency as their 
surface area is larger. Wang et al. (2013) reported the synthesis of HCDs prepared from bovine 
serum albumin after increasing the time for the solvothermal reaction. Although DOX was 
adsorbed onto the surface, it showed a decreased loading ratio (6 wt.%) in comparison to other 
previously mentioned conjugates, as can be seen in Fig. 1.24. Nonetheless,  HCDs did not 
interfere in the pharmacodynamic activity of DOX and showed rapid drug release in acidic pH 
(<5) [134].  
Equally, Gong et al. (2016) reported hollow CDs (HCDs) with high drug loading capacity and 
demonstrated effective DOX complexing through electrostatic interactions. PNHCDs-DOX 
composites showed remarkable pH-sensitive release, with only ~3% release at physiological 
pH in comparison to 96% at pH 5 after a 24-hour period. Conjugates also showed increased 
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inhibition against cancer cell proliferation and similar in vivo efficiency in comparison to free 
DOX [135].  However, despite positive results HCDs have not yet achieved widespread use, 
possibly due to complications during synthesis and sample postprocessing.  
 
Fig. 1.24 – Phosphorus and nitrogen-doped hollow carbon dots entered cells through 
endocytosis and showed efficient doxorubicin release near nuclei. Reprinted with permission 
from Gong et al. (2016). Copyright (2016) American Chemical Society [135]. 
 
CDs can be used within multicomponent drug delivery systems 
In addition to nanoparticle-based systems, pH-responsive drug delivery has also been explored 
using other structures. Wang et al. (2017) showed the versatility of CD-DOX conjugates within 
chitosan nanogels for drug delivery with NIR and pH-triggered release.  Conjugates were 
shown to easily cross the blood-brain barrier due to their small hydrodynamic size (~78 nm) 
and surface charge (+20.2 mV). The mechanism of uptake is speculated to be adsorptive 
transcytosis due to similarities with chitosan or albumin-based nanocarriers. In vivo drug 
delivery was highly effective, with a significant reduction of tumour volume at day 18 post 
injection [136].  
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Inorganic compounds such as metal organic frameworks (MOFs) and nanoscale MOFs 
(NMOFs) have also been utilised for this application, taking advantage of their high porosity, 
tuneable properties, and tailorable structures; these highly crystalline and microporous 
structures such as zeolitic imidazolate frameworks (ZIFs) have high surface area and have been 
explored as drug carriers. He et al. (2014) reported the synthesis of C-dots@ZIF-8 
nanocomposites for pH-responsive delivery of chemotherapy drug 5-fluorouracil and 
bioimaging. Cumulative drug release after 48 hours was higher in acidic conditions (92% at 
pH 5.5) in comparison to physiological conditions (67% at pH 7) [137]. Interestingly, this work 
was extremely similar to that carried out by Xu et al. (2016) in which ZIF-8 was used as a 
carrier for DOX-loaded CDs in a one-pot reaction [138]. Fig. 1.25 shows ZIF-8 and the 
composite CDs@ZIF-8 are similar in surface chemistry but drastically different in 
photoluminescence. Fahmi et al. (2015) reported the synthesis of composites consisting of 
manganese ferrite nanoparticles (CM), CDs, and DOX for dual-mode MRI/fluorescence 
imaging and drug delivery. Drug-loaded composites (DCCM) was shown to enter cells through 
receptor-mediated endocytosis, with pH-selective drug release. Neutral conditions showed 
significantly reduced DOX release (22%) after 72 hours in comparison to acidic conditions 
(pH 5, 75% and pH 6, 60%)[139]. 
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Fig. 1.25 – CDs@ZIF-8 show similar photoluminescence and surface chemistry, indicating 
complexation. TEM images show ZIF morphology is not affected by CD/DOX loading. 
Adapted from Xu et al. (2016) with permission the Royal Society of Chemistry[138]. 
 
Photodynamic (PDT) and photothermal (PTT) therapy 
As previously described, PDT is an FDA-approved non-invasive cancer treatment which makes 
use of light-sensitive molecules called photosensitisers (PS) that accumulate in tissue. These 
compounds are capable of producing ROS under irradiation, leading to cell death in the 
affected area [140]. ROS production is the result of a PS passing from an excited triplet state 
after absorbing energy to a ground state, passing energy to nearby oxygen (Fig. 1.26). 
Likewise, PTT employs photoactive compounds to generate heat and ablate cancerous tissue 
[113]. These treatments have gained increased research interest due to their high specificity, 
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spatial-temporal selectivity due to light activation, and ease of application. 
Nanoparticle synthesis often leads to undesired outcomes such as surface contamination with 
salts, inconsistent functionalisation, and wide size dispersions, which can affect their 
properties. Furthermore, nanoparticles are dynamic, changing their behaviour constantly and 
depending on time after synthesis, environmental conditions such as temperature and humidity, 
and mode of storage. For example, silver nanoparticles were shown to “age”, with surface 
chemistry changing over time and subsequently leading to variations in toxicity after periods 
of 1-6 months of storage [141]. These changes are commonly not immediately apparent and 
are often not taken into account and reported in the literature, leading to issues with inconsistent 
and unreproducible results [142]. 
 
Fig. 1.26 – Schematic showing immune response to PDT. Irradiation causes PS excitation 
and producing ROS such as singlet oxygen (1O2). Continuous 1O2 production leads to cell 
damage and eventual death, inciting an immune response in the affected area. Reprinted from 
Hwang et al. (2018) through the Creative Commons CC-BY license [143]. 
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Drug loading strategies 
PS can be loaded through covalent crosslinking  
Covalent crosslinking is a common method for conjugating nanoparticles with other molecules. 
Reactions are varied and can be adapted for use with a wide variety of functional groups and 
include hydrazide-aldehyde, amine-carboxyl, thiol-maleimide, thiol-thiol, and gold-thiol 
bonding, among others. Fowley et al. (2015) showed covalent crosslinking could be used to 
conjugate CDs to protoporphyrin IX (PpIX), a porphyrin sensitizer used in PDT that produces 
singlet oxygen [144]. Amide crosslinking based on EDC/NHS (1-ethyl-3-(3-
dimethylaminopropyl)carbodiimide/N-hydroxysuccinimide) chemistry showed excellent 
results as it made use of the high density of carboxyl groups on CD surface to bind molecules 
at concentrations ranging from 10 to 30 μM, which can be seen in Fig. 1.27. Intriguingly, they 
observed a fluorescence resonance energy transfer (FRET) from CDs to PpIX. This likely 
caused quenching of CD-based fluorescence but did not significantly change to singlet oxygen 
production. 
 
Fig. 1.27 – Schematic representation of EDC/NHS crosslinking. Compound 1, containing 
carboxylic acid, is prepared for binding as an amine-reactive ester is formed. The 
intermediate o-acylisourea is protected from hydrolysis by NHS/Sulfo-NHS. Conjugation 
with a stable primary amine group leads to the formation of an amide bond. 
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Electrostatic interactions can increase loading efficiency 
In comparison, loading through electrostatic interactions is an easier and more cost-effective 
method of drug loading on CDs. Wu et al. (2018) used a tetraplatinated porphyrin complex 
(PtPor) bound to CDs by electrostatic interactions (CQDs@PtPor) to improve its solubility and 
cytocompatibility. Singlet oxygen production of CQDs@PtPor increased in comparison to 
PtPor, likely caused by decreased aggregation in water  [145]. In addition to the crosslinking 
strategies, other modifications can be made to improve or add properties to CDs based on 
external stimuli. Wu et al. (2015) evaluated the PDT efficiency of 5-aminolevulenic acid (5-
ALA), a precursor of PpIX, alongside CDs and triphenylphosphonium (TPP), a coumarin 
derivative which can target mitochondria. 5-ALA was bound to CDs through a photocleavable 
carbamate bond to enable intracellular release which can be triggered by one or two-photon 
excitation. Although two-photon irradiation was slightly less effective than single-photon, the 
increased tissue penetration and specificity for 5-ALA/PpIX makes it a valuable tool for PDT. 
However, the time required for 5-ALA release can vary from 10 minutes (5% release) to >120 
min (80% release), which may limit its effectiveness. Annexin V-FITC/PI staining confirmed 
the proapoptotic effect of PDT-induced cell death. Furthermore, it was shown that both violet 
(400-450 nm) and red (645-655 nm) light irradiation after 30 minutes were able to trigger 5-
ALA release through photolysis and cause significant cell death [146]. 
PS can be embedded within CDs through host-guest chemistry  
Host-guest encapsulation is the result of various non-covalent interactions arising from the 
entrapment of a “guest” molecule within a larger “host”, which envelops it. The formation of 
these complexes gives rise to new nanomaterials with intriguing properties that can be 
exploited for theranostic applications, which can be seen in Fig. 1.28 [148]. Typically, CDs are 
synthesized through microwave-assisted pyrolysis. The addition of a “guest” to the precursor 
solution allows CDs to form around these molecules, eventually encapsulating them. However, 
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only molecules which are not affected by synthesis temperatures can be used. Previously, CDs 
have been used as hosts red/near-NIR dyes cresyl violet (CV), Nile blue (NB), and zinc 
phthalocyanine (ZnPc) to enhance their optical properties while retaining water solubility and 
surface chemistry [148]. Zheng et al. (2016) fabricated a host-guest embedded CD composite 
(CyCD) with the hydrophobic cyanine dye CyOH [2-((E)-2-((E)-2-chloro-3-((E)-2-(1-(2-
hydroxyethyl)-3,3-dimethylindolin-2-ylidene) ethylidene)cyclohex-1-en-1-yl)vinyl)-1-(2-
hydroxyethyl)-3,3-dimethyl-3H-indol-1-ium iodide] alongside PEG800 for PTT. CyCDs 
showed improved dispersibility in media and high photothermal conversion efficiency (38%) 
under 808 nm laser irradiation. Furthermore, composites exhibited significantly reduced dark 
toxicity caused by CyOH uptake and could be detected using NIR imaging [67].  
 
Fig. 1.28 – Host-guest encapsulation of Nile Blue (NB) and Zinc phthalocyanine (ZnPc) 
within CDs changes optical properties, enhancing emissions in red and NIR regions. Adapted 




He et al. (2018) also showed host-guest embedding with CDs significantly improved 
diketopyrrolopyrrole (DPP) solubility in water. Singlet oxygen production in DPP CDs was 
approximately 26.7%, which was very similar to that of free DPP at 31.2%. Confocal 
microscopy showed conjugates entered cells primarily through endocytosis and escaped 
lysosomes, residing in the cytoplasm. DPP CDs showed high cytocompatibility (IC50 = 820 
μg/ml) in the absence of light irradiation. In vivo PDT experiments demonstrated a significant 
reduction of tumour size after irradiation with a 540 nm laser [149]. Li et al. (2017) also 
synthesised photosensitiser-loaded CDs in a one-pot reaction using chitosan and mono-
hydroxylphenyl triphenylporphyrin (TPP-CDs). This composite material shows larger and 
more hydrophobic compounds can be effectively incorporated into the amorphous carbon core 
of CDs while maintaining its single oxygen production and other photophysical properties. 
Irradiation with 625 nm light (16 mW/cm2, 1 hr) showed significant cell death in vitro after 
internalization through endocytosis [150]. The above results confirm guest CyOH and DPP 
molecules are capable of PTT and PTT even while embedded within a carbon core. 
Additionally, CD-based fluorescence can be used for image-based diagnosis in vivo after 
composite accumulation, improving treatment efficiency. 
Treatment efficiency may vary according to loading strategy  
Previous studies have demonstrated the effectiveness of CD-based conjugates for PDT. 
However, it is unclear which loading strategy is preferable to use as both covalent crosslinking 
and host-guest chemistry have shown exceptional results. Aguilar Cosme et al. (2019) 
demonstrated the versatility of CDs as carriers by fabricating two different protoporphyrin IX 
(PpIX) conjugates based on amide crosslinking (PpIX-CD) and host-guest embedding 
(PpIX@CD). Conjugates were loaded with 34-48% PpIX and were capable of efficient singlet 
oxygen production after loading. Additionally, conjugates showed decreased aggregation in 
water compared to free PpIX due to the abundant hydrophilic groups on the CD surface. 
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Furthermore, PpIX-CD and PpIX@CD demonstrated an equivalent PDT effect in C8161 
melanoma cells to PpIX at lower concentrations and decreased dark toxicity. [151] 
Interestingly, there was no significant difference between crosslinked and host-guest 
encapsulated conjugates. However, host-guest chemistry required greater control over the 
reaction conditions to ensure homogeneity and reproducibility. In contrast, amide crosslinking 
yielded more consistent results but suffered from low product yield and increased cost due to 
the additional reaction and purification steps required for fabrication.  
PDT uptake and efficiency benefit from targeting 
As previously stated, targeted drug delivery using carrier systems has been shown to improve 
PDT treatment efficiency. Small molecule targeting has several advantages such as ease of 
linkage, stability, and low cost. Choi et al. (2014) synthesised folic acid-coated PEG-CDs and 
successfully loaded ZnPc through - interactions (CD-PEG-FA/ZnPc) to improve PDT. HeLa 
cells showed rapid CD-PEG-FA/ZnPc and CD-PEG-FA internalization in comparison to CD-
PEG particles, which did not enter cells despite prolonged incubation. Conjugates displayed 
comparable singlet oxygen yield to ZnPc after cell lysate was added to the cell culture, likely 
due to the competitive displacement of ZnPc from conjugates to other biomolecules [152].  
Beack et al. (2015) reported similar results, demonstrating the effectiveness of chlorin e6 (Ce6), 
CD and hyaluronate (HA) composite for improved transdermal delivery. This system took 
advantage of the overexpressed HA receptors on cancerous tissue to improve targeting and 
uptake. Amide coupling was used to bind ce6 and HA to CDs in two different reactions. 
Improved solubility and singlet oxygen generation was observed in conjugates, with Ce6 and 
Ce6-CD conjugates did not show significant phototoxicity after irradiation, suggesting HA-
mediated endocytosis significantly improved intracellular uptake. Fig. 1.29 shows how Ce6-
CD-HA conjugates increased transdermal delivery in mice with B16F10 cancer cells [153]. 
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Fig. 1.29 – Ce6 was conjugated with CDs and covered with hyaluronic acid to improve 
dispersibility in water and improve tissue penetration. NIR excitation enabled transdermal PS 
activation. Reprinted from Beack et al. (2015) with permission from Elsevier [153]. 
 
Nonetheless, the ultrasmall size of CD-based conjugates may not always ensure binding to 
extracellular domains for receptor-mediated endocytosis. Multivalent targeting, or the use of 
multiple targeting moieties, could increase the affinity between both molecules and ensure 
rapid uptake.  
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CDs may possess intrinsic cell targeting 
Although there have been many reports of targeting molecules being used in CD-based 
systems, CDs may also possess inherent targeting abilities for different organelles. Hua et al. 
(2014) fabricated CDs with intrinsic passive mitochondria tracking and formed a composite 
with photosensitiser Rose Bengal. Although compounds such as TPP can be used for 
mitochondria targeting, there are concerns regarding their cytotoxicity and lack of tracking 
capabilities. Unlike previously described conjugates, Rose Bengal was conjugated through 
DCC/HOBt chemistry. CDs showed better performance compared to the commercially 
available MitoTracker Green dye commonly used for staining. Furthermore, the loading 
efficiency of Rose Bengal was determined to be 12.5%, with singlet oxygen production and 
decreased aggregation being observed after conjugation. CDs-RB showed efficient PDT effect 
after irradiation with a 532 nm laser at intensities ranging from 10 – 50 mW/cm2 for a total of 
5 minutes [154].  
Huang et al. (2012) demonstrated nucleus-targeting CDs could be used to improve the 
photosensitizer fluorescence detection (PFD) of Ce6. This system is capable of direct and 
indirect Ce6 excitation through FRET.  Confocal microscopy confirmed conjugate uptake and 
accumulation near the nuclei using the characteristic Ce6 fluorescence peaks as reference. CD-
Ce6 also showed low cytotoxicity and high laser-triggered phototoxicity. Mice with 
subcutaneous MGC803 gastric cancer xenografts showed rapid compound accumulation and 
NIR fluorescence imaging was used to monitor PDT in vivo. The fluorescence intensity was 
used to estimate the optimal time for PDT (based on particle accumulation): 8 hours post 
injection paired with 671 nm laser excitation. Conjugation with CDs alone improved both the 
circulation lifetime and the tumour uptake through the EPR effect [155]. However, the exact 
mechanism by which CDs exhibit targeting is unclear, though it appears to be passive in nature 
as opposed to active. 
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PDT in hypoxic microenvironments requires nitric oxide 
PDT efficiency in hypoxic microenvironments is a challenging prospect primarily due to low 
oxygen availability for ROS production and low light penetration into tissue. Nitric oxide (NO) 
based treatments have seen success in these cases, bypassing the need for oxygenation. Fowley 
et al. (2015) continued their previous work by demonstrating hypoxic tumours could be treated 
using CDs loaded with a nitroaniline derivative NO photodonor by irradiation with NIR light 
at 800 nm, shown in Fig. 1.30. The main advantage of this system is the coupling of CDs in 
order to use FRET for two-photon based excitation of the photodonor, as their absorption 
windows typically are outside the therapeutic window (650 – 1350 nm). NO release was not 
significantly affected after conjugation and there was no evidence of aggregation in water. 
BxPC-3 induced tumours in mice were shown to be susceptible to two-photon activated NO 
release [156].  
 
Fig. 1.30 – Schematic representation of CD and NO photodonor linking. Nitric oxide can be 
produced in environments with low partial oxygen pressure. Reprinted from Fowley et al. 
(2015) with permission from the Royal Society of Chemistry [156]. 
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In situ oxygen production is also an alternative for improving photosensitiser efficiency in 
hypoxia. Jia et al. (2018) synthesised a new conjugate by combining CDs (Mn-CD) formed by 
manganese (II) phthalocyanine (Mn-Pc) alongside 1,2-Distearoyl-sn-glycero-3-
phosphoethanolamine-poly(ethylene glycol) (DSPE-PEG).  Mn-CDs showed catalytic activity 
in the presence of H2O2, generating oxygen and improving PDT effectiveness. The manganese 
within the phthalocyanine can also be used to detect conjugate accumulation through bimodal 
fluorescence/magnetic resonance imaging. Mn-CDs showed red-shifted absorption spectra due 
to the aromatic moieties of Mn-Pc. DSPE-PEG increased colloidal stability in water, phosphate 
buffered saline (PBS), and serum-supplemented Dulbecco’s Modified Eagle’s Medium 
(DMEM). Irradiation with a 635 nm laser produced significant cell death in vitro and in vivo, 
with an enhanced PDT effect in hypoxia confirming the catalytic activity of Mn-CDs [157].  
NIR absorption can overcome light scattering in tissue 
Light scattering within deep tissue is a key limiting factor in PDT as efficiency is directly tied 
to the amount of energy that can be delivered efficiently. Indirect photosensitiser excitation is 
a strategy that has been used to compensate for the low red-NIR absorption of some 
compounds, although it is limited due to their low two-photon cross section of many dye-based 
PDT agents. In comparison, CDs have a cross section around three orders of magnitude higher, 
making them ideal carriers for a PDT nanocomposite system. Fowley et al. (2013) 
demonstrated CDs could effectively be loaded onto CDs for PDT through indirect excitation 
via FRET. Singlet oxygen was shown to be generated through both one and two-photon 
irradiation and conjugates remained stable in a wide range of pH values. PpIX-loaded CDs 
exhibited significantly reduced dark toxicity and enhanced PDT effect, possibly due to the 
decreased intracellular aggregation [144].  
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Composite nanomaterials can improve CD-based conjugates in PDT 
CD synthesis with one-pot reactions in contact with organic and inorganic materials have 
produced novel composites with intriguing photophysical properties that can be used in 
biomedical applications. Zheng et al. (2016) also showed carbon nitride (C3N4) doped CDs 
(PCCN) bound with PpIX and targeting peptide RGD could be used for efficient PDT in 
hypoxic cell microenvironments. Carbon nitride is capable of water splitting, which was used 
to increase the oxygen concentration upon light irradiation at 630 nm (Fig. 1.31). This 
enhanced the cancer killing capabilities of PpIX, with PCCN showing positive results 
compared to PpIX when used in an oxygen concentration of 1% in comparison to the 
physiological levels of 2 – 13%. Oxygen production was shown to be faster than consumption 
through PDT. In vivo biodistribution showed preferential uptake in tumour tissue, decreased 
accumulation in nonspecific tissue, and improved PDT efficiency [158].  
 
Fig. 1.31 – Alternate strategies for PDT in hypoxic environments can make use of other 
nanomaterials, such as carbon nitride. Water-splitting produced enough oxygen in hypoxic 
regions for effective PDT with PpIX. Reprinted with permission from Zheng et al. (2016). 
Copyright (2016) American Chemical Society [158]  
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Combination of PDT and PTT can produce a synergistic effect 
Embedded compounds maintain their specific properties while benefitting from increased 
cytocompatibility and hydrophilicity in a similar manner to host-guest encapsulation. Wang et 
al. (2014) combined the functionality of magnetic iron (III) oxide (Fe3O4) nanocrystals and the 
low cytotoxicity of CDs to form a multifunctional composite capable of multimodal imaging, 
PTT, and drug delivery. The mesoporous shell of the nanoparticles allowed high efficiency 
loading of doxorubicin to form a dual anticancer treatment, which could be released with or 
without NIR excitation. However, composites were shown to have slightly high dark toxicity 
at concentrations over 40 μg/ml. Nonetheless, a combination treatment of DOX with PTT 
significantly reduced cell viability and was able to be used alongside magnetic resonance 
imaging [159].  
Guo et al. (2018) used transition metal doping with copper (CuII) through N-Cu-N 
complexation to endow CDs with NIR absorption, photothermal conversion, and singlet 
oxygen production capabilities according to the amount of Cu present in the particle (Cu,N-
CDs). Changes in the hydrothermal synthesis significantly affected the PDT/PTT properties as 
they are likely linked to both particle size and surface chemistry. Fig. 1.32 shows the 
mechanism for simultaneous PDT/PTT in CDs. NIR absorption was achieved by increasing 
the available Cu content on the CD surface and 808 nm laser excitation (1 W/cm2) showed both 
singlet oxygen production and photothermal conversion [160]. Peng et al. (2018) utilised the 
photothermal conversion ability of Prussian blue nanoparticles (PBNPs) along with the 
hydrophilicity of CDs to form conjugates for enhanced PDT and imaging. CD/PBNPs showed 
a slightly deformed cubic shape, with Fe2+–CN–Fe3+ functional groups on their surface. 
CD/PBNPs did not show significant cytotoxicity at concentrations of up to 0.6 mg/ml and in 
vivo blood chemistry tests did not find any adverse effects. In vitro and in vivo PTT with 808 
nm laser irradiation showed effective cell killing and tumour ablation after 10 minutes as 
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temperature increased up to 55 °C due to the high photothermal conversion (30%) [161]. Nandi 
et al. (2017) used CDs to improve the cytocompatibility of tungsten disulphide (WS2) nanorods 
for PTT and bioimaging. WS2-CDs showed increased colloidal stability in water and blue-
shifted fluorescence after covalent conjugation. Composites also showed increased 
cytocompatibility in comparison to WS2 and other similar metal chalcogenide structures. PTT 
was carried out using a 700 nm laser and verified by observing the Raman shift at the 
characteristic peak for WS2 (352 nm)  [162]. 
 
Fig. 1.32 – Photoactivation with an 808 nm NIR laser of copper-doped CDs can produce a 
simultaneous PDT and PTT effect. Adapted from Guo et al. (2018) with permission from 
Elsevier [160]. 
 
Variations in synthesis lead to CDs capable of PDT/PTT  
CDs have been shown to have extremely heterogeneous photophysical properties which are 
affected by a multitude of factors including the fabrication route and reagents, leading to 
changes in surface chemistry and size. Recently, CDs have been shown to be capable of PDT 
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and PTT effects as red and near-infrared emissions were achieved. Ge et al. (2016) fabricated 
CDs capable of singlet oxygen production and photothermal conversion under laser irradiation 
at 635 nm. CDs showed very high photostability and sustained singlet oxygen production. 
Photothermal conversion was also shown to be effective, with a maximum of 50 °C reached 
after 10-minute irradiation (635 nm, 2 W/cm2). Dual PDT/PTT treatments showed significant 
cell death in comparison to single PDT or PTT groups. HeLa-bearing nude mice showed 
accumulation of CDs in tumours, kidneys, and liver within 10 hours post injection. Although 
the combined PDT/PTT effect from CDs was not sufficient to cause complete tumour ablation, 
tissue damage was apparent through the appearance of scar tissue [163]. However, variations 
in synthesis conditions can also lead to changes that can affect therapeutic efficiency in vivo, 
such as stability in serum. Jia et al. (2017) designed a CD-based nanosphere (CDNS) through 
ionic self-assembly in the presence of sodium dodecylbenzenesulphonate and passivated with 
(PEG)-NH2. These CDs are capable of singlet oxygen production but suffer from inefficient 
accumulation in target tissue and low circulation lifetimes in blood. [164].  
PTT-capable CDs have also been used as part of a hybrid system for simultaneous PDT/PTT. 
Sun et al. (2019) utilised ce6 and red-emissive CDs (RCDs) capable of photothermal 
conversion to form composites (Ce6-RCDs).  Ce6 was conjugated on RCDs through an amide 
condensation reaction and showed broad absorption up to the NIR region along with effective 
singlet oxygen production. Cell viability assays demonstrated high efficiency even at low laser 
power intensity (671 nm, 0.5 W/cm2). Additionally, ce6-RCDs also showed potential as 
multimodal bioimaging with fluorescence, photoacoustic imaging, and photothermal-guided 
imaging. The laser-triggered PDT/PTT treatment combined with imaging-guided treatment 
makes this strategy highly interesting [165]. Although reproducibility is a key factor as many 
of these effects are size and surface-dependent, the prospect of CDs as a new type of PDT/PTT 
agents is highly interesting due to their excellent stability and cytocompatibility. 
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Gene delivery 
Gene delivery has a wide variety of applications such as antisense and RNAi therapy in addition 
to cell transfection with plasmid DNA (Fig. 1.33). There have been various systems for 
delivery that have been investigated, which can be separated into three main categories: 
modified siRNA, viral vectors, and non-viral vectors. Although viral vectors show very high 
efficiency, there are various concerns regarding the immunological response caused by residual 
viral elements. In contrast, non-viral vectors can be designed with biocompatible materials with 
tuneable properties to enhance gene delivery. These systems need to be capable of preventing 
degradation, serum inactivation, and be capable of nuclear targeting [166]. Carriers have 
typically been based on positively charged polymer or lipid carriers such as polyethyleneimine 
(PEI25k) due to their facile binding to DNA and advantageous intracellular trafficking leading 
to rapid uptake. However, these systems are typically highly cytotoxic as their delivery 
efficiency increases. This is possibly caused by the interaction of cationic compounds to 
mitochondria which cause impaired function and ultimately cell death [167]. 
 
Fig. 1.33 – Gene delivery typically makes use of a vector or carrier to aid cellular uptake 
while avoiding degradation. Reprinted from Begum et al. (2019) through the Creative 
Commons CC BY license [168]. 
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DNA and RNA effectively bind to cationic CDs 
Carrier systems using nanoparticles have seen increasing research interest as efficiency reaches 
or even surpasses the current gold standards for gene delivery, such as Lipfectamine2000. Cao 
et al. (2018) used cationic CDs to condense gene plasmid SOX9 (pSOX9). CD/pSOX9 
transfection showed a significant change in chondrogenic differentiation after delivery to 
mouse embryo fibroblasts [169]. Zhou et al. (2016) utilised a different approach for CD 
synthesis, using alginate as both a carbon source and cationization agent. CD/pDNA complexes 
showed equivalent transfection efficiency to Lipofectamine2000 and significantly more than 
PEI, while maintaining high water solubility and cytocompatibility. Composite internalization 
was shown to begin through caveolae and clathrin-mediated endocytosis. As mentioned 
previously, weight ratios under 20:1 (CD/pDNA) showed significantly increased delivery 
efficiency [170].  Furthermore, modification of surface chemistry through other chemical 
reactions has been shown to be highly efficient at increasing DNA binding affinity. Dou et al. 
(2015) demonstrated PEI-functionalised CDs could be used for simultaneous antimicrobial 
properties and gene delivery capabilities. Particles were further modified using benzyl bromide 
to quaternize the amine groups on the surface for increased bactericidal effect against gram-
negative bacteria. Quaternary linear PEI passivated CDs showed increased inhibition of both 
Gram positive (E. coli) and negative  (S. aureus) bacteria at a minimum inhibitory 
concentration of 16 μg/ml. Quaternization also improved the gene transfection capability of 
CDs by a factor of 104-fold after optimising loading ratios [171]. 
Carriers can shield genetic material and prevent degradation 
The degradation of genetic material before arrival in the target site significantly impacts 
effectiveness. Nanoparticles have been previously used to circumvent these limitations by 
providing protection while maintaining low toxicity. Kim et al. (2017) utilised PEI-passivated 
CDs for siRNA (short interfering RNA) delivery through electrostatic interactions. CD/siRNA 
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complexes protected the cargo from ribonuclease-mediated degradation, prolonging the 
circulation lifetime and delivery efficiency. In vitro studies demonstrated rapid intracellular 
uptake and low cytotoxicity within HeLa and MDA-MB-231 cells. Furthermore, in vivo gene 
silencing experiments showed efficient GFP knockdown and tumour growth inhibition. Real-
time fluorescence imaging was used to observe the gradual intracellular siRNA release over a 
period of 12 hours [172]. Liu et al. (2019) also used a protein crosslinker sulfosuccinimidyl 4-
(N-maleimidomethyl)cyclohexane-1-carboxylate (sulfo-SMCC) to bind siTnf and CDs for 
the enhancement of chondrogenesis in mesenchymal stem cells (MSCs). CD-SMCC-siTnf 
showed reduced inflammatory response after MSC transfection and effective gene silencing as 
siRNA was protected from nucleases. This system was shown to be more cytocompatible and 
stable in comparison to bPEI25k. Additionally, an in vivo mouse model showed positive results 
in cartilage defect healing [173]. Fig. 1.34 shows siRNA delivery in real time could be achieved 
using CDs as additional imaging probes. 
 
Fig. 1.34 – Fluorescence imaging was used to monitor real-time siRNA uptake in human 
mesenchymal stem cells. While fluorescein-labelled siRNA was used, this system could be 
utilised with only CD-SMCC fluorescence. Reprinted from Liu et al. (2019) through the 
Creative Commons CC BY-NC-ND license [173]. 
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Shell-based systems have also shown great success as controlled release can be adjusted to 
react in different environmental cues. Zhao et al. (2018) used hyperbranched PEI end-capped 
disulfide-bond-bearing hyperbranched poly(amido amine) (HPAP) functionalised CDs for 
improving TNF-related apoptosis-inducing ligand (TRAIL) gene delivery. An outer shielding 
layer of mPEG-PEI600 increased the circulation lifetime of the composite. The HPAP shell can 
be degraded by glutathione, triggering intracellular DNA release in target cells. Furthermore, 
dimethlymaleic acid (DMMA) was used to form a charge-convertible particle (PPD@HPAP-
CDs/pDNA) by covalently binding it to mPEG-PEI600. Complexes showed in vivo tumour 
growth inhibition and high cytocompatibility with PPD@HPAP-CDs/pDNA obtaining the 
highest efficiency [174]. 
CD surface chemistry impacts gene delivery through surface charge 
CD-based gene delivery systems primarily make use of electrostatic interactions for DNA 
loading, taking advantage of high cationic functional group density on CD surfaces. Liu et al. 
(2012) fabricated PEI-functionalised CDs for plasmid delivery making use of the branched 
amine-rich polymer to bind DNA in a one-pot reaction. This system was shown to be capable 
of condensing DNA at very low concentrations but was affected by zeta potential variations as 
synthesis conditions were adjusted. Longer reaction times showed decreased gene delivery 
efficiency, possibly due to the destruction of amine groups leading to faster DNA degradation 
while bound to PEI-CDs. PEI-CD-DNA complexes showed more efficient delivery and lower 
toxicity in comparison to pristine PEI25k [50]. Wang et al. (2017) showed similar results with 
carbon dots used for plasmid DNA and siRNA delivery. CDs were modified using 2-
((dodecyloxy)methyl)oxirane to produce amphiphilic particles (ACDs) which were able to 
condense plasmid DNA at an ACD/DNA ratio of 4:1, whereas non-modified PEI-CDs were 
not capable of this even at an 8:1 ratio. ACDs were shown to have significantly higher 
transfection efficiency than commercially-available reagent Lipofectamine 2000. [87]  
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Inorganic and supramolecular structures have been shown to work in tandem with CDs to 
improve their properties for gene delivery. Cheng et al. (2014) grafted poly[2-(dimethylamino) 
ethyl methacrylate]-b-poly[N-(3-(methacryloylamino) propyl)-N,N-dimethyl-N-(3-
sulfopropyl) ammonium hydroxide] (PDMAEMA-b-PMPDSAH) to CDs through surface-
initiated atom transfer radical polymerization (ATRP) to fabricate a gene delivery system (CD-
PDMA-PMPD), which is detailed in Fig. 1.35. DNA condensation was achieved in weight 
ratios of 0.8 to 1.2, with an average particle zeta potential of 30 mV. Furthermore, this 
conjugate demonstrated reduced protein adsorption and increased transfection efficiency in 
comparison to PEI25k, which was adversely affected by increasing protein concentration in 
media. [175].  
 
Fig. 1.35 – ATRP was used to graft zwitterionic polymers onto CDs, functioning as 
multicolour imaging probes with high DNA condensation efficiency. Outer layers protected 
DNA from degradation and nonspecific interactions. Transfection efficiency was improved 
13 to 28-fold in comparison to lipofectamine 2000. Reprinted with permission from Cheng et 
al. (2014). Copyright (2014) American Chemical Society [175]. 
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Similarly, Das et al. (2015) compared chitosan/amine functionalized silica nanoparticles 
(ASNPs) and CDs as carriers to compensate for the low half-life of dsRNA. CDs were 
passivated using PEI which allowed highly effective siRNA complexation and loaded with 
SRC and SNF7 genes, shown in Fig. 1.36. These samples showed the best results in A. aegypti 
larvae transfection compared to ANSPs. CDs were found to retain 100% of dsRNA up to 72 
hours after loading regardless of pH and particles could be tracked in vivo using fluorescence 
imaging systems [176]. 
 
Fig. 1.36 – siRNA-loaded CDs showed fast complexation, retention, and effective gene 
silencing in mosquito larvae compared to chitosan and silica-complexed siRNA. Reprinted 
with permission from Das et al. (2015). Copyright (2015) American Chemical Society [176]. 
  
Targeted delivery with CDs as carriers can reduce immune response 
Gene delivery with nanoparticles can reduce or eliminate the immune response found with viral 
vectors. In some cases, this strategy can be more efficient as larger payloads can be 
administered. Targeted delivery can be used to further improve this as it improves cargo release 
within a specific site [177]. Jaleel et al. (2019) utilised folate-functionalised CDs to decorate 
graphene-reinforced chitosan nanoparticles coated with diamine PEG for tumour-targeted 
delivery of pDNA containing Tnf. CDs were shown to be effective at guiding the conjugate 
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and could be used to monitor uptake in real time [178]. Wu et al. (2016) used a similar 
approach, with folate-conjugated CDs passivated with PEI for siRNA delivery. Simultaneous 
siRNA loading and intracellular delivery was confirmed using EGFR and cyclin B1 in H460 
lung cancer cells. A synergistic gene silencing effect was observed when loading both siRNAs 
in comparison to single-loaded particles. In addition, nude mice bearing H460 tumours showed 
growth inhibition after aerosol-based delivery of nanoparticles, as inhalation rapidly led to 
accumulation within the lungs [179]. 
Bioimaging for detection of successful gene delivery 
Image-based detection of gene delivery has been shown to be highly successful at evaluating 
DNA/RNA internalization and accumulation within specific cells. Gene-carrying vectors with 
fluorescence can be used to monitor gene uptake in real-time and elucidate more specific 
mechanisms of nanoparticle trafficking using tools such as confocal laser scanning microscopy 
(CLSM). Its high spatial resolution combined with multiple imaging modes for fluorescence 
probes has been used to resolve gene delivery in both human cells and animal tissues up to a 
single-particle level [180]. Therefore, highly fluorescent imaging probes capable of gene 
delivery are suitable for this application. Pierrat et al. (2015) fabricated CDs with high quantum 
yield with bPEI25, a hyperbranched cationic polymer, for improving pulmonary nucleic acid 
delivery. Compared to PEI/plasmid-based transfection, CDs showed similar efficiency and 
cytotoxicity. However, bPEI25k/siRNA complexes caused significantly more cell death 
compared to CD/siRNA. This suggests CD surface chemistry and synthesis protocol play an 
important role in toxicity. Nonetheless, CD/pDNA complexes showed enhanced transgene 
expression in vivo compared to bPEI25k. They also displayed an equivalent efficiency to the 
cationic lipid formulation GL67A, which is considered to be a gold standard for transfection 
[181].  
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Likewise, Hu et al. (2014) fabricated CDs with extremely high quantum yields (54.3%) for 
EGFP plasmid delivery. It was shown that the loading weight ratio was a key factor in the 
improvement of transfection efficiency as CD/DNA complexes were formed [182]. 
Fluorescence-based imaging can also be useful for quantifying cargo release at various time 
points. Noh et al. (2013) used negatively charged CDs to form covalently bound conjugates 
with a double-stranded DNA oligonucleotide to monitor miRNA124a expression during 
neuronal differentiation in vitro using fluorescence imaging. The fold expression change was 
obtained by comparing total fluorescence intensity at various timepoints in CHO cells at 
concentrations up to 100 pmol [183]. 
CDs doped with heteroatoms show higher loading efficiency. It has been shown that CDs can 
be doped with heteroatoms to improve their existing properties or introduce new ones. Nitrogen 
and phosphorus doping have been used to increase CD photoluminescence by introducing 
additional surface defects, while simultaneously conferring a positive charge suitable for 
loading DNA/RNA [184].  
Wang et al. (2018) evaluated the effect of nitrogen/phosphate ratios in CDs on siRNA loading. 
Cy3-labelled siRNA was shown to be increasingly more effective as the N/P ratio was 
increased. The available siRNA was completely complexed by CDs at a 20:1 ratio [185]. Zuo 
et al. (2018) synthesised fluorine-doped CDs (F-CDs) from tetrafluoroterephthalic acid and 
branched PEI. Fluorination has been previously shown to decrease the surface energy of 
cationic polymers, making electrostatic interactions more favourable at lower concentrations. 
EGFP transfection efficiency was shown to increase two-fold after fluorine doping. 
Additionally, it was shown that the incorporation of fluorine atoms in aromatic rings increased 
F-CD fluorescence without compromising the electrostatic interactions for gene delivery. F-
CDs showed improved stability and carrying efficiency in high serum concentrations and low 
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DNA concentrations, outperforming both Lipofectamine2000 and PEI25k (Fig. 1.37) [186].  
 
Fig. 1.37 – Fluorine-doped CDs showed improved gene delivery efficiency compared to 
undoped CDs (UCDs) and the gold standard lipofectamine 2000. Reprinted with permission 
from Zuo et al (2018). Copyright (2018) American Chemical Society [186]. 
 
Bioimaging 
Advantages of CDs as bioimaging probes 
Biomedical imaging has seen great advances as nanotechnology has been used to fabricate new 
contrast agents with exceptional performance. Multimodal imaging has grown as a tool for 
medical diagnosis as contrast agents can be simultaneously detected through techniques such 
as magnetic resonance imaging (MRI), fluorescence microscopy, or computed tomography 
(CT). Luminescent nanoparticles are poised to be an integral part of a new generation of 
theranostics systems, integrating therapy, imaging, and diagnosis. Nanoparticle-based probes 
have several advantages including increased stability in physiological conditions, resistance to 
photobleaching, high quantum yield, and resistance to degradation. Conventional dyes are 
severely limited by their rapid bleaching and low water solubility in addition to increased 
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toxicity after intracellular uptake [187]. 
Photoluminescence in CDs varies according to synthesis conditions 
Intrinsic fluorescence is one of the most important properties of CDs and has attracted research 
interest since they were first reported. Their photoluminescence has been shown to be a 
multifaceted process affected by the amorphous carbon core with sp2 hybridization and C=O/C-
N functional groups (Fig. 1.38). Surface passivation with polymers like PEG and PEI, or with 
small molecules like EDA have been shown to efficiently enhance photoluminescence in CDs 
and can be readily linked to other bioactive molecules [188].  
Zhai et al. investigated the role of various passivating agents in the amine/carboxyl ratios of 
microwave-synthesized CDs. Quantum yield was shown to increase with total reaction time, 
though overheating the solution led to the destruction of many surface functional groups, thus 
lowering photoluminescence [53]. Guo et al. (2018) made use of an oil/water interface based 
on CuSO4-H2O2 catalytic-oxidation to control CD surface chemistry during synthesis. This 
allowed them to obtain more control over their photoluminescence, though the use of styrene 
could limit their solubility in water [189]. While surface passivation is certainly useful, non-
passivated CDs can also exhibit improved quantum yields. Bhunia et al. (2013) demonstrated 
the effect of pristine CD photoluminescence based on synthesis temperature. They were able 
to fabricate CDs with distinct emission maxima using the same reagents, with quantum yields 
ranging from 6 – 30% [190].  
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Fig. 1.38 – CD photoluminescence is excitation-dependent and increased with PEG1500N 
passivation. Multicolour PL can be observed after excitation at various wavelengths using a 
ban-pass filter. Adapted with permission from Sun et al. (2006). Copyright (2006) American 
Chemical Society [191]. 
 
Multiphoton imaging with CDs 
Multiphoton imaging is another key area of opportunity for CDs, as they intrinsically possess 
high two-photon cross sections. This property has been used to extend their capabilities within 
bioimaging applications, particularly in confocal laser scanning microscopy [192]. Yang et al. 
(2009) showed CDs could be readily used as imaging probes with both single and two-photon 
excitation. Their efficiency as contrast agents was determined to be similar to commercially 
available CdSe/ZnS PEG-functionalised quantum dots while showing high cytocompatibility 
and photostability [46]. In addition to multiphoton imaging, high-intensity NIR femtosecond 
lasers have also been used to indirectly excite loaded molecules through FRET [130,153,156].  
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Tuneable photoluminescence is influences by multiple factors  
Nonetheless, multicolour tuneable photoluminescence in CDs has been difficult to achieve due 
to limited control over surface chemistry and nanoparticle dimensions. Lu et al. (2014) utilised 
a rapid screening approach for CD synthesis based on the variation of synthesis conditions and 
reagents using a microreactor. Their evaluation of 89 combinations of reagents, time, and 
temperature indicated that these factors do not cause a significant change in 
photoluminescence. However, it was determined that the addition of nitrogen-containing 
compounds effectively improved quantum yield [193]. There have been reports indicating 
specific reagents can be used to obtain blue, green, or red emission. Jiang et al. (2015) observed 
variations in CDs fabricated using three phenylenediamine isomers [o‐phenylenediamine 
(oPD), m‐phenylenediamine (mPD), and p‐phenylenediamine (pPD)]. Solvothermal synthesis 
using the same conditions led to drastically different PL spectra, with green (oPD-CDs), blue 
(mOPD-CDs), and red (pPD-CD) emissions obtained at 365 nm excitation [194]. Likewise, 
Meiling et al. (2016) observed the use of Tris-acetate buffer with starch as a precursor greatly 
improved CD quantum yield. They also observed an increase in absorbance as reaction time 
was increased from 5 to 120 minutes [195]. 
Near-infrared (NIR) and infrared (IR) imaging with CDs 
Imaging of tissue is typically difficult due light scattering in tissue and low depth penetration. 
The use of the NIR windows NIR-I (700-900 nm) and NIR-II (1000-1900 nm) circumvents 
these limitations, providing substantially decreased tissue autofluorescence and scattering, 
leading to better signal-to-noise ratios [196].  CDs typically have very poor absorption in the 
NIR/IR region, with the bulk of absorbance centred in the ultraviolet and near ultraviolet (<400 
nm). Huang et al. (2013) circumvented this limitation by coupling CDs to the NIR dye ZW800. 
CD-ZW800 showed similar absorption peaks to ZW800 and demonstrated good stability in 
serum-supplemented media, suggesting longer circulation lifetime in vivo [61]. Geng et al. 
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(2018) used a different strategy to improve CD absorption in the NIR region by introducing 
pyrrole and graphitic structures, with N-O-CDs showed a quantum yield of 16.1% (Fig. 1.39) 
[197]. However, this strategy inevitably leads to sample variability as there is no way to 
differentiate between CDs containing introduced moieties. Tao et al. (2012) reported red-
emissive CDs after oxidizing the by-products of carbon nanotubes and graphite. Although CD 
photoluminescence is decreased with red or NIR excitation, tissue autofluorescence is reduced 
even further, leading to a much higher signal-to-noise ratio [37]. 
 
Fig. 1.39 – N-O doped CDs show strong NIR absorption due to the presence of pyrrolic and 
graphitic residues on surface edges. IR imaging and PPT were shown to be effective using an 
808 nm laser at the absorption maxima. Reprinted from Geng et al. (2018) with permission 
from Elsevier [197].  
 
Heteroatom doping significantly increases CD quantum yield 
Doping with different elements has also been used to great success to increase CD quantum 
yield, with amine-containing compounds being routinely used in many methodologies due to 
its simplicity and low cost, as can be seen in Fig. 1.40. Other elements have also been utilised 
as dopants for these nanoparticles, such as phosphorus and bromide. Zhou et al. (2014) 
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demonstrated phosphorus could form surface defects on the CD surface as a result of its larger 
size, affecting photoluminescence. QY was shown to be highly dependent on both 
quinine/phosphorus bromide ratios and total reaction time. However, phosphorus-doped CDs 
showed reduced photostability in comparison to pristine CDs [54].  
 
 
Fig. 1.40 – CDs are versatile and can be doped with complexed iron ions before synthesis. In 
vitro and in vivo imaging can be done due to their excellent water dispersibility and 




Likewise, Parvin and Mandal (2017) synthesized CDs with exceptionally high quantum yield 
(30% in green, 78% in red). P-doped CDs showed high efficiency in fluorescence microscopy 
and photoacoustic imaging in mice [55]. The co-doping of phosphorus and nitrogen has been 
linked with increased graphitization in the carbon core. Gong et al. (2015) demonstrated that 
this increase leads to higher red-shifted emissions as a result of more prevalent -conjugation 
and lowered bandgap. XPS and FT-IR analysis confirmed the presence of phosphate functional 
groups on the CD surface and showed variable fluorescence emission in different pH values 
[199]. Nonetheless, there is no consensus on optimal doping ratios to achieve consistent 
increases in photoluminescence. 
Photon upconversion (UC) is misattributed to CDs 
The conversion of long wavelength light (NIR/IR) to short wavelength light (visible) is known 
as photon upconversion (UC). UC-capable nanoparticles offer numerous advantages as they 
take advantage of the therapeutic window in biological tissue: background fluorescence from 
tissue is reduced and lower light intensities are needed in comparison to two-photon excitation 
[200]. Although CDs have been frequently cited to be capable of UC, there are conflicting 
reports throughout the literature [5,42]. It is unclear how carbonaceous nanoparticles can 
achieve single photon upconversion and the exact mechanism has not yet been elucidated. Wen 
et al. (2014) determined previous experimental setups did not consider the second order 
diffraction from the fluorometer light source. The lack of a long pass filter would cause a false 
fluorescence signal as lower-wavelength light leaks and hits the sample [201].  Despite this, 
multiple new publications continue to state CD upconversion is possible without the use of 
other compounds. 
Lanthanides (Ln), also known as rare earth metals, are metal ions capable of efficient UC and 
have been widely used as the main components in UC nanoparticles. Wu et al. (2016) did not 
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observe UC in Yb+3 and Nd+3-doped CDs, though doping showed strong photoluminescence 
emission at 998 nm and 1068 nm, respectively. Ln-doped CDs did not show significant toxicity 
up to around 500 μg/ml. Interestingly, neither Yb+3 or Nd+3 affected the amorphous carbon 
core of CDs [202]. Chen et al. (2016) synthesised Eu+3-doped CDs to improve optical 
properties, with Eu-CDs showing two distinct emission peaks at 460 nm and 600 nm. High 
resolution TEM images demonstrate CDs lack any crystal lattices [203]. Likewise, Zhang et 
al. (2016) found europium and terbium doping improved CD photoluminescence, showing a 
similar dual emission behaviour when irradiated with 360 nm light. Furthermore, they observed 
CD fluorescence was more resilient to pH changes in comparison to Eu+3 [204].  
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Conclusions and outlook 
In this review the current trends in CDs and CD conjugates within biomedical applications 
including evaluation of their cytotoxicity, drug delivery, gene delivery, and bioimaging were 
detailed. Since their discovery in 2004, CDs have moved past from being considered 
newcomers to the field of carbon nanomaterials to become a highly versatile and useful 
component for a multitude of applications. Since then, CDs have been shown to be highly 
convenient nanoparticles because of their tuneable photoluminescence, cytocompatibility, and 
surface chemistry. There has been great progress in the development and refinement of 
synthesis strategies, use of alternative reagents, passivating agents, and dopants, leading to 
enhanced optical properties.  
However, there are still many factors that have yet to be completely understood, despite great 
advances in understanding their photophysical properties. Reports from the literature have 
shown that PL and low cytotoxicity are a result of a combination of factors, from synthesis 
conditions to carbon precursors and passivation. Furthermore, the limitations on product yield, 
nonstandard purification methodologies, and variable batch reproducibility limit comparison 
between different CD conjugates. Nonetheless, current research has shown these nanoparticles 
are a viable alternative to established materials such as semiconductor quantum dots, graphene, 
graphene quantum dots, and metallic nanoparticles.  
Biomedical applications have seen generally positive results from in vivo toxicological and 
biodistribution studies, though in vitro cytotoxicity studies have shown great variation. There 
are ongoing concerns regarding their long-term toxicity after administration, which need to be 
addressed before further advancement into clinical use. Nevertheless, the use of different in 
vivo models such as nematodes and zebrafish has improved our understanding on particle 
biodistribution, blood circulation lifetime, and renal clearance. Equally, 3D cell culture models 
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and CAM assay have shown the importance of conjugate evaluation prior to further in vivo 
testing as the effect of CD loading through various mechanisms such as cross-linking or host-
guest chemistry on conjugate efficiency is unclear.  
Conjugates have continuously demonstrated high efficiency as part of drug delivery platforms 
in PDT/PTT, chemotherapy, and antimicrobial applications. Recent progress has also included 
CDs capable of ROS production and photothermal conversion and enhanced 
photoluminescence. Drug loading has been shown to be possible with many standard 
compounds such as doxorubicin, protoporphyrin IX, and chlorin e6 through different 
conjugation strategies. Tailoring of surface chemistry has significantly improve, with gene 
delivery demonstrating better performance in comparison to the gold standards in the field 
because of high loading ratios and low toxicity in cationic CDs. Bioimaging with CDs as probes 
has seen great advances as heteroatom doping, host-guest chemistry, and synthesis 
methodologies have produced particles with high quantum yields and NIR/IR emission, 
enabling their use as platforms for theranostics. 
Most studies in the field of CD conjugates have been concentrated on the synthesis of new 
composites and their subsequent in vitro evaluation. In vivo studies have also become widely 
used alongside cell culture to evaluate acute toxicity and bioimaging. This has led to the 
fabrication of numerous carefully designed and increasingly more complex drug delivery 
systems with increased therapeutic efficiency for PDT, PTT, and chemotherapy. However, 
very few studies have directly compared CD-drug conjugates to determine the effect of drug 
loading strategies on therapeutic efficiency. Likewise, conjugate evaluation has been focused 
on cell monolayers and murine models with limited studies carried out in other models such as 
cancer spheroids. Future work should focus on 1) increasing reproducibility during synthesis 
and conjugation and 2) improving in vitro/in vivo toxicological evaluation. 
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In the following chapter, the synthesis and drug loading of CD conjugates is discussed. 
Microwave reactor synthesis was selected as the fabrication route as this approach has shown 
consistent results and is the most widely used in the literature. PpIX was bound to CDs through 
two strategies: host-guest encapsulation (PpIX@CD) and amide cross-linking [PpIX-CD and 
(PpIX-CD)p]. Dialysis before and after crosslinking was shown to be a crucial step in sample 
post-processing to ensure higher product yields. Conjugates were characterized with various 
analytical techniques. Samples showed 34 - 48% PpIX loading efficiency and similar singlet 
oxygen production to PpIX for all samples. Host-guest embedding with various loading ratios 
showed diminishing PpIX content as initial concentration was increased. (PpIX-CD)p appeared 
to be the best candidate due to its high singlet oxygen production. In contrast, PpIX-CD and 
PpIX@CD showed increased water solubility. Results indicated newly synthesized CDs could 
produce a PDT effect through activation with 405 nm irradiation. 
In Chapter 3, in vitro PDT was evaluated in a C8161 human melanoma cell line. Ultra-low 
fluence was selected to prevent possible PpIX photobleaching. Dark toxicity was evaluated at 
1 - 100 µg/ml. Conjugates all demonstrated a 6 to 7-fold decrease in toxicity compared to PpIX. 
These values were used to determine the best concentration range for phototoxicity evaluation 
(1 - 10 µg/ml). PpIX-CD and PpIX@CD showed a 3.2 to 4.1-fold increase in photo-toxicity 
index (PI) at concentrations >1 µg/ml. In contrast, (PpIX-CD)p showed a significantly reduced 
PDT effect in all conditions. Confocal microscopy showed rapid intracellular uptake of 
conjugates near the nucleus. Results demonstrated an enhanced PDT effect from conjugates to 
the control at equal PpIX concentrations. 
In Chapter 4, multicellular spheroids were used to evaluate previously obtained PDT 
parameters from cell monolayers. Spheroids are a 3D cell culture model capable of replicating 
in vivo tumour morphophysiological conditions such as hypoxia, tissue depth, drug resistance, 
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and variable diffusion rates. Previous PDT conditions were shown to be ineffective with low 
damage to spheroids. Hence, fluence rates (2.5 - 10 J/cm2) and doses (1 – 10 μg/ml) were 
adjusted. Furthermore, fractionated light treatments were introduced to take advantage of 
sensitization to PDT over longer incubation periods. Viability was measured through LDH 
release and DNA quantification assays. Spheroids showed significant cell death and loss of 
sphericity after treatment. Light sheet microscopy was used to observe PDT-induced damage 
and determine conjugate penetration throughout spheroids. Results showed conjugates 
maintained equivalent PDT efficiency at relative PpIX concentrations. 
Finally, Chapter 5 details the use of automated parameter extraction through computer-assisted 
image processing to monitor PDT in spheroids. Spheroid morphology has been previously 
stated to be related to viability, though the exact parameter was unclear.  Results showed 
various parameters are relevant for different experiment stages. Spheroid variability was shown 
to be linked to sphericity in the days following seeding. Pre-screening individual spheroids 
significantly reduced variability between experimental groups. Total spheroid surface area was 
shown to be the most important indicators of spheroid viability. Furthermore, it was shown that 
this parameter could be used to screen unsuccessful PDT conditions, being capable of 





Chapter 2 - Synthesis and characterization of CDs and CD-PS conjugates 
Introduction 
The previous chapter established CD-based conjugates have great potential in drug delivery 
for PDT. A systematic literature review identified that drug loading strategies for CD-PS 
conjugates have not been directly compared to determine the best approach to increase PDT 
efficiency. In this chapter, a systematic comparison of the efficiency of three novel CD-PS 
conjugates: PpIX-CD, (PpIX-CD)p, and PpIX@CD, obtained through different crosslinking 
strategies was undertaken. 
Photodynamic therapy 
Photodynamic therapy (PDT) has seen advances in recent years as an alternative cancer 
treatment due to its non-invasive nature, specificity and selectivity  [205].  The term “PDT” 
describes a range of protocols based on the excitation of photosensitizers (PS) in the presence 
of oxygen to singlet oxygen (1O2) leading to tumour ablation [206]. PDT has been proven to 
be clinically effective presenting positive results in basal cell carcinoma, endobronchial lung 
cancer, and non-muscle invasive bladder cancer [207–209]. Highly controlled light dosimetry 
and rapid drug uptake maximizes the effectiveness of the treatment and prevents damage to 
surrounding tissue [210]. 
Although some have also grouped sensitizers as being first, second or third generation, this has 
caused confusion as to their differences (Fig. 2.1). Huang et al. (2005) stated that in many 
cases, newer drugs are not immediately better than previous ones due to a variety of factors 
[212]. Therefore, when discussing new photosensitising molecules, novelty does not equal 
higher efficiency. The characteristics of a good photosensitizer depend on the perspective with 
which we evaluate them. The clinical approach is primarily focused on various aspects related 
to toxicity and pharmacokinetics.  
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PS administration and treatment should ideally not produce any additional harmful by-
products, possess an NIR/IR excitation wavelength for maximum tissue penetration, and be 
selectively accumulated within the target tissue (with minimal toxicity to the rest of the 
organism). These are among the nineteen points proposed by Allison et al. (2004) for clinically 
relevant guidelines in determining the usefulness of a photosensitizer [213]. In comparison, a 
chemistry-focused approach emphasises the importance of a high quantum yield and high 
singlet oxygen production efficiency, as well as low dark toxicity as key photosensitizer 
properties [214]. Nonetheless, both publications highlight that the most important quality of a 
PS is its efficient activation in tissue – an effect that is mainly related to the absorption 
wavelength of the photosensitizer.  
 
Fig. 2.1 – Porphyrins and phthalocyanines are well-known PS families. The abundance of 
pyrrole groups and facile modification has led to many the formation of numerous derivatives 




Nanoparticle-photosensitizer conjugates have received increased interest due to several 
advantages such as; (i) large surface-volume ratios for increased loading efficiency, (ii) the 
formation of amphiphilic compounds to avoid aggregation, and (iii) the enhanced permeability 
and retention effect for increased accumulation in tumours due to “leaky” vasculature [215–
217]. Moreover, conjugates can also function as bioimaging probes to form multifunctional 
theragnostics platforms through photodynamic diagnosis (PDD) [218]. Porphyrins are 
naturally occurring heterocyclic molecules composed of pyrrole rings connected by 
methylylidene bonds. These molecules are found in living organisms acting as electron and 
oxygen transporters or metalloenzymes through the chelation of metal ions by coordination. 
PS-loaded conjugates are also capable of ROS production and subsequent cancer killing effect 
after light exposure (Fig. 2.2). 
 
Fig. 2.2 – Schematic detailing PDT mechanism. Reactive oxygen species produced by 
photosensitizers lead to cell death and eventual tumour ablation. Reprinted from Hong et al. 
(2016) through the Creative Commons CC BY-NC-ND license [211]. 
Protoporphyrin IX (PpIX) is a well-characterised endogenous porphyrin photosensitizer, 
normally present in minor concentrations within cells as part of the heme biosynthesis pathway. 
Dormant cancer cells have been proven to accumulate high concentrations of PpIX and are 
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more susceptible to PDT [167]. However, PpIX is limited as a photosensitizer mainly due to 
elevated dark toxicity and rapid aggregation. This leads to decreased photoactivity as singlet 
oxygen production is attenuated [220,221]. Recent advances have focused on utilising carriers 
and chemical modifications to improve water solubility and increase cellular viability [222]. 
For example, Homayani et al. (2015) demonstrated that hydroxyl-group modification can 
increase the water solubility of PpIX, reducing dark toxicity and increasing cellular uptake  
[222]. 
CD conjugates as photosensitisers 
CDs have shown similar success in biomedical applications in comparison to other 
nanomaterials such as semiconductor quantum dots, nanodiamonds, graphene, and carbon 
nanotubes [3,71,100,223]. Nanoparticle-based drug delivery has been shown to improve 
intracellular drug uptake and reduce the likelihood of cargo degradation. [97]. The rapid 
intracellular uptake of CDs and CD-based conjugates has been shown to be time and dose-
dependent and is a combination of both passive uptake and caveolae and clathrin-mediated 
endocytosis [224]. Moreover, CDs can be further modified by doping with heteroatoms and 
surface passivation with a variety of molecules such as polyethylene glycol to achieve better 
photophysical properties [225]. CDs have previously been used as carriers for a wide variety 
of compounds, including doxorubicin, rhodamine B, dsDNA, siRNA and ciprofloxacin 
hydrochloride [119,176,226–228].   
CDs have tuneable photoluminescence ranging across the visible spectrum which depends on 
their synthesis conditions, affecting quantum yield, determining excitation-dependent or 
independent emission, and type of photoluminescence decay [229]. In vitro studies 
demonstrate rapid intracellular uptake and do not show significant toxicity even at extremely 
high concentrations [53]. In vivo and ex vivo imaging in BALB/c mice show similar results 
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with no observable toxicity and rapid clearance from the reticuloendothelial system  [69]. 
Furthermore, CDs have previously demonstrated comparable two-photon cross-sections to 
those of commercially-available quantum dots, making them highly valuable as probes for 
bioimaging applications [192]. 
Drug loading strategies for enhanced PDT 
Recently, CD-PS crosslinking has recently gained research interest. CDs have extremely high 
surface area to volume ratios which make them ideal candidates for drug loading and cross-
linking. There are several different types of crosslinking corresponding to the type of bond that 
is formed: physical bonds between molecules are primarily electrostatic and hydrophobic 
interactions, which are non-covalent and thus easily broken. In comparison, chemical linking 
forms covalent bonds between molecules, which provides a more rigid link and prevents their 
separation while increasing stability [230]. Most crosslinking methods are highly specific to 
functional groups and ensure correct linking orientation, preventing homodimer formation.  
Carbodiimide chemistry, also known as EDC/NHS chemistry, is based on the formation of a 
peptide bond between a primary amine and a carboxyl. It is especially useful as there are not 
many compounds that are able to react with carboxyl groups. EDC (1-Ethyl-3-(3-
dimethylaminopropyl) carbodiimide) is a compound that forms an o-Acylisourea ester in the 
presence of a carboxyl. This intermediate group is unstable in water and can suffer hydrolysis, 
returning it to its original state.  It can also react with a primary amine to form a peptide bond, 
realising isourea as a secondary product. EDC is highly water-soluble and can be used by itself 
for crosslinking. The use of NHS (N-Hydroxysuccinimide) or sulfo-NHS (N-
hydroxysulfosuccinimide) results in a stable ester that can resist drying and is reactive to 
amides. This series of reactions are widely used in crosslinking proteins, nanoparticles and 
other molecules [231]. Photosensitizers such as chlorin e6, Rose Bengal and PpIX have been 
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previously covalently linked through carbodiimide chemistry, the latter of which showed a 
PDT effect under two-photon excitation [144,153,232]. Similarly, recent advances have shown 
embedded photosensitizers are capable of singlet oxygen production while embedded on 
nanoparticles [148,150]. 
CD formation and synthesis 
The process by which carbon dots are formed is a combination of carbonization and nucleation. 
Dissolved molecules in the solution become rapidly oxidized and decompose, with nucleation 
beginning simultaneously [21]. Fu et al. (2015) developed a model using three different 
aromatic compounds (anthracene, pyrene and perlyene) within a poly (methyl methacrylate) 
matrix to mimic the optical properties found in carbon quantum dots. The results demonstrated 
that absorbance was influenced by the molar percentage of each PAH, indicating that the 
amorphous carbon core also increases photoluminescence as surface defects were introduced 
[233]. Absorbance changes after CD formation can be easily seen, as the solution passes from 
a transparent liquid to shades of pale yellow, up to black [234]. There is also a distinct odour 
that is likely due to the formation of polycyclic aromatic hydrocarbons (PAH) within the 
solution. These compounds are formed during incomplete combustion and have multiple 
benzene rings [235].  
Synthesis routes have advanced substantially from the initial arc-discharge reaction that led to 
their discovery. CDs can be fabricated through both top-down and bottom-up approaches, as 
can be seen in Fig. 2.3. These include laser ablation [237], microwave-assisted pyrolysis [238], 
combustion [239], arc-discharge [1], solid-state carbonization [240], electrochemical oxidation 
[241], and acid reflux [242], among others. The use of a one-pot reaction is beneficial as the 
cost-efficiency is generally higher; production yields can be increased with less quantity of 
reagents and purification can be achieved with less intermediate phases. The production of CDs 
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can be stated to be a completely “green synthesis” methodology, if the particles are produced 
from biomatter or simple carbohydrates. Furthermore, most synthesis protocols do not use 
additional solvents or contaminating agents such as heavy metals [243].  
 
Fig. 2.3 – CD synthesis is highly versatile. Fabrication of samples can be top-down: 
produced from a pre-existing structure such as carbon allotropes, or bottom-up: based on the 
pyrolysis of organic compounds. Reprinted from De et al. (2017) with permission from the 
Royal Society of Chemistry [236].  
It has been shown that each fabrication method influences physical and optical properties of 
the nanoparticles, including particle size, surface functionality and photoluminescence. 
Deionised water is the most common aqueous medium for CD synthesis and typically yields 
particles with negative zeta potential and high hydrophilicity. On the other hand, hydrophobic 
CDs have been reported by means of using different aqueous media such as ethanol [244] and 
dimethylformamide [245]. Ionic liquids have also been used as precursors to simultaneously 
fabricate hydrophilic and hydrophobic CDs in a one-pot reaction [246].   
Microwave synthesis, also known as microwave chemistry, is the use of microwave radiation 
to produce a chemical reaction and has been an invaluable research tool for the synthesis of 
new compounds. The use of microwaves has several advantages over other related CQD 
synthesis methods. The heating by microwaves does not depend on thermal conductivity, 
leading to a variety of thermochemical reactions caused by differential absorption of 
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microwaves and variable dielectric heating rates [247].  
Although reactions can take place within commercial microwaves, specialised reactors have 
been shown to yield much better results for nanoparticle synthesis. There are several additional 
disadvantages to utilizing commercial microwave ovens. This is mainly due to the variability 
that is caused by the microwave itself, as it was not designed to reliably reproduce heating 
conditions. Aside from external modifications, there is no method of dependable measurement 
of temperature and pressure. Microwaves are also randomly directed within the equipment, 
resulting in uneven heating of the solution and localized “hot-spots” [248]. Finally, the lack of 
a cooling mechanism results in the shutdown of the machine, preventing lengthy reactions as 
the equipment overheats. These conditions severely limit the usefulness of a domestic 
microwave, and as such it has been mostly displaced by specialized microwave synthesizers.  
Microwave reactors can conduct organic and inorganic synthesis in a highly controlled 
environment, increasing experimental reproducibility. The high pressure and continuous 
stirring of the solution during the reaction, combined with the instantaneous and homogeneous 
temperature increase results in more reproducible reactions compared to the uneven heating 
and low temperature thresholds found in commercial equipment. This aspect becomes more 
important as the cost of the materials used increases, as is the case with lanthanide-doped 
nanoparticles. However, there are limitations to the use of microwave reactors. The most 
notable is the relatively smaller reaction volumes that must be used. Reaction vessels for 
microwave reactors are typically in the 5 – 25 ml range as higher volumes are difficult to 
manage because of the pressure within [249]. Thus, microwave-assisted pyrolysis was selected 
out of the possible fabrication routes for its ease of access, low cost, adaptability, and reliability. 
Additionally, hydrothermal synthesis was evaluated as a possible synthesis route for increasing 
product yield per reaction. Fig. 2.4 shows a general scheme for CD conjugate synthesis. 
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Fig. 2.4 – CD conjugates were synthesised with two distinct loading strategies. Host-
guest encapsulated (PpIX@CD) samples were produced in a one-pot reaction. CA-EDA CDs 
were used to produce amide bond-linked (PpIX-CD and (PpIX-CD)p) conjugates. S-EDA 
CDs were embedded with PpIX in a one-pot encapsulation step. 
 
Aim: Fabricate carbon dot-protoporphyrin IX conjugates capable of efficient singlet oxygen 
production. 
Objectives: 
 Determine the best synthesis route for obtaining nitrogen-doped CDs with high yield 
and reliability. 
 Select CD samples based on strongest photoluminescence and advantageous surface 
chemistry for crosslinking using primary amine groups (-NH2). 
 Improve amide crosslinking and host-guest encapsulation of PpIX with CDs. 
 Assess conjugate photophysical properties including singlet oxygen production and 




In the following section, all chemicals were obtained from Sigma Aldrich, UK unless stated 
otherwise. The vessels used for measurement and reactions were of inert material. In all 
synthesis routes, CDs were prepared using sucrose or citric acid as a primary carbon source 
and ethylenediamine as a passivating agent and nitrogen source. Varying passivating 
agent/carbon source ratios (w/w) were tested. All reagents were dissolved prior to heating in 
deionised water at room temperature. 
Citric acid monohydrate, sucrose, ethylenediamine, protoporphyrin IX, sodium chloride, 
resazurin sodium salt, (N-(3-Dimethylaminopropyl)-N’-ethylcarbodiimide), N-
Hydroxysuccinimide, formaldehyde, phenalenone, 2-(N-Morpholino) ethanesulfonic acid, 
acetone, dimethyl sulfoxide, 2-mercaptoethanol and N,N-dimethylformamide were acquired 
from Sigma Aldrich (United Kingdom). Dulbecco’s Modified Eagle’s Medium (DMEM, high 
glucose), Dulbecco’s Modified Eagle’s Medium (DMEM, high glucose, without phenol red), 
foetal bovine serum (FBS), phosphate buffer saline (PBS), and trypsin – 
ethylenediaminetetraacetic acid solution were obtained from Thermo Fisher (United 
Kingdom). Syringe filters with a 0.2 μm pore size were acquired from Sarstedt (United 
Kingdom). 1 kDa molecular weight cut-off (MWCO), 6.4 ml/cm dialysis tubing was acquired 
from Spectrum Labs (United States of America). All chemicals were used as received unless 
stated otherwise. Deionized water was used for all buffers and samples in experiments. Septa 
steel ring caps and 35 ml glass reaction vessels were obtained from CEM Corporation (United 
Kingdom). 
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Carbon dot synthesis 
Domestic microwave synthesis 
A Daewoo KOR-6L65 domestic microwave (700 W maximum power) was used to fabricate 
carbon dots. The carbon source and passivating agent were mixed in a 100 ml deionised water 
in a glass beaker. This solution was placed in magnetic stirring until no more powder could 
dissolve in the aqueous phase. The beaker was then transferred to the microwave and heated 
for 3,5, and 10 minutes until a visible colour change was observed. CDs were moved using 
safety gloves and allowed to cool until reaching room temperature. 
Microwave reactor synthesis 
CA-EDA CDs were synthesized utilising 5 g of citric acid and 1.25 g of EDA dissolved in 
100 ml of deionized water and stirred until no visible precipitate remained. This process was 
repeated for S-EDA CDs with 5 g of sucrose and 1.25 g EDA. A CEM Discover SP microwave 
reactor was used to heat the precursor solutions for 5 minutes at constant 150°C (200 W 
maximum power and 17 bar threshold). The resulting yellow-coloured solution was cooled to 
room temperature using nitrogen and centrifuged at 5000 rotations per minute (rpm) for 30 
minutes to remove debris from carbonization.  
Host-guest embedding 
Host-guest encapsulated CDs were synthesised through this method. All samples were obtained 
by adding an additional reagent to the carbon and nitrogen source mixtures, typically in ≥1% 
w/w ratios.  
PpIX-based conjugates (PpIX@CD) were fabricated by adding 50 mg PpIX to the previously 
mentioned sucrose solution. Additional stirring was used to properly mix all components 
before pyrolysis. Reaction parameters were also adjusted to high stirring speed. 
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Dimethylformamide (DMF) was used as a solvent instead of water to produce PpIX@CD-
DMF, synthesized by mixing 5 g of sucrose, 1.25 g EDA, 75 ml deionised water and 75 ml 
DMF. Additionally, the quantity of PpIX was adjusted to produce various conjugates at 
different w/w ratios (0.1 – 2%). Likewise, a variety of compounds were tested for host-guest 
embedding in addition to PpIX: heparin, Nile blue, and naphthol green. These were added in 
the same ratios as PpIX and were pyrolysed with the standard parameters. 
Hydrothermal synthesis 
CDs were synthesised using a Series 4760 300 ml general purpose non-stirred pressure vessel 
(Parr Instrument Company, United States) fitted with a thermocouple (part no. A472E). In 
summary, 5 g of citric acid or sucrose were added to 1.25 g ethylenediamine and dissolved in 
100 ml deionised water. The solutions were placed in glass jars for transport. Synthesis was 
carried out by heating the vessel with an isomantle up to 140 – 200 °C for 6 hours. The solutions 
were left to cool until reaching room temperature. 
Sample processing 
The solutions were centrifuged at 2000 rpm for 10 minutes to eliminate remaining insoluble 
ashes from the water. This step was repeated as many times as necessary for each solution. The 
CD-containing liquid was dialysed against deionised water using a pre-wetted Spectra/Por 6 
dialysis tubing made from regenerated cellulose (Spectrum Labs, United States of America). 
The membrane has a 1 kDa molecular weight cut off (MWCO) and is capable of carrying up 
to 6.4 ml/cm of liquid. The dialysis membrane was stored in 0.05% sodium azide solution when 
not in use.  
A 2L or greater glass beaker was filled with deionised water and placed under the lowest 
possible magnetic stirring speed (200 rpm). Around 15 – 20 cm of tubing was used taken and 
fitted with clips to prevent sample leaking. A glass pipette was used to carefully transfer the 
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CD solution to the membrane.  Deionised water was replaced every 2 hours or when an 
appreciable colour change was observed. In total, all samples were dialysed for 48 hours. 
Afterwards the solutions were transferred to plastic containers and placed in storage at -80° C. 
A Labconco Triad freeze-drying system removed the remaining water, using the following 
parameters: -10°C shelf temperature, -60°C collector temperature, 0.1 mbar internal vacuum 
pressure, 0.5 degrees per minute, 48-hour main drying step. Each solution was frozen in 20 ml 
portions to maximize surface area and enhance sublimation. An additional drying step was 
performed, with the equipment slowly equalising the samples to room temperature. The powder 
samples were collected and weighed prior to storage at -20 °C. Silica gel packets were used as 
an additional desiccant for stored powders at room temperature.  
Amide crosslinking 
Standard protocol 
The standard protocol for amide crosslinking is used mainly with proteins. Briefly, 1 mg/mL 
PpIX was dissolved in 1 mL 0.1 M 4-morpholinoethanesulfonic acid (MES) at pH 4.5-5 and 
thoroughly mixed. 0.4 mg (1-ethyl-3-(3-dimethylamino) propyl carbodiimide, hydrochloride 
(EDC) and 0.6 mg N-hydroxysuccinimide (NHS) were added to the solution and left to react 
for 15 minutes in the dark. EDC was quenched with 1.2 μl 2-mercaptoethanol. Subsequently, 
1 ml of a 1 mg/mL solution of CDs were added and allowed to react at room temperature for 8 
hours. The reaction was quenched with hydroxylamine and the conjugates were recovered via 
dialysis. 
Modified crosslinking protocol 
The following protocol for amide crosslinking was adapted from Yildiz et al. (2010) and 
Fowley et al. (2013). [144,250] All containers were protected from light to prevent bleaching 
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as PpIX is a light-sensitive compound. 100 mg of PpIX was added to 20 ml dimethylformamide 
(DMF) and placed in stirring (200 rpm) until completely dissolved. Afterwards, 25 mg EDC 
(6.25 mM) and 50 mg NHS (21.72 mM) were added to the solution, which was left stirring for 
30 minutes. 100 mg CDs (citric acid / ethylenediamine) were added to 20 ml deionised water, 
stirred until completely dissolved, and added to the PpIX solution. The solution was left stirring 
overnight and transferred to a separate beaker. The same processing procedure was used for 
conjugates, with centrifugation removing insoluble PpIX and dialysis removing excess 
reagents and waste. After centrifugation, the pellet was suspended in deionised water and 
considered a separate sample. Samples were freeze-dried and stored for further use. 
Characterisation 
Ultraviolet-Visible (UV-Vis) spectroscopy  
UV-Vis spectra were obtained using a Varian Cary 50 spectrophotometer (Cary Instruments, 
United States). Conjugates were diluted in deionised water to 5 μg/ml prior to measurement 
and subjected to ultrasonic processing to break up aggregates. The equipment was calibrated 
before each use according to the manual and the same deionised water was used as a blank for 
the measurements. A total of 2.5 ml of diluted conjugate was placed within a disposable 
polystyrene cuvettes of 4.5 ml volume and 10 mm path length (Fisher Scientific, United 
Kingdom). Absorbance was measured in the range of 250 – 750 nm. 
Fluorescence spectroscopy 
A Fluoromax 4 spectrofluorometer (Horiba Ltd., Japan) was used to obtain fluorescence 
spectra from samples. Conjugates were diluted as previously stated. Deionised water was used 
to calibrate the equipment prior to use. A quartz cuvette (3.5 ml volume and 10 mm path length) 
was filled with 3 ml of solution. Fluorescence was measured in the range of 350 – 750 nm with 
various excitation wavelengths. 
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PpIX content was estimated according to a previously established method by Gunter et al. 
[251]. In summary, PpIX was diluted to 0.4, 0.8, and 1.6 μg/ml solutions in deionised water. 
The emission of the solution was measured (λex = 400 nm, λem = 658 nm) and fitted using linear 
regression. CD emission at λex = 400 nm was subtracted from all samples to estimate the PpIX 
content of conjugates. 
Fourier-transform infrared spectroscopy (FTIR) 
Infrared spectra were obtained with a Nicolet iS50R FT-IR in photoacoustic mode. Powdered 
samples were carefully placed onto the crystal and pressed firmly to ensure contact in the 
sample holder. Spectra were obtained as either survey (16 measurements) or complete (512 
measurements) in the range of 4000 – 450 cm-1. Samples were recovered for further use and 
stored as detailed previously. 
Transmission electron microscopy (TEM) 
A Tecnai G2 Spirit transmission electron microscope (FEI Company, United States) was used 
to obtain images. Conjugates were diluted as previously detailed, with aggregates being 
removed with a UP50H ultrasonic probe (Hielscher Ultrasonics GmbH, Germany) prior to 
imaging.  Using a micropipette, 10 μl drops of conjugates dilutions were placed onto copper 
coated TEM grids (SPI Supplies, United States) and left to dry at room temperature for 1 
minute. Images were obtained magnifications ranging from 18,500 to 68,000×. 
Singlet oxygen generation 
This method was replicated from a previous paper by McKenzie et al. (2017) [252]. 
Phenalenone was used as a reference compound to indicate 95% singlet oxygen generation. 
Conjugates were dissolved in DMF and subsequently diluted to an absorbance value of 0.1 (± 
0.01) at 355 nm. A Q-SW Nd:YAG 355 nm laser (Ls-1231M LOTISII 2006 model) was used 
to irradiate the samples with 8 ns pulses with 50, 100, and 200 mJ. This was repeated 4 times 
 135
per power and solution to generate an average singlet oxygen decay signal. An InGaAs 
photodiode 3 mm active area (J22D-M204-R03M- 60-1.7, Judson Technologies, United States) 
coupled with a digital oscilloscope (TDS 3032B Tektronix, United States) and a high-contrast 
bandpass filter fitted on the front of the detector (1277 nm centre wavelength, 28 nm FWHM, 
custom-made by Izovac, Belarus) were used to detect the decay of singlet oxygen (1O2) to 
triplet oxygen (3O2). The corrected initial amplitudes were obtained with the following 
equation: 




Subsequently, singlet oxygen generation was calculated with the corrected initial amplitudes 
for all samples and reference with the following equation: 
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X-ray photoelectron spectroscopy (XPS) 
X-ray photoelectron spectroscopy (XPS) analysis was carried out with a monochromated Al-
kα X-ray source, two analysis points per sample and a total scan area of 700 x 300 μm using 
an Axis Ultra DLD system (Kratos Analytical, United Kingdom). 5 mg of conjugate powder 
samples were mounted on between indium foil and a paper label to mitigate the risk of 
differential charging. Survey scans were collected in the range of 1200 to 0 eV binding energy 
(160 eV pass energy, 1 eV intervals, and 300 seconds per sweep – with 4 sweeps collected). 
High-resolution C 1s spectra were collected at 20 eV pass energy and 0.1 eV intervals. The 
influence of indium foil on each sample was removed considering a surface composition of 
26.8 at% O, 19.4 at% In, and 53.8 at% C. 
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Thermogravimetric analysis (TGA) 
Sample analysis was carried out using a Q50 analyser (TA Instruments). Briefly, approximately 
1 mg of sample was placed on a platinum sample holder, which was cleaned with acetone. CDs 
and conjugates were heated at 10 °C/min from room temperature until reaching 1000 °C. After 
each run, the sample holder was cooled, cleaned, and set up for the next analysis.  
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Results and discussion 
Domestic microwave and hydrothermal synthesis 
Synthesis conditions were not suitable using the domestic microwave 
CDs were first synthesised using a domestic microwave to pyrolyze carbon-containing 
compounds dissolved in water at maximum power for 1 – 10 minutes. A variety of carbon 
sources were selected for CD synthesis from those previously used in the literature 
[55,149,253] (Table 2.1). While sucrose (S) and citric acid (CA) have high solubility in water, 
chitosan required an acetic acid solution and additional mixing time. The solutions changed 
colour during pyrolysis, from pale yellow to dark black with an oil-like residue. This colour 
depends on factors such as the amount of precursor within the solution, the type of carbon 
source, reaction, and heating rate. Sucrose and citric acid samples showed effective 
decomposition at 3 and 5 minutes, producing amber to black CD suspensions. Solutions 
containing chitosan were more difficult to handle and produced significantly more char than 
CA and sucrose samples. The solution may smell sweet due to formation of compounds as 




Table 2.1 - Compounds used for CD synthesis 






Sucrose Carbon source Disaccharide 342.30 g/mol C12H22O11 N/A 





60.10 g/mol C2H8N2 8 °C 
Polyethylenimine Branched 
polymer 





380 - 480 
g/mol 
C2nH4n+2On+1, 4-8 °C 
Protoporphyrin IX Cargo Porphyrin 562.66 g/mol C34H34N4O4 >350 °C  
 
Reaction times greater than 5 minutes showed a rapid evaporation of the water and eventual 
char formation. Likewise, samples with over 5 grams total of combined reagents rapidly 
formed aggregates which coalesced at the bottom of the beaker. Char formation could be 
slightly decreased as the concentration of carbon source was adjusted, though it did not 
completely prevent their appearance. The solution colour was noticeably lighter as less total 
mass was used. Furthermore, the handling of the glassware was difficult due to its rapid heating 
and spillage of solution, even after adjusting settings in the microwave. 
Hydrothermal synthesis was affected by char formation 
Hydrothermal synthesis allowed much larger volumes to be processed at once in comparison 
to domestic microwave, with a maximum of around 250 ml in comparison to 50 ml. Although 
the use of a closed vessel allowed higher temperatures and constant monitoring, there were still 
issues with this method. Fig. 2.5 shows char formation could not be avoided as there was no 
internal stirring mechanism and the cleaning required several days as this residue was not easily 
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removed. Therefore, pyrolysis with domestic microwave and via hydrothermal treatment 
proved inefficient due to the lack of control over experimental parameters and low product 
yield. Synthesis through this method limits reaction efficiency and prevents the use of solvents 
other than water. Nonetheless, CA and sucrose showed positive results in comparison to 
chitosan and were selected to continue with microwave reactor synthesis. 
 
 Fig. 2.5 – Samples produced through domestic microwave synthesis. CD samples 
obtained by domestic microwave-assisted pyrolysis of sucrose and PEG-400. The colour 
change can be observed from the precursor solution (left) to CD solutions. Char formation 
after carbonization can be seen at the bottom of the beaker (right). 
 
Microwave reactor synthesis 
CD precursor solutions were pyrolysed using a microwave reactor to produce aqueous CD 
suspensions. Although CDs may be obtained from the pyrolysis of any organic matter, the 
additional processing steps required to remove contaminants led to the use of laboratory-grade 
reagents [256]. Microwave-assisted pyrolysis was selected as the synthesis route because of its 
adaptability, ease of use, reproducibility, and rapid reaction time, shown in Fig. 2.6. In 
comparison, other protocols like hydrothermal synthesis or combustion are more difficult to 
standardize. The microwave reactor could not maintain a constant temperature over 200°C 
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without surpassing the designated internal pressure safety threshold of 17 bar using the 
maximum volume of 40 mL CD precursor solution. Temperatures under 120°C did not produce 
a noticeable colour change in the solutions.  
 
Fig. 2.6 – Microwave reactor synthesis setup. Precursor solution is placed within vessel 
with metal-reinforced cap (left). The solution is pyrolysed with the Discover SP microwave 
reactor setup (middle) and recovered after cooling (right). 
 
The final reaction temperature (150 °C) and time (5 minutes) was chosen as it produced the 
best product yield, and has previously been shown to be adequate for rapid CD synthesis with 
citric acid as a molecular precursor [257]. A minimal amount of char was produced after the 
reaction as stirring within the vessel ensured homogeneous heating. The carbon source 
concentration was further adjusted from 0.25 g/ml to <0.1 g/ml. As was previously observed, 
the increase of reaction time and temperature led to a darker solution colour and formation of 
aggregates. Samples without constant stirring rapidly produced aggregates and vessel 
overheating. In total, 6 samples were obtained, which are detailed in Table 2.2. 
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Table 2.2. Samples synthesised via microwave reactor 












Optimisation of synthesis using various carbon-containing compounds 
CDs were synthesized utilizing microwave-assisted pyrolysis of a carbon source (citric acid or 
sucrose) and a passivating agent (PEG400, PEI, or EDA). PEG has been shown to effectively 
passivate CDs for biomedical applications due to its non-toxicity and low immunogenicity. 
However, it has also been shown to act as a carbon source for CD formation due to its thermal 
decomposition at 120°C [258]. PEI and EDA also undergo similar processes during 
carbonization and become part of the amorphous carbon core. However, their main advantage 
is the enhancement of photoluminescence through nitrogen doping, which introduces 
additional surface defects. Furthermore, nitrogen-doped CDs possess available primary amine 
functional groups which can be used in amide cross-linking. The best reaction conditions for 
product yield and photoluminescence were determined to be 150°C and 5 minutes respectively 
to prevent excessive formation of aggregates. This methodology was utilized to produce CA-
EDA (citric acid-based) and S-EDA (sucrose-based) CDs.  
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Host-guest embedding PpIX within CDs 
Host-guest embedding has been shown to effectively encapsulate a variety of molecules within 
CDs, such as NIR dyes and photosensitisers [145,148]. The mechanism of encapsulation is 
thought to begin after initial carbon precursor carbonization. CD synthesis has been shown to 
be caused by the aggregation of furfural derivatives and polycyclic aromatic hydrocarbons 
from the decomposition of the various carbon sources [259]. The nucleation of these 
compounds leads to the formation of an amorphous carbon core around several guest 
molecules, effectively trapping them. Fig. 2.7 shows the effect of changing PpIX wt% during 
one-pot synthesis. 
 
Fig. 2.7 – PpIX@CD samples change according to wt%. Lower percentages such as 0.5 




Initial experiments led to the formation of large ash-like aggregates during the carbonization 
of citric acid and sucrose. These ashes decreased in quantity as temperature, time, and carbon 
source quantity were optimised. In particular, the adjustment of the initial carbon source 
concentration and continuous stirring the solution throughout the process ensured minimal char 
formation. Nonetheless, it is difficult to avoid precipitate formation in embedded CDs during 
microwave synthesis, as has been previously reported in the literature [148]. Though this 
fraction can be removed through centrifugation or chromatography, a large quantity of the 
guest molecule is lost after synthesis. Fig. 2.8 shows variations in colour with increasing PpIX 
wt% after synthesis and dialysis. 
 
Fig. 2.8 – Freeze-dried PpIX@CD conjugates. A noticeable colour change can be seen as 
PpIX wt% increases. 
 
Thermal degradation limits host-guest embedding in CDs 
However, there is a key limitation in host-guest embedding with CDs that limits its versatility 
in comparison to crosslinking or other noncovalent interactions: the guest molecule must have 
a thermal stability higher than the reaction temperature for CD synthesis. Heat-sensitive 
molecules such as peptides, nucleic acids, or proteins cannot withstand the heat and would 
eventually be pyrolysed, acting as a secondary carbon source. PpIX has greater thermal 
0.25%0.1% 0.5% 1% 2%0%
PpIX@CDs
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stability in comparison to the other reagents used for CD synthesis (citric acid or sucrose, 
ethylenediamine), ensuring only sucrose-based particles are formed [260,261]. This is 
expanded upon in the section detailing TGA results. 
Amide crosslinking 
Refining crosslinking protocol improved product yield 
EDC-NHS cross-linking ensures the directional cross-linking of CDs to PpIX and avoid the 
formation of dimers. The standard protocol is that of protein cross-linking with an activation 
buffer for the component with carboxyl groups (0.1 M MES, 0.5 M sodium chloride in 
deionised water) at pH 6. However, PpIX has very low solubility in water and readily 
aggregated even at low concentrations (<50 μg/ml). Yildiz et al. (2010) fabricated a similar 
conjugate using a 1:1 DMSO/water solution to improve compound solubility prior to cross-
linking [250]. Various water-miscible solvents for PpIX were tested to improve crosslinking 
efficiency, including acetone, DMSO, and DMF. The choice of solvent was limited by CD 
solubility and compatibility with the dialysis membrane. After several trails, DMF was 
determined to be the most suitable solvent for PpIX. Interestingly, MES buffer did not 
significantly improve PpIX loading in comparison to a solution containing only EDC and NHS. 
The addition of excess EDC (>6.25 mM) and NHS (>21.72 mM) did not show significant 
changes to conjugate yield. 
After crosslinking, the solution was left to stand at room temperature to observe precipitation. 
This led to the separation of the less soluble fraction, named (PpIX-CD)p, from PpIX-CD, 
which can be clearly seen in Fig. 2.9. The remaining aggregates were removed after increasing 
centrifugation to 20 minutes and 12,000 rpm. (PpIX-CD)p showed significantly reduced 




Fig. 2.9 – Crosslinked conjugates are separated by centrifugation. The solution gradually 
separated into two fractions: PpIX-CD and (PpIX-CD)p. 
 
EDC-NHS linking has also been used to bind multiple molecules to CDs simultaneously. 
Zheng et al. (2016) demonstrated efficient PDT with a carbon nitride (C3N4)-based 
multifunctional nanocomposite (PCCN) consisting of CDs, Arg-Gly-Asp (RGD) motif, and 
PpIX. PCCN demonstrated water-splitting ability to produce singlet oxygen production while 
in a state of hypoxia with a PpIX content of 9.6% [158]. Despite decreasing total loaded PpIX 
in comparison to the previously described conjugates, it has the advantage of cell-specific 
targeting which could enhance their PDT efficiency. 
EDC/NHS crosslinking is a better alternative due to water solubility 
Incorrect crosslinking results in random coupling between molecules and leads to the formation 
of large aggregates, as dimers and eventually polymers begin to form. These less-soluble 
particles can significantly decrease treatment efficiency and generally present diminished 
photoluminescence due to self-quenching [262]. Hua et al. (2017) reported CDs could be 
covalently bound to PpIX [263]. They utilised the DCC/HOBt (dicyclohexylcarbodiimide/1-
hydroxybenzotriazole) coupling strategy, also known as Steglich esterification. Cellular uptake 
5 minutes 1 hour After centrifugation
Precipitate
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and decreased toxicity prior to photoactivation were observed. Interestingly, these conjugates 
presented a similar size (25.2 ± 5.7 nm) to that of PpIX-CD (25  10 nm) but showed a lower 
PpIX loading efficiency of 23.3% in comparison to 43.3% (PpIX-CD) and 35.59% 
(PpIX@CD). Furthermore, they reported an intrinsic nucleolus-targeting capability better than 
the only commercially-available dye SYTO RNASelect [264]. These particles have also been 
used to conjugate photosensitizer Rose Bengal and the mitochondria targeting moiety 
triphenylphosphonium with CDs [154,265]. This reaction is widely known and extensively 
used in the pharmaceutical industry. DCC/HOBt benefits from the lack of hydrolysis during 
the reaction and lower total cost compared to EDC [266].  
However, the choice of DCC/HOBt over EDC/NHS linking was unexpected as the former is 
not completely suitable for use with CDs. DCC and EDC are zero-length crosslinkers, meaning 
they form direct interactions between molecules through binding [267]. Although DCC has an 
extraordinarily high activation efficiency, it is limited by almost non-existent water solubility 
and formation of dicyclohexylurea after linking, requiring additional filtration steps to remove 
it from the solution. [268]. CDs are typically not soluble in organic solvents, which are required 
for DCC crosslinking. Furthermore, EDC is highly water soluble and its reaction by-product 
urea can be easily removed through dialysis [269]. Therefore, DCC is the less desirable choice 
for carbodiimide-based crosslinking of CDs in comparison to EDC. 
In summary, three samples containing PpIX were obtained, as detailed in Fig. 2.10. CA-EDA 
CDs were used to crosslink PpIX using EDC/NHS chemistry, forming PpIX-CD (soluble 
fraction) and (PpIX-CD)p (insoluble fraction). PpIX@CD was synthesized using a one-pot 




Fig. 2.10 – Schematic detailing newly synthesized PpIX-loaded conjugates. 
Sample processing 
Purification was carried out in several steps throughout synthesis and cross-linking. The use of 
centrifugation at 10,000 rpm successfully removed the largest aggregates. Generally, samples 
with higher quantities of sucrose, citric acid, and PpIX required additional rounds of 
centrifugation. Likewise, initial experiments showed greater precipitate formation as reaction 
times were increased.  
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Dialysis was a crucial part of sample post-processing 
Dialysis removed remaining compounds from synthesis and cross-linking such as polycyclic 
aromatic compounds, buffer salts, and unbound PpIX [233]. As was observed with 
centrifugation, samples fabricated with greater amounts of carbon precursors or PpIX required 
additional time from 24 to 96 hours. These samples required additional water changes during 
the initial process as contaminants rapidly passed through the membrane, seen as a noticeably 
colour change in Fig. 2.11. 
 
Fig. 2.11 – Dialysis was repeated to remove contaminants. The process was repeated until 
no colour change could be observed. Water was changed regularly to speed up contaminant 
removal. Approximately 50 ml of CD solution could be processed per container. 
 
Freeze-drying was affected by impurities within samples 
Freeze-drying produced a reddish to black powder which was subsequently weighed and stored 
in a dry environment away from light until used. Dialysis was found to be a necessary 
processing step for CD conjugate synthesis as particle recovery was impossible without its use, 
Water is discarded and replaced
1 hr 3 hr
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resulting in a black sticky residue which was unable to be completely dried into powder form, 
seen in Fig. 2.12. In contrast, CD suspensions could be directly transferred after dialysis and 
successfully freeze-dried, resulting in a flaky powder being recovered, seen in Fig. 2.13. 
 
Fig 2.12 – Dialysis significantly changes product quality. The repetition of this process 
successfully removed most contaminants from the suspension and prevented sample 








Fig. 2.13 – Sequential rounds of freeze-drying ensured complete removal of residual 
water. CDs were recovered and stored to prevent rehydration due to ambient moisture. 
 
In summary, CDs were synthesized using microwave-assisted pyrolysis of citric acid or sucrose 
and ethylenediamine. The photosensitising drug PpIX was loaded onto CDs through amide 
crosslinking, producing two separate components: PpIX-CD and (PpIX-CD)p. Likewise, host-
guest chemistry led to the synthesis of PpIX@CD with varying amounts of embedded 
porphyrin in a one-pot reaction. Conjugates showed increased solubility in water compared to 




Fig. 2.14 – PpIX conjugates show variable dispersibility in water. After initial addition to 
solution, PpIX@CD and (PpIX-CD)p remained suspended and remained as such until mixed. 




CD                 PpIX             PpIX-CD             (PpIX-CD)p         PpIX@CD
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Characterisation 
Photoluminescence (PL) spectroscopy 
Synthesised samples were first analysed using FL spectroscopy to determine their emission 
spectra. Fluorescence was measured in the range of near ultraviolet and visible light spectra 
(lex = 300 - 500 nm) to match the typical absorbance maxima found in CDs. Emissions were 
detected in the range of 390 – 750 nm for all samples. 
CD samples showed clear variations in photoluminescence, mostly based around the 
passivating agent that was used alongside the carbon source. Citric acid (CA) CDs showed 
higher emissions in comparison to sucrose-based CDs. Most samples showed high PL values 
in the range of 350 – 375 nm. PEG-coated CDs exhibited significantly reduced emissions 
across all wavelengths. These differences are much more apparent at lower excitation 
wavelengths, particularly 300 nm (Fig. 2.15). In comparison, PEI and EDA passivated CDs 
showed similar values regardless of excitation. PL increase is likely caused by the integration 
of nitrogen within CDs during one-step synthesis. Heteroatom doping has been shown to be an 
effective method for increasing CD emission and can be achieved using a nitrogen-rich carbon 
source or passivating agent during synthesis [38]. Nitrogen doping produced favourable results, 
yielding particles with enhanced photoluminescence in the desired excitation wavelengths for 
use with PpIX. 
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Fig. 2.15 – Comparison of emission at 300 and 400 nm excitation with various molecules 
used for passivation. EDA-coated CDs demonstrated significantly higher 
photoluminescence at both 300 and 400 nm excitation compared to PEG and PEI. 
 
Interestingly, all samples show a combination of excitation dependent and independent 
photoluminescence. Excitation-independent behaviour in CDs has been observed with 
excitation wavelengths in the UV (around 280 - 380 nm) [270]. However, most reported CDs 
display excitation-dependent emission, where higher excitation wavelengths cause slight 
spectral shifts. Multicolour fluorescence could also be achieved by optimising the solvent and 
pH [271]. Nonetheless, all synthesized samples have a similar range of photoluminescence, 
rising from approximately 400 nm and dropping at 600 nm (Fig. 2.16).  
In theory, further improvement of synthesis conditions could lead to red-shifted emission and 
increased quantum yield. Preliminary evaluation of newly synthesized samples using PL 
spectroscopy indicated that the use of ethylenediamine produced the best and most consistent 
results that could overlap with PpIX absorbance maxima (405 nm). Therefore, S-EDA and C-
EDA CDs were selected for use in PpIX crosslinking. 
























































Fig 2.16 – Fluorescence spectra of synthesized CD samples from various carbon sources 
using excitation wavelengths ranging from 300-500 nm. PEG-coated samples showed 
drastically reduced photoluminescence in comparison to amine-rich PEI and EDA.   
  





















































































































































































Photoluminescence at 405 nm excitation is needed for in vitro tests 
Fluorescence for PS conjugates was measured by matching the maximum excitation 
wavelength to the LED used for in vitro tests (lex = 405 nm), shown in Fig. 2.17. PpIX@CD 
was compared to S-EDA CDs while PpIX@CD and (PpIX-CD)p were compared to CA-EDA 
CDs.  Fluorescence spectra demonstrate a dual emission behaviour from all conjugates. CD-
related emissions are attenuated in conjugates, while PpIX-related emission peaks >600 nm are 
very similar between all samples. (PpIX-CD)p showed greatly reduced fluorescence to all 
samples in the range of 420 – 550 nm. PpIX loading in conjugates showed various ratios: PpIX-
CD (41%), (PpIX-CD)p (34%), and PpIX@CD (48%). 
 
Fig. 2.17 – Fluorescence spectra of conjugates separated by CD subtype. 
A dual emission behaviour was observed in all conjugates with intense and broad emissions at 
the 420-520 nm range similar to CD samples in literature [272]. Drug loading through both 
amide cross-linking and embedding directly reduced CD fluorescence. However, S-EDA CDs 
(within PpIX@CD) did not show the same decrease of photoluminescence after PpIX loading 
compared to PpIX-CD and (PpIX-CD)p. It is likely that porphyrin embedding  increases the 











































prevalence of surface defects, which have been shown to enhance CD-based 
photoluminescence [273]. Nonetheless, all samples show a reduction of photoluminescence. 
This is likely caused by quenching of CD-based emissions through conjugate aggregation and 
obstruction of surface defects, which have been reported to heavily contribute to CD 
photoluminescence [274]. In particular, (PpIX-CD)p exhibited a near complete depletion of 
CD-related emissions. However, porphyrin-associated peaks to not seem to be greatly affected 
by either embedding or amide cross-linking at its emission peaks at 617 and 677 nm. This is 
possibly due to its outer location within the conjugate as PpIX binds to the CD surface through 
its carboxyl group. Additionally, the use of a DMF/water mixture during PpIX@CD synthesis 
could also have cause a change in emission.  
Conjugates show variable PpIX content 
PpIX loading was calculated as stated in the literature by using a calibration curve with diluted 
porphyrin in its linear range (0.4 – 1.6 μg/ml), seen in Fig. 2.18. PpIX content was estimated 
by comparing the relative intensities of the 658 nm peak while exciting the solution at λex = 
404 nm of PpIX [251]. CD fluorescence from both CA-EDA and S-EDA was subtracted from 
each conjugate to estimate drug loading. Through these observations, the total quantity of PpIX 
that could be introduced efficiently with host-guest embedding in CDs without precipitate 
formation is approximately 1 wt%. In comparison, previously reported Nile Blue embedded in 
PEG-based CDs used a 1:10 weight ratio and exhibited a higher degree of aggregate formation. 
This required centrifugation at 20,000 g and the use of an aqueous gel separation column to 
recover the sample [275]. 
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Fig. 2.18 – Loading in conjugates was calculated using a PpIX calibration curve. The 
curve was based on PpIX fluorescence at the absorbance maximum (λmax = 405 nm). 
Conjugates were diluted and compared to estimate PpIX content. 
 
Host-guest embedded samples showed significant variation. As expected, increasing porphyrin 
wt% in the precursor solution led to gradual increases in final PpIX content from 0.1 to 1 wt%, 
shown in Fig. 2.19. Intriguingly, samples doped with 2 wt% PpIX did not follow this trend, 
showing lower loading efficiency in comparison to 1 wt%. It is possible that the reaction time 
used for PpIX@CD synthesis was not enough to pyrolyse all available sucrose and EDA, 
causing only partial encapsulation of all available porphyrin. Reaction times for microwave 
synthesis are extremely varied and have been evaluated up to a total length of 30 minutes [276]. 
Nonetheless, it is highly likely that the precipitate formed during PpIX@CD 2% synthesis 
corresponds to unbound PpIX. Thus, PpIX@CD (1 wt%) was selected to be used in all further 
studies due to its high PpIX content. 
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Fig. 2.19 – Fluorescence spectra of PpIX host-guest encapsulated conjugates. All 
samples show fluorescence corresponding to the characteristic emission bands. PpIX loading 
efficiency was calculated as previously detailed. 
 
Ultraviolet-visible spectroscopy (UV-Vis)  
Absorbance and fluorescence spectra were obtained utilising conjugates suspended in PBS at 
pH 7. CDs typically have a strong and broad absorption in the ultraviolet region, followed by 
a constant decrease as excitation wavelength increases [277]. In general, absorption below 375 
nm has been attributed to π–π* transitions of the carbon dot surface, mainly from C=C and 
C=N bonds [278]. Nonetheless, conjugate absorbance was dominated by PpIX with a high 
absorption band at approximately 405 nm, followed by a small peak at 500 nm. PpIX-CD and 
(PpIX-CD)p showed similar absorbance while PpIX@CD showed a 40% decrease at equal 
concentrations. 































Fig. 2.20 – Absorbance spectra of PpIX, PpIX-CD, (PpIX-CD)p and PpIX@CD in 
water. 
Fourier transform infrared spectroscopy (FT-IR) 
Infrared spectra obtained from PpIX and PpIX-CD were found to be nearly identical. Similarly, 
this was observed between CA-EDA, S-EDA CDs, (PpIX-CD)p and PpIX@CD. FT-IR 
spectroscopy was used to evaluate conjugate surface chemistry in the range of 4000-700 cm-1. 
CA-EDA CDs were found to be very similar to S-EDA CDs, likely due to the similarity of 
their carbon sources. Conjugates were divided as previously mentioned in two groups based 
on their similarities to CDs or PpIX. The assignment of peaks was carried out by comparing 
IR spectra to those found in the literature for CD samples (Table 2.3).  
Peaks attributed to C-C stretching at 1680cm-1 can be seen in all samples. However, the small 
1720 cm-1 peak corresponding to C=O stretching and the broad -OH peak at around 3000 cm-1 
were not observed in PpIX-CD and PpIX (Fig. 2.21). In comparison, these peaks were seen in 
all other samples including PpIX@CD and (PpIX-CD)p (Fig. 2.22). The characteristic amide 
band can be observed in CD, (PpIX-CD)p and PpIX@CD around 1570 cm-1 and is absent in 
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PpIX-CD. Peaks in the range of 1395-1216 cm1 can be ascribed to C=C, C=N, and C=C-O 
respectively. The small sharp peaks at 1075 and 1059 cm-1 can be seen in samples 
corresponding to C-O and C-H groups. The reduction of available amine functional groups 
during amide cross-linking is likely the cause for variation between spectra. These slight 
variations between samples can be observed particularly in the distinctive amide I peak at 
~1570 cm-1. The change in the availability of primary amines can also be seen in the region of 
918-625 cm-1 which has been previously linked to N-H wag in carbon dots [195]. Samples 
show a small amount of water in the 3000 cm-1 region, which corresponds to -OH. This broad 
peak shows some absorbed humidity is present in all samples regardless of freeze-drying (Fig. 
2.23). 
Table 2.3.  FT-IR peak assignation. Table with assigned FT-IR peaks in conjugates in the 
range of 2000 - 700 cm-1. 
Peak (cm-1) Assignment Reference 
1720 C=O stretching Sellitti et al. (1990) [279] 
1680 C=C stretch Lei et al. (2016) [280] 
1570 N-H bending Liu et al. (2016) [281] 
1395 O-H/C-N Lei et al. (2016) [280] 
1338 C=N Liu et al. (2016) [281] 
1216 C=C-O Liu et al. (2016) [281] 
1075 C-O Liu et al. (2016) [281] 
1059 C-H bending Sellitti et al. (1990) [279] 




Fig. 2.21 – FT-IR spectra comparing surface chemistry of CA-EDA samples. The 
characteristic amine band (N-H) does not appear in PpIX-CD, indicating complete 
crosslinking using EDC/NHS. 
 
Fig. 2.22 – FT-IR spectra comparing surface chemistry of S-EDA sample PpIX@CD. 


















Fig. 2.23 – Full FT-IR spectra of CA-EDA and S-EDA conjugates. 
Changing PpIX% for embedded samples did not change surface chemistry 
PpIX@CD samples did not show a significant difference in surface chemistry between each 
other, as can be observed in Fig. 2.24. The C-C stretch at 1680 cm-1 could be seen in all samples, 
whereas the opposite was seen with the C-H band at 1059 cm-1, which increased at 0.1, 0.25 
and 2 wt%. Primary amines appear to be more available in these samples, as can be seen in the 
region of 918-625 cm-1, which was mentioned previously. However, the characteristic amide 
band at 1570 cm-1 can be seen in all samples with similar intensity, indicating the presence of 
nitrogen on the surface. 
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Fig. 2.24 – FT-IR spectra comparing surface chemistry of PpIX host-guest encapsulated 
samples. 
Transmission electron microscopy (TEM) 
Transmission electron microscopy (TEM) revealed a quasispherical particle morphology for 
all CD and conjugate samples, with CDs being observed as small aggregates (Fig. 2.25). with 
an average diameter of 25  10 nm (PpIX-CD) and 17  6 nm (PpIX@CD). (PpIX-CD)p 
exhibited a highly variable particle size range of 15 – 100 nm. Conjugates displayed an 
irregular quasispherical morphology, with aggregates forming regardless of the concentration 
and sample grid-loading combination that was tested. CA-EDA and S-EDA CDs showed an 
average particle size below 10 nm and a more defined spherical morphology. Finally, PpIX 




















Fig. 2.25 – CDs form small aggregates in water suspension. TEM images of CDs at 690× 
(a) and 68,000× (b). CDs form small aggregates (<200 nm) at higher concentration (a). 
Individual particles can be seen after diluting stock solutions and sonicating samples (b). 
 
TEM images demonstrate a size and morphology variation between conjugates, which could 
be caused by the synthesis strategy and influences particle solubility. This can be seen with 
particle aggregation for various samples in Fig. 2.26. PpIX-CD was fabricated in a controlled 
and directed cross-linking reaction utilising purified CA-EDA CDs and PpIX. Results show 
PpIX-CD and PpIX@CD form reduced aggregates under 200 nm in size while both (PpIX-
CD)p and PpIX quickly form aggregates. Conjugates show reduced solubility in water in 
comparison to base CDs but are more soluble than PpIX in concentrations below 25 μg/ml. 
Solutions with conjugates show slight precipitation after several hours of ultrasonic processing. 
Additionally, (PpIX-CD)p was determined to be the most heterogeneous sample due to its wide 
size distribution.  
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Fig. 2.26 – CD-PS conjugates show decreased aggregation in water. TEM images of 
conjugates at 30,000× (A) and 68,000× (B). Conjugates show irregular morphology and less 





Host-guest embedding relied on the one-pot synthesis of PpIX@CD which produced slightly 
larger aggregates, with some variations which can be seen in Fig. 2.27. CD nucleation and 
growth is altered by various synthesis conditions, such as temperature and type of carbon 
source. This could be further affected by the use of hydrophobic compounds and may have led 
to greater size variation in PpIX@CD compared to PpIX-CD [282]. Therefore, host-guest 
embedding appears to be a less reliable and reproducible strategy for drug loading in CDs in 
comparison to amide cross-linking. 
 
Fig. 2.27 – PpIX-loaded CDs can form aggregates depending on synthesis conditions. 
PpIX@CD formed some separate porous nanoparticles, seen at 49,000× (right). PpIX-CD 
aggregates caused by dimerization could be seen at 49,000× (right). 
 
Aggregates could be seen in all samples regardless of conjugation strategy or PpIX 
concentration. Imaging of PpIX@CD showed the presence of a minute amount of porous 
particles, which have been previously reported in the literature [135]. These structures are 
approximately ten times larger than the previously observed PpIX@CD conjugates. PpIX@CD 
also showed the formation of self-assembled nanostructures after the sample dried on the TEM 
grid, which can be seen in Fig. 2.28. These tubular structures are likely caused by hydrophobic 
interactions, formed through π–π stacking of the internal pyrrole rings found within PpIX. 
Similarly, PpIX-CD showed the formation of aggregates of approximately 250 – 400 nm in 
50 nm20 nm
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size, which could be formed as multiple CDs and PpIX molecules are bound through amide 
bonds. 
 
Fig. 2.28 – PpIX@CD self-assembles at higher concentrations. TEM images of 
PpIX@CD show tendril-like structures forming from aggregates, with individual particles 
becoming clearer at higher magnifications. 
 
Finally, (PpIX-CD)p readily aggregated in water in all concentrations (0.1 – 10 μg/ml) and 
after processing the solution with an ultrasonic probe. The formation of these aggregates is 
likely the cause of its low photoluminescence due to rapid quenching. It is likely these 
200 nm





aggregates contain a high concentration of PpIX as they are similar in appearance with more 
defined edges instead of an amorphous form, shown in Fig. 2.29. 
 
Fig. 2.29 – (PpIX-CD)p rapidly forms large aggregates in water. TEM image at 18,500X, 
individual particles can be observed around the edges of the aggregate. 
 
Singlet oxygen generation confirms PpIX loading and potential use for PDT 
Singlet oxygen production was determined by the time-resolved measurement of its 
characteristic luminescence at 1270 nm. Samples were excited utilising a 355 nm Nd:YAG 
laser at 50, 100, and 200 mJ (Fig. 2.30). Phenalenone (PH) in DMF was used as a standard 
indicating 100% singlet oxygen production. PpIX was determined to produce an average of 
92.18% singlet oxygen. 1O2 production in conjugates was also calculated with values of 63.79% 
(PpIX-CD), 77.10% (PpIX-CD)p and 51.62% PpIX@CD. 
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Fig. 2.30 – Singlet oxygen yield of conjugates in DMF. Corrected initial amplitude of 
lifetime generated singlet oxygen against the power of a 355 nm Nd:YAG laser to calculate 
singlet oxygen yield of each sample. Phenalenone was used as a control for 95% production. 
 
Singlet oxygen (1O2) production alone initially indicates (PpIX-CD)p is the best conjugate for 
PDT, while PpIX-CD and PpIX@CD appear to have reduced efficiency. However, this is 
because DMF was required for the measurement. 1O2 yield was likely affected by the increased 
solubility of (PpIX-CD)p in organic solvents, as this conjugate readily aggregates in water. 
Nonetheless, we observed all the samples showed decreased singlet oxygen emission in 
comparison to PpIX. Our results indicate fluorescence emission intensity of the conjugates 
cannot be directly linked to singlet oxygen yield.  
X-ray photoelectron spectroscopy (XPS) 
XPS analysis with survey and high resolution C1s scans determined conjugates have little to 
no difference in surface composition with PpIX (Table 2.4). Carbon dot compositions are very 
similar between CA-EDA and S-EDA samples, with only slight variations in C and O. The 
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pure PpIX sample is close to what is expected given its chemical formula (C34H34N4O4). If 
hydrogens in this sample are neglected, it has concentration values of 82.6 at% C, 8.2 at% N 
and 9.0 at% O, as seen in Table 2.4 as compared to 81% C, and 9.5% N and O theoretically. In 
comparison, CD conjugates demonstrate small increases in oxygen. The high resolution C1s 
spectra peak positions are given relative to C-C/C-H being at ~285.0 eV, and it is assumed the 
lowest carbon peak position is C-C/C-H as no carbides were expected in these samples. There 
was no distinction in peak position between both C-C and C=C type bonds and are therefore 
expected to be the major peak. 
Table 2.4.  Surface composition (atomic%) of PpIX and CD-conjugates. 
Sample C O N Na Cl 
CA-EDA 56.7 37.4 5.8 <0.1 0.1 
S-EDA 59.1 35.4 5.4 <0.1 0.1 
PpIX 82.6 9.0 8.2 <0.1 0.2 
PpIX-CD 81.6 9.6 8.6 <0.1 0.2 
(PpIX-CD)p 76.4 13.5 9.7 <0.1 0.4 
PpIX@CD 82.1 9.4 8.3 <0.1 0.2 
 
XPS analysis demonstrated there is little to no variation in the carbon envelopes of conjugates 
and PpIX. C=C bonds seen in the high resolution C1s spectra could present -* transitions, 
which could lead to small intensities at higher binding energies but should not be considered 
true XPS peaks. We observed that the C-N environment is the major component and is seen at 
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a higher binding energy and slightly reduced peak positions. This is possibly due to the 
influence of carbons attached to nitrogen in PpIX and conjugates as it contains a porphyrin 
core with a tetrapyrrole macrocycle, giving it an aromatic nature [283]. 
Thermogravimetric analysis (TGA) 
TGA analysis showed a clear difference between CDs and PpIX conjugates, seen in Fig. 2.31. 
The thermal desorption of water physically adsorbed on the samples caused a slight weight loss 
at temperatures lower than 120°C, which is consistent with previous reports [284]. CDs showed 
a slight drop in mass as thermal stability until approximately 188°C – slightly above the thermal 
decomposition temperatures of citric acid (176°C) and sucrose (185°C), respectively 
[260,285]. The weight loss continued as external oxygen-containing functional groups were 
oxidized at temperatures in the range of 200 - 500°C. In contrast, PpIX showed great thermal 
stability up to approximately 300°C, which is well past the CD synthesis temperature of 150°C. 
The majority of PpIX molecular mass is based on its pyrrole ring which begins thermal 
decomposition around 340-450°C as evidenced by TGA analysis. Although there is a slight 
mass reduction from 26-360°C, this has been mainly linked to the breaking of reactive bonds 
outside the ring [261]. Therefore, it is highly likely host-guest embedding does not significantly 
alter PpIX structure and functionality during microwave-assisted synthesis. 
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Fig. 2.31 – PpIX loading increases CD thermal stability. TGA demonstrates CDs 
decompose at lower temperatures compared to PpIX and its conjugates. 
 
Conjugates showed increased thermal stability due to PpIX loading and exhibited similar 
thermal decomposition. PpIX-CD and (PpIX-CD)p showed similar behaviour to PpIX, with 
mass loss at 345 and 450°C. Additionally, there is a slight reduction in mass around 230°C. In 
contrast, PpIX@CD does not show significant mass loss at 345°C, instead showing two clear 
peaks at 232 and 460°C. The first is likely related to the oxidation of CD surface groups, which 
are exposed in PpIX@CD, while crosslinked conjugates are completely bound with PpIX. The 
second peak corresponds to the degradation of the pyrrole ring of PpIX embedded on the CD 
surface. These variations in weight loss (% loss per °C) can be observed in Fig. 2.32. 




















Fig. 2.32 – TGA of CDs and drug loaded conjugates. Conjugates show slight variation 
from PpIX. PpIX@CD showed increased weight loss around 200 °C. 



















































































































































In summary, CDs were fabricated with citric acid or sucrose as carbon sources and 
ethylenediamine as a passivating agent. Microwave synthesis showed higher product yield and 
better control over parameters in comparison to domestic microwave or hydrothermal 
synthesis. However, small reaction volumes are a limiting factor in CD synthesis through this 
method. The comparison of various carbon sources and passivating agents led to the selection 
of citric acid, sucrose, and EDA for CD production. Dialysis was shown to be a crucial part of 
sample post-processing as freeze-drying is unsuccessful without it. 
Afterwards, PpIX was successfully loaded in carbon dots to form drug-loaded conjugates using 
two different strategies. Host-guest encapsulation of PpIX in various wt% with a one-pot 
reaction produced composites with varying PpIX content. A total of 1 wt% led to the highest 
drug loading, which was named PpIX@CD. Likewise, amide crosslinking was used to 
synthesize PpIX-CD through a modified protocol. The less soluble fraction of (PpIX-CD)p was 
recovered after centrifugation. Host-guest embedding was shown to be a viable and cost-
effective alternative to carbodiimide crosslinking for loading PpIX. Nonetheless, sample 
variability requires the optimization of synthesis conditions as a limit for drug loading could 
be observed after changing initial drug weight percentage. Similarly, EDC/NHS crosslinking 
showed greater variability as a separate fraction of conjugates were obtained following 
processing with dialysis and centrifugation.  
Particles were shown to increase in size and behave similarly to PpIX as seen with TGA and 
FT-IR evaluation. TEM showed conjugates aggregate less than PpIX but are still less 
hydrophilic than CDs. PpIX loading in carbon dot conjugates reduced CD-attributed 
photoluminescence and singlet oxygen generation in all conjugates regardless of drug loading 
percentage after excitation with 405 nm light. Although this suggests PDT is possible with all 
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three conjugates (PpIX-CD, (PpIX-CD)p and PpIX@CD), characterisation alone is not 
sufficient to determine which sample is the best suited for in vitro PDT. Interestingly, results 
suggest host-guest encapsulated samples are a better alternative to crosslinked CD conjugates. 
These observations will be taken forward in the next chapter as in vitro evaluation may show 
possible differences between samples and treatment conditions to determine the best 




Chapter 3 – Phototoxicity and bioimaging of conjugates in cell monolayers 
Introduction 
In the previous chapter, there was a brief introduction on photodynamic therapy (PDT) and the 
usefulness of nanoparticle-drug conjugates. PpIX-loaded CDs were shown to be capable of 
singlet oxygen production and increased water solubility. The next step requires the biological 
evaluation of PDT using cell culture; cytotoxicity evaluation of new photosensitising 
compounds is a necessary step to assess variations in treatment efficacy. In vitro evaluation of 
cytotoxicity is typically carried out using an assay to measure metabolic activity, which is often 
defined as the number of “healthy” cells in a sample. The commercially-available assays MTT 
(3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide and resazurin (also known as 
Alamar Blue) are examples of well-known and established methods for estimating cytotoxicity 
in cell monolayers [286]. 
PDT can cause cell death through both apoptosis and necrosis in cancerous tissue, inflicting 
damage to proteins, DNA, and lipids [287–289]. Necrosis is more common with high drug 
concentrations due to PS dark toxicity, apoptosis is generally preferred as there is no cellular 
ablation and release of factors such as cytokines, which affect healthy surrounding cells [290]. 
Treatment efficiency can vary depending on many factors, including lesion type, size, and 
location. Additionally, PS effectiveness is variable, fluctuating according to its concentration 
and localization within the tissue. ROS generation is highly influenced by the concentration of 
oxygen in the tumour microenvironment. This limits PDT effectiveness on hypoxic tissue and 
tumours located below the tissue penetration depth of the light [206]. 
Fluorescence-based microscopy techniques have also been used to determine photosensitiser 
uptake and intracellular localisation. In particular, confocal laser scanning microscopy (CLSM) 
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is a tool with high sensitivity which can be used to observe nanoparticles with micrometre 
resolution. The use of multiple filters and laser lines, including two-photon excitation, enables 
the acquisition of three-dimensional imaging through optical sectioning [291]. 
In the following chapter, the evaluation of cytotoxicity and bioimaging capabilities of CDs and 
PpIX conjugates will be discussed. Fig. 3.1 shows a summary of the synthesised PpIX-
containing samples from Chapter 2. 
 
Fig. 3.1 – Schematic detailing conjugates used for in vitro PDT. PpIX-CD and (PpIX-
CD)p were fabricated through amide crosslinking. The latter corresponds to the insoluble 
(precipitate) fraction separated from PpIX-CD after centrifugation. PpIX@CD was obtained 
using a one-pot reaction. 
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Aims: Demonstrate differences in cytotoxicity and PDT efficiency of PpIX-loaded conjugates 
and PpIX using a metastatic human cancer cell line.   
Objectives: 
 Determine maximum in vitro concentration for conjugates based on dark toxicity (LC50). 
 Evaluate the effects of light dose and conjugate concentration on in vitro PDT. 





In the following section, all chemicals were obtained from Fisher Scientific, UK unless stated 
otherwise.  
Materials 
Protoporphyrin IX, resazurin sodium salt, and dimethyl sulfoxide were acquired from Sigma 
Aldrich (United Kingdom). Dulbecco’s Modified Eagle’s Medium (DMEM, high glucose), 
Dulbecco’s Modified Eagle’s Medium (DMEM, high glucose, without phenol red), phosphate 
buffer saline (PBS), 4′,6-diamidino-2-phenylindole. (DAPI), and trypsin–
ethylenediaminetetraacetic acid (EDTA) solution were obtained from Thermo Fisher (United 
Kingdom). Syringe filters with a 0.2 μm pore size were acquired from Sarstedt (United 
Kingdom). All chemicals were used as received unless stated otherwise. Deionized water was 
used for all buffers and samples in experiments. Septa steel ring caps and 35 ml glass reaction 
vessels were obtained from CEM Corporation (United Kingdom). 
2D cell culture – monolayer 
Cell culture 
Conjugates were diluted in sterile deionised water at a concentration of 1 mg/ml to make a 
stock solution. Standard cell culture media DMEM (Dulbecco’s Modified Eagle Media) was 
used to make working solutions at various concentrations. An ultrasonic probe was used to 
break up aggregates in the stock solution before mixing via vortex. The conjugate-
supplemented media was covered with aluminium foil and stored at 4°C for further use.  
Cells were donated by Dr. Helen Bryant from the Medical School, University of Sheffield. The 
cell lines C8161 (human melanoma) and U2-OS (human osteosarcoma) were cultured in 
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standard conditions (37°C, 5% CO2) using DMEM with 10% foetal calf serum (FCS) (Lonza, 
United Kingdom), 1% penicillin-streptomycin, and 1% glutamine. Each plate was passaged 
after reaching ~90% confluence. C8161 is a human cutaneous amelanotic melanoma cell line 
which has been shown to be highly aggressive, invasive, and metastatic, making it an ideal 
model for PDT [292]. U2-OS is a human osteosarcoma cell line, ideal for microscopy due to 
their large size. 
Evaluation of cytotoxicity 
Nanoparticle-supplemented DMEM was prepared utilising a stock solution (1 mg/ml) of each 
conjugate, at concentrations from 1–100 μg/ml. Full media with serum was used to make all 
conjugate dilutions. Solutions were subjected to ultrasonic processing with a Hieschler UP50H 
ultrasonic probe, with filter sterilisation prior to use in cell culture. Dilutions were stored at 
4°C until used. 
Growth media was prepared utilising phenol red-free DMEM with the following: 10% foetal 
calf serum, 1% antibiotics (penicillin and streptomycin) and 1% glutamine. C8161 melanoma 
cells were used from passage 10 to 20 and were cultured in a T75 plate 5% CO2 at 37°C, until 
reaching approximately 90% confluence. Cells were detached using 0.25% Trypsin-EDTA. 
Afterwards, cells were diluted to 6 × 104 cells/ml; each well of a 96-well plate was seeded with 
100 μl of cell suspension and placed in the incubator overnight to allow attachment. 
Dark toxicity 
Growth medium was replaced with 100 μl of conjugate dilutions (1–100 μg/ml) and DMEM 
was added to untreated cells to act as a control. The plates were covered with aluminium foil 
and returned to the incubator for 3 hours. Each well was washed with PBS and fresh media 
was added, with plates remaining in the incubator for an additional 18 hours (totalling 24 
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hours). After incubation, each well was washed with PBS and 200 μl growth media was 
replaced prior to the metabolic activity assay.  
Light-activated toxicity 
Growth medium was replaced with 100 μl of conjugate dilutions (1–10 μg/ml) and DMEM 
was added to untreated cells to act as a control. Cells were returned to the incubator for 3 hours 
to allow particle uptake. Afterwards, all wells were washed using PBS and 200 μl phenol red-
free media was added. A M405L2 ThorLabs mounted LED with a collimator adapter (405 nm, 
2.76 mW/cm2) was used to induce light-activated toxicity. Cells were placed under illumination 
for 3 minutes and subsequently returned to the incubator. Metabolic activity measurements 
were taken at 24, 48 and 72-hour time points (post light activation). 
Metabolic activity assay 
A 1 mM resazurin solution was prepared by dissolving 25.18 mg of resazurin sodium salt in 
100 ml sterile PBS. The solution was filter sterilized using a 0.2 μm syringe filter. 100 μl of 
media was taken from each well and transferred to a new plate. Metabolic activity was assessed 
by adding 20 μl to each well. The plates were read using a Biotek ELx808 Microplate Reader 
at 570/585 nm with a sensitivity of 50. Conjugate LD50 values were obtained and converted 
into PpIX-adjusted concentrations (μM) based on the previous estimated PpIX content of each 
sample. 
Confocal light scanning microscopy 
Fluorescence images were obtained using a Zeiss LSM510 Meta confocal microscope fitted 
with a two-photon Ti-Sapphire laser. U2-OS cells were seeded in six-well tissue culture plates 
at a density of 1 × 105 cells per well. Cells were placed in the incubator for 2 hours to allow 
cell attachment. A 1 μg/ml solution of each conjugate was prepared. Wells were washed with 
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PBS and growth media was replaced with 2 ml of conjugate solution. The plate was returned 
to the incubator for 30 minutes. Immediately afterwards the wells were washed with PBS and 
fixed using 3.7% formaldehyde and 300 nM 4′,6-diamidino-2-phenylindole. (DAPI). 
Image acquisition. 
Images were obtained using 488 nm (15%), 543 nm (15%) and 800 nm (6.5%) laser lines. 
Confocal laser scanning microscopy was performed using an Achroplan 40×/0.75 N.A. water 
immersion objective. Z-stacks were defined as a 210.4 ×210.4 × 7.2 μm area with a pixel time 
of 51.2 μs. 
Statistical analysis 
Experiments carried out with three independent repeats in triplicates (N = 3, n = 3) and results 
were normalized using untreated controls. Statistical analysis was carried out using GraphPad 
Prism version 7.04. A normality test was performed on each data set to confirm the use of 
ANOVA. The comparison of metabolic activity was evaluated by 2-way ANOVA analysis 
with Dunnett’s test for multiple comparisons, with adjusted P values < 0.05 considered 
statistically significant. Data was presented as means ± SEM (standard error of the mean). 
Charts include symbols representing adjusted P values, which are shown below. 
Table 3.1 – List of symbols used to represent significance 
P value Symbol 






Results and discussion 
Considerations for using PpIX-loaded CD conjugates for PDT in cell culture 
It has been previously established that colloidal stability of nanoparticle suspensions depends 
on a multitude of factors including concentration and hydrophilicity. The addition of serum 
further complicates this by causing nanoparticle-protein interactions and changing 
sedimentation rates. Additionally, spatial distribution of nanoparticles is affected by the 
administration route, which can lead to drastically different experimental outcomes [35]. 
DMEM-conjugate solutions over 10 μg/ml exhibited a distinct colour change from golden 
yellow to increasingly darker shades of red with the addition of both PpIX and conjugates. 
Sedimentation was apparent for all conjugate samples over 50 μg/ml, while CDs did not show 
observable aggregation even while at concentrations > 1 mg/ml. The use of ultrasonic 
processing effectively removed aggregates prior to their addition to cells. 
Two separate parameters were chosen for the evaluation of conjugate cytotoxicity: dark 
toxicity (inherent toxicity of the particles prior to light exposure) and light-activated toxicity. 
The average lethal concentration at which metabolic activity is reduced by 50% (LD50) was 
estimated using these concentrations. The photo-toxicity index (PI) was also calculated to make 
direct comparisons between conjugates and PpIX. PI links dark and light-activated toxicity – 
higher PI values indicate greater efficiency with lower photoactivation LD50 and increased 
dark toxicity resistance to PS. 
Dark toxicity evaluation 
Carbon dots and PpIX show significantly different dark toxicity values 
CA-EDA and S-EDA CDs were used as controls for CD-induced toxicity and showed good 
cytocompatibility, with >80% metabolic activity even at concentrations of 100 - 250 μg/ml at 
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24 hours, which can be seen in Fig. 3.2. These values are similar to those previously reported 
by Hill et al. (2016) and Xu et al. (2016) for nitrogen-doped CDs (N-CDs) fabricated through 
microwave pyrolysis [39,43]. Surface charge and functional groups are a determining factor in 
CD cytocompatibility: pristine (negative) and PEG-coated (neutral) particles having higher 
LD50 values in comparison to amine (positive) CDs [51]. 
However, N-CDs have been shown to have increased photoluminescence in comparison to 
non-passivated samples and benefit from the availability of primary amine groups for 
crosslinking [55]. In contrast to CDs, PpIX showed significant toxicity at concentrations over 
2.5 μg/ml and an LD50 of ~14.6 μg/ml, which is similar to the literature [293]. Previous studies 
have shown that the overexpression of ATP-binding cassette transporter ABCB6, involved in 
the regulation of porphyrin synthesis, is a key factor in PpIX accumulation within cancer cells 
[294].
 
Fig. 3.2 – CDs and PpIX have significantly different effects on metabolic activity due to 
dark toxicity. PpIX shows a sharp drop in viability after 10 μg/ml (a). In comparison, CD 
cytocompatibility can be clearly seen, with cells maintaining high metabolic activity (>80%) 
at ultrahigh concentrations of 100 μg/ml (b). All samples were compared to the negative 












































































Conjugate toxicity varies according to crosslinking strategy 
PpIX-loaded particles showed a similar decrease in metabolic activity after incubation, as was 
observed with PpIX in Fig. 3.3. PpIX@CD showed slightly higher dark toxicity than 
crosslinked samples at lower concentrations. Nonetheless, total dark toxicity was improved 
significantly as LD50 concentrations increased approximately 6-fold higher than free PpIX 
regardless of loading strategy. PpIX-CD and (PpIX-CD)p showed significant difference to 
PpIX after 5 μg/ml, while PpIX@CD showed a slightly lower improvement at 10 μg/ml. 
Interestingly, (PpIX-CD)p demonstrated the lowest dark toxicity of all samples (~100.5 μg/ml).  
Fig. 3.4 shows all samples together, with CDs and PpIX-loaded CDs displaying a significantly 
higher metabolic activity than PpIX at concentrations >10 µg/ml. 
 
Fig. 3.3 – Conjugates show significantly improved cytocompatibility in comparison to 
PpIX. The improvement was observed regardless of crosslinking strategy. PpIX@CD was 
slightly more toxic than PpIX-CD or (PpIX-CD)p at lower concentrations (<5 μg/ml). Each 




















































































































































Fig. 3.4 – CDs and conjugates have lower dark toxicity than PpIX. PpIX-CD and 
PpIX@CD show similar drops in metabolic activity with increasing concentrations. (PpIX-
CD)p appears to be the most cytocompatible conjugate, closely mirroring CA-EDA until 
around 50 μg/ml. (N=3, n=3) 
 
PpIX-adjustment of conjugate concentrations reveals differences between samples 
Conjugates were previously shown to have varying amounts of loaded PpIX, with PpIX@CD 
(48%) and PpIX-CD (41%) having greater loading efficiency than (PpIX-CD)p (34%). These 
values were used to adjust concentrations from “Particle (ug/ml)” to “PpIX (μg/ml)”, which 
can better reflect the changes in dark toxicity, seen in Fig. 3.5. Adjusted LD50 values showed 
a 3-fold increase in comparison to the drug alone. Interestingly, PpIX@CD exhibited the 
highest LD50 of all samples while containing the highest PpIX concentration at 80.8 μM PpIX-
adjusted (95.4 μg/ml), compared to PpIX-CD (64 μM PpIX-adjusted, 88.5 μg/ml) and (PpIX-
CD)p (60.3 μM PpIX-adjusted, 100.5 μg/ml).  
Nanoparticle toxicity may be influenced by solubility in an aqueous environment, incubation 















































water, is the likely cause of toxicity as it readily aggregates [295]. The decrease in dark toxicity 
of CD-based conjugates is likely a combination of more innocuous intracellular localization 
and decreased formation of aggregates after uptake due to the presence of crosslinked 
nanoparticles. In summary, dark toxicity was uniformly improved in PpIX-loaded conjugates 
and concentrations of 0.5 – 10 μg/ml were selected for further evaluation of phototoxicity. 
 
Fig. 3.5 – PpIX-adjusted concentrations show improved cytocompatibility in conjugates. 
Samples demonstrated decreased dark toxicity after changing values to %PpIX (μg/ml). 
Conjugates showed a similar drop in metabolic activity to PpIX until 4 – 5 μg/ml.  


































































































Conjugate weight PpIX content (%)
 188
Light-activated toxicity 
Selection of light source for PDT 
Previously, conjugates were shown to have an absorbance maximum around 400 nm, with a 
dual emission behaviour stemming from both CDs and loaded PpIX. Singlet oxygen generation 
was also previously demonstrated to be possible after excitation with an Nd:YAG 355 nm laser. 
There were two available options for activating PpIX: a laser (Vortran Stradus 405 nm) and a 
ThorLabs 405 nm mounted LED. The use of a laser allows control over laser power (up to 
maximum 200 mW) with a small spot size of approximately 0.25 – 0.36 cm2. However, 
maintaining irradiation at a constant rate was difficult and only one well from a 96-well plate 
can be treated at a time. In comparison, the mounted LED has lower maximum power output, 
but can easily irradiate a much larger area without causing damage to adjacent tissue through 
heat. LEDs have also been used individually or within arrays to treat patients clinically [296]. 
Although LED output is low (2.76 mW/cm2) it is sufficient to deliver ultralow PDT doses 
which have been reported previously [297]. Furthermore, low irradiance has been shown to be 
beneficial, as photobleaching is significantly diminished below 5 mW/cm2 [298]. 
Determination of maximum LED spot size for consistent photoactivation 
An initial photoactivation test was carried out to determine the maximum area in which light 
exposure produces consistent cell death (Fig. 3.6). Outer wells were excluded from all 
experiments as they serve as evaporation barriers for the inner wells, leading to variable cell 
growth and inconsistent results. Cells treated with solution of 2.5 μg/ml PpIX showed 
drastically reduced metabolic activity after light activation for 3 minutes depending on LED 
height. Wells within the LED spot showed significantly reduced metabolic activity, with values 




Fig. 3.6 – Heatmap indicating variation in phototoxicity. The position of the LED spot 
was adjusted to cover most of the 96 well plate. Wells on the top right corner show a reduced 
PDT effect due to insufficient light exposure. Outer rows and columns were not used as 
media evaporation causes variance in cell growth. 
 
The duration of light toxicity was evaluated at 1, 2, and 3 minutes total light exposure (1- and 
2-minute exposure shown in Fig. 3.7). PpIX and conjugates showed significant light toxicity 
at all concentrations and mostly did not show variation among each other. Initial results show 
PpIX-loaded CDs can produce an equivalent PDT effect to PpIX in vitro. Additionally, both 
PpIX-CD and PpIX@CD showed good photostability during singlet oxygen generation testing. 
This indicates longer timescales or repeated light treatments could be possible without inducing 
bleaching. Further phototoxicity evaluation used 3-minute light exposure due to the greater 
reduction in metabolic activity.  
























Fig. 3.7 – Phototoxicity varies according to total light exposure duration. A 2-fold 
increase in light exposure duration leads to increased variability at higher conjugate 
concentrations. Each conjugate was compared to the positive control PpIX. (N=3, n=3)  
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Calculation of fluence enables comparison with previously published work 
Fluence, also known as radiant exposure, is the total energy output by a light source in a defined 
area, expressed as J/cm2. Together with irradiance, which is expressed in W/cm2, it is possible 
to compare multiple light activation methodologies. Total light exposure (He) is calculated by 








In which Qe is the radiant energy, A is the area, Ee corresponds to the irradiance, and t is the 
time of exposure to irradiation [299]. The total power output was estimated to be 2.76 mW/cm2 
by considering the spot size diameter and maximum power output from the LED as was 
previously set with the driver. This value was close to the average irradiance indicated by the 
manufacturer (2.46 mW/cm2). Thus, a 3-minute period of light exposure is estimated to be 
0.49 J/cm2, which is a very low light dose for PDT. Kah et al. (2008) used a similarly low light 
dose 1.44 J/cm2 (LED irradiance 4 mW/cm2) with gold nanoshells for in vitro PDT, showing 
cell monolayers are susceptible to phototoxicity with low irradiance [300].  
Increased irradiance can be achieved through a variety of means. The most common method is 
the use of lasers, high-powered LEDs or LED arrays and was previously sought after to produce 
an enhanced PDT effect. However, greater irradiance and fluence values have been shown to 
cause significant problems. Photobleaching becomes much more likely as light intensity 
increases and has been shown to be an oxygen-dependent process in PpIX [301]. The bleaching 
dose for PpIX was estimated to range between 1.8 – 3.5 J/cm2 at an irradiance of 5 mW/cm2. 
Robinson et al. (1998) determined that exposure for >1000 seconds reduced PpIX fluorescence 
by over 90% [298]. Additionally, high fluence leads to rapid oxygen depletion within the target 
area. This reduces PDT efficiency as tumours are commonly within a hypoxic 
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microenvironment [302]. Low fluence PDT (< 25 J/cm2) has gained interest as a method for 
bypassing these aforementioned issues and has shown positive results clinically [303]. Ericson 
et al. (2005) showed a significant improvement in treatment outcome as irradiance was adjusted 
from 75 mW/cm2 to 30 mW/cm2 [304]. This highlights the importance of PDT parameter 
screening when selecting different conditions for treatment. 
CDs are not capable of producing a significant PDT effect 
Pre-mixed nanoparticle suspensions were sonicated and vortexed to remove any aggregates 
that formed during storage. CA-EDA and S-EDA CDs were also used to determine if CDs 
alone contribute to cell death after light irradiation. Yi et al. (2017) previously reported N-
doped CDs (N-CDs) capable of singlet oxygen generation due to contributions from surface 
defects [305]. However, results indicate both control samples (CA-EDA / S-EDA) do not 
significantly affect metabolic activity, with equal results regardless of light irradiation duration 
and intensity. This difference could be due to the difference in synthesis conditions. N-CDs 
were synthesized through the solvothermal processing of anthracite in DMF, leading to 
particles with very low oxygen content. While singlet oxygen generation from CDs may be 
capable of enhancing the PDT effect, water solubility is likely to be affected.  
PpIX and conjugates show variable efficiency during photoactivation 
Light activated toxicity of conjugates demonstrated similar LD50 values between PpIX, PpIX-
CD and PpIX@CD, seen in Fig. 3.8. In contrast, (PpIX-CD)p showed a significant difference 
from all other samples with a reduced PDT effect at concentrations over 2.5 μg/ml. (PpIX-
CD)p had previously shown a high singlet oxygen yield in DMF but failed to produce a 
significant phototoxic effect in comparison to the control. This diminished water solubility in 
comparison to PpIX-CD may be caused by the formation of multiple covalent bonds during 
cross-linking leading to self-quenching. As a result, it showed drastically reduced efficiency 
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compared to other PpIX-conjugates with a LD50 of 7.2 μg/ml. (PpIX-CD)p has also previously 
shown high particle size dispersion, further reducing its value as a photosensitizer.  
 
Fig. 3.8 – Light-activated toxicity of CA-EDA conjugates (3-minute light exposure, 24-
hour post light). (PpIX-CD) showed markedly diminished PDT efficiency in comparison to 
other samples. PpIX-CD and PpIX@CD showed equal performance to PpIX at 
concentrations >1 μg/ml (p <0.05). (N=3, n=3) 
 
PpIX-CD and PpIX@CD demonstrated significant difference from PpIX ≤ 1 μg/ml (24 hours) 
but did not show a significant difference at concentrations of > 2.5 μg/ml in any time point. 
Results suggest conjugates are capable of an enhanced PDT effect compared to PpIX, though 
the exact mechanism is unclear. Fowley et al. (2013) first reported the formation of a PpIX and 
CD conjugate with a Förster resonance energy transfer (FRET) mechanism for enhanced PDT, 
where dark toxicity was reduced as a result of improved PpIX dispersibility in aqueous media. 
Furthermore, single and two-photon activation of the conjugates was shown to effectively 
induce phototoxicity [144]. Therefore, it is possible an enhanced PDT effect could be produced 
by PpIX-CD and PpIX@CD due to the same FRET mechanism, using either a lower 
wavelength for CD excitation or via two-photon irradiation. Two-photon (2P) PDT is a highly 













































































targeted treatment for a wide variety of conditions such as brain tumours and other deep-seated 
cancers, while limiting damage to surrounding healthy tissue. However, it is limited by an 
extremely small area due to the energy constraints of high-powered lasers. Although two-
photon photosensitisers have been successfully fabricated and evaluated in vitro, a considerable 
improvement is expected using vectors such as CDs for more efficient intracellular localisation. 
Cell monolayers slowly recover from PDT treatments at all concentrations 
Cell cultures were monitored for an additional 48 and 72 hours post light exposure. Metabolic 
activity in vitro shows a slight recovery at both time points regardless of conjugate type or 
concentration, which can be seen in the Fig. 3.9 and tables A4.1, A4.2 (Chapter 4 Annex). 
PpIX-CD and PpIX@CD followed the same pattern as PpIX >1 μg/ml at all time points, with 
a sharp drop at 24 hours. In contrast, (PpIX-CD)p continuously exhibited decreased 
phototoxicity at all concentrations with high variability, particularly at 72 hours. This variation 
could be caused by cellular response to various sub-lethal concentrations of PSs and light 
treatments. Charara et al. (2017) showed lipophilicity was a key factor in ongoing toxicity even 
after irradiation, with porphyrin-based PS suppressing the metabolism and proliferation of 
MCF-7 cells [306]. However, it is possible that this same mechanism also influences dark 
toxicity for these compounds. 
There are post-illumination effects that lead to cell death after sustained damage by singlet 
oxygen production. Direct damage to organelles includes cytochrome C release and B-cell 
lymphoma 2 (Bcl-2) damage, both of which are involved in the mitochondrial pathway of 
apoptosis [307]. Tumour necrosis factor receptor (TNFR), mitogen-activated protein kinases 
(MAPK), and nuclear factor Kappa-B (NF-κB) both play key roles in apoptosis signalling 
within cells affected by PDT. In comparison to the ordered cell death seen in apoptosis, necrosis 
is a faster and more chaotic form of cell death caused by physical or chemical damage. 
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Fig. 3.9 – Light-activated toxicity of CA-EDA conjugates varies after PDT. 3 minutes of 
light exposure reduces metabolic activity by over 75% after 24 hours of treatment, but slowly 
recovers over a 72-hour period. (N=3, n=3) 























































































































































































PDT-induced damage induces apoptosis through interaction with cellular components 
The exact mechanism of cell death in PDT varies according to a variety of factors including 
subcellular localization of the PS, light dose, oxygen concentration, and cell type [308]. 
However, most research agrees that high dose PDT, which includes high PS concentrations, 
high fluence rates, or both, tend towards necrosis. Likewise, reducing PS concentrations and 
fluence rates appears to guide cells towards apoptosis [309]. 
The intracellular localization of conjugates may also benefit the action mechanism of singlet 
oxygen. The intracellular accumulation of PpIX in mitochondria has been previously reported 
based on its uptake by binding to a mitochondrial translocator protein involved in the heme 
biosynthesis pathway [310]. Additionally, porphyrins have been shown to inhibit several 
important mitochondrial enzymes leading to the inhibition of oxidative phosphorylation [311]. 
PpIX-based conjugates appear to follow these previously described interactions, with the 
advantage of slightly increased water solubility due to the presence of CDs. However, the 
mechanism of cell death after photoactivation of CD-PpIX conjugates is still unclear. PpIX-
induced cell death has been shown to be p53-dependent and independent; Zawacka-Pankau et 
al. (2007) proposed PpIX sensitizes cancer cells making them susceptible to PDT and 
disrupting proliferation through the destabilization of the HDM2-p53 complex in the 
mitochondria [312]. The previous results suggest that the variation of incubation time before 
light exposure may also influence phototoxicity. 
Additionally, results suggest singlet oxygen generation may not be directly linked to increased 
phototoxicity for CD conjugates, as it was previously shown that these values were equal or 
below those obtained from PpIX. Interestingly, PpIX-CD and PpIX@CD only showed slight 
differences in efficacy versus PpIX at all timepoints (Fig. 3.10). This indicates both loading 
strategies are highly efficient methods for improving PDT outcome in vitro. 
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Fig. 3.10 – PpIX-CD and PpIX@CD show similar PDT efficiency to PpIX at 
concentrations >1 μg/ml. In contrast, (PpIX-CD)p shows a constant difference at all 
timepoints with concentrations >1 μg/ml. Each comparison was made between the control 
(PpIX) and conjugates. (N=3, n=3) 
 198
Photo-toxicity index is significantly increased in PpIX-CD and PpIX@CD 
Photo-toxicity index (PI), also known as photocytotoxicity index, is a ratio used to compare 
the effectiveness of photosensitisers. This value is calculated by dividing the LD50 of dark 
toxicity by the LD50 of light toxicity [252]. PpIX-CD and PpIX@CD PI values were improved 
significantly from 14.6 to 46.6 and 59.6 respectively compared to free PpIX, representing a 2.8 
and 3.5-fold increase, seen in Table 3.2. In contrast, (PpIX-CD)p showed slightly reduced PI 
due to its poor phototoxicity but high cytocompatibility compared to PpIX. Therefore, PDT 
efficiency was improved due to the decreased dark toxicity of conjugates. This result highlights 
the importance of photosensitiser cytotoxicity and solubility in PDT effectiveness.  
Table 3.2. PpIX-CD conjugates improve PDT efficiency. 
PPIX % 















0 CA-EDA 0 >100 N/A N/A N/A N/A 
0 S-EDA 0 >100 N/A N/A N/A N/A 
100 PpIX 92.2 14.6 25.8 1.0 1.0 14.6 
43.10 PpIX-CD 63.8 88.6 67.3 1.9 1.9 46.6 
53.13 (PpIX-CD)p 77.1 100.5 99.5 7.2 7.2 13.9 




Confocal scanning laser microscopy (CSLM) 
Confocal laser scanning microscopy (CSLM) was used to observe PpIX-CD and PpIX@CD 
uptake and distribution in osteosarcoma cells (U2-OS). Conjugates were premixed and added 
to cells for incubation for 3 hours. 
CDs can be used as nonspecific bioimaging probes 
CDs showed extremely rapid uptake and fluorescence at all concentrations (1 – 250 μg/ml). 
Fluorescence was observed along the cytoplasm, which is commonly seen in CDs [313]. 
Interestingly, small aggregates can be seen above the cell nuclei. This suggests both CA-EDA 
and S-EDA have a slight affinity for the nucleus in comparison to another subcellular 
localisation. While organelle targeting CDs have been previously reported, results do not 
indicate any other specific binding [314]. CDs were also shown to be capable of weak two-
photon absorption alongside DAPI. However, intensity was diminished possibly due to particle 
self-quenching and aggregation. 
PpIX-loaded conjugates show similarities to PpIX intracellular localisation 
CSLM imaging of PpIX, PpIX-CD and PpIX@CD demonstrated similar behaviour as 
bioimaging probes and are mostly distributed along the cytoplasm, with strong emission at 543 
nm excitation. Fig. 3.11 shows of PpIX and drug-loaded conjugates distributed along the centre 
of cells. In contrast to CDs, these samples did not form aggregates on the nucleus, instead 
remaining on its periphery. Cancer cells have been shown to have increased mitochondria in 
the perinuclear area, which is consistent with our observations [61]. Z-stacks showed both CDs 
and conjugates did not penetrate within the nuclei, while PpIX, did not show a specific 
subcellular localisation.  
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There are small differences between the samples; PpIX-CD appears to have slightly more 
aggregates in comparison to PpIX@CD. However, the latter shows weaker fluorescence 
emission at 488 nm. Interestingly, this is also observed with 543 nm excitation, despite its 
higher drug content. This could be caused by the obstruction of surface defects during PpIX 
encapsulation. Nonetheless, conjugate concentration appears to be higher near the nucleus for 
PpIX-CD and PpIX@CD (Fig. 3.12). Additionally, rapid uptake of all conjugate samples was 
observed at various concentrations and time points.  
Unsurprisingly, (PpIX-CD)p has a noticeably decreased fluorescence intensity in comparison 
to all other samples, which can be seen with its sharply decreased emission at 488 and 543 nm. 
This signal reduction could be caused by multiple factors. It was previously observed that 
(PpIX-CD)p rapidly aggregates due to its poor water solubility. This has been shown to cause 
quenching as carbon dots and PpIX [220,315]. These results indicate PpIX-CD and PpIX@CD 




Fig. 3.11 – CD-PS conjugates can be used as probes for fluorescence imaging. CSLM 
images of U2-OS osteosarcoma. PpIX-CD and PpIX@CD have similar emissions to both 
CDs and PpIX, while (PpIX-CD)p has greatly decreased fluorescence emission. Conjugates 





Fig. 3.12 – CD-PS conjugates show non-specific intracellular localisation. CSLM of 
conjugates show accumulation in the perinuclear area and cytosol. Both PpIX@CD and 
PpIX-CD (not shown) particles did not penetrate within the nucleus, which can be seen 
through the comparison of z-slices. Lower z-slices (left) do not show brightness with DAPI 
staining while CD and PpIX fluorescence is high. Conversely, higher z-slices (right) clearly 





The evaluation of cytotoxicity is a crucial component of research into new nanomaterials. PDT 
and other similar biomedical applications require compounds that are simultaneously highly 
efficient and biocompatible. Conjugation with nanoparticles as carriers has been used to 
improve drug solubility and enhance their therapeutic effect. Previously, characterisation 
showed similarities between conjugates and PpIX in surface chemistry, but improved stability 
in water. 
Dark toxicity was evaluated to determine the inherent cytocompatibility of nanoparticles in 
cells. CDs showed high cytocompatibility in vitro at concentrations up to 250 μg/ml with 
minimal variations between samples (CA-EDA and S-EDA). PpIX-containing CDs showed a 
2.2 to 3.7-fold decrease in dark toxicity compared to PpIX. Interestingly, (PpIX-CD)p showed 
the highest LD50 (100.5 μM PpIX) compared to PpIX-CD (88.5 μM PpIX)and PpIX@CD 
(95.4 μM PpIX). 
Light-activated toxicity was evaluated to determine differences between conjugates. PpIX-CD 
and PpIX@CD showed equivalent light-induced toxicity to PpIX in concentrations >1 μg/ml, 
leading to a 3.2 to 4.1-fold increase in photo-toxicity index (PI). These results demonstrated 
host-guest encapsulated PpIX@CD and carbodiimide-linked PpIX-CD conjugates produce 
similar PDT effect to that of PpIX with a lower drug concentration, increasing the therapeutic 
window of the compound. In contrast, (PpIX-CD)p showed decreased phototoxicity in 
comparison to PpIX. Further monitoring of cells revealed post-illumination suppression of 
proliferation at 48- and 72-hours post exposure. 
Confocal light scanning microscopy demonstrated rapid intracellular uptake and accumulation 
of conjugates. CDs were rapidly taken up by cells and remained within the cytoplasm, forming 
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small aggregates within the nuclei. In contrast, PpIX-loaded particles were located within the 
periphery of the cell nucleus, suggesting accumulation near mitochondria. PpIX-CD and 
PpIX@CD showed strong photoluminescence at low concentrations (1 μg/ml) similar to both 
PpIX and CDs. In contrast, (PpIX-CD)p showed rapid quenching and low photoluminescence. 
CD-based conjugates have great potential in biomedical applications as carriers in PDT, as well 
as biomedical applications related to theragnostics, drug delivery, and bioimaging. 






Chapter 4 – Phototoxicity and bioimaging of CD-PpIX conjugates in a 
cancer spheroid cell model 
 Introduction 
Clinically, solid tumours grow in varied locations within the body, occupying a three-
dimensional (3D) space in which characteristic conditions such as hypoxia, drug resistance, 
and dormancy appear [316]. The complex interaction between tissue oxygenation, 
vascularisation, light absorption, and drug biodistribution makes selecting ranges for PDT 
parameters difficult. Thus, animal models are often used early in the translational process. 
However, the testing these novel agents/formulations is more complex than for many non-light 
activated small molecules by the requirement for light and oxygen for activity, hence the need 
custom models to study PDT. 
Currently, in vivo tumour xenograft mouse models are the gold standard for PDT evaluation, 
with PS being administered by subcutaneous injection or topical application, shown in Fig. 4.1. 
Human tumour xenografts have also been explored for PS evaluation but are susceptible to 
infections [317]. Although in vivo models have been widely successful, they are limited by 
high costs and strict regulatory controls. The evaluation of multiple PDT parameters and 
treatment combinations becomes increasingly more difficult due to the number of animals 
required. Thus, there is an urgent need for better models of PDT for PS evaluation prior to in 
vivo testing.  
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Fig. 4.1 – In vivo mouse models are the current gold standard for cancer drug testing. 
Typically, there are two distinct approaches: human xenografts make use of cancer cell lines, 
while syngeneic models use allografts from immortalised mouse cancerous tissue. Adapted 
from Noble and Mishra (2019) with permission from Springer Nature [318]. 
 
 
In comparison, traditional cell culture using cell monolayers (2D) cannot accurately replicate 
these conditions in vitro due to vastly different diffusion rates and cell-cell in 3D versus 2D 
[319]. The recreation of tumour microenvironment and tissue architecture is key to understand 
tumour biology and develop new strategies for treatment. There are various models used for 
this purpose, which include organotypic tissue cultures from patients [320], scaffolds for tissue 
engineering [321], organoids [322], and spheroids [323]. 
Multicellular tumour spheroids (MCTS) are a well-known 3D cell model which resemble 
tumours morphologically and biologically. Spheroids can be grown using a variety of 
immortalised cell lines or patient-derived tissue samples [324]. Their growth can be stimulated 
by preventing cells from attaching to a suitable surface, which promotes the formation of cell-
cell interactions, production of extracellular matrix, and compaction. In turn, this leads to the 
formation of biologically relevant zones: an outer layer with rapidly proliferating cells, an 
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intermediate layer with cells in a state of quiescence, and an inner necrotic layer caused by 
hypoxia and nutrient deficiency (Fig. 4.2) [325]. Spheroids have demonstrated higher drug 
resistance in comparison to cell monolayers as there are more barriers for delivery such as 
binding to the extracellular matrix, membrane proteins, cell membranes, or cell-cell junctions 
[326]. PDT is particularly limited by the availability of oxygen diffused within the cell 
microenvironment. Furthermore, hypoxic inner regions lead to inefficient diffusion and the 
development of necrotic cores, which have also been shown to influence drug response [327]. 
Nonetheless, spheroids have seen increasingly more research interest in the area of PDT. Their 
innate properties, ease of production, and similarities to in vivo tumours makes them ideal for 
PDT parameter screening in comparison to cell monolayers [328]. 
 
Fig. 4.2 – 3D cell culture models improve the relevance of in vitro drug evaluation. 
Cancer spheroids can replicate relevant morphophysiological characteristics of in vivo 
tumours like hypoxia and increased drug resistance. They have also been widely used in 
high-throughput screening and are easily produced with inexpensive reagents. Nonetheless, 
their single cell line lineage and inability of long-term culture limit their usefulness in 
comparison of organoids. 
Cell monolayer Cancer spheroid (MCTS)
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However, standardisation of spheroid culture is difficult, mainly due to variability during initial 
stages of growth. The method of preventing cell adhesion influences heterogeneity in spheroids 
grown in identical conditions. Spheroid size is also directly linked to drug resistance, with 
larger (500 μm) spheroids showing up to a 22-fold increase difference compared to cell 
monolayers with PDT. Spheroids >250 μm showed a 40-50% decrease in drug uptake, while 
100 μm spheroids did not show a significant difference from cell monolayers during 
exponential or plateau growth phases [329]. Therefore, identifying an appropriate phase of 
spheroid development is crucial for evaluating drug phototoxicity. Fig. 4.3 shows a summary 
of previously used PpIX-containing conjugates used for in vitro PDT in Chapter 3. 
 
Fig. 4.3 – Schematic detailing conjugates used for in vitro PDT. PpIX-CD and (PpIX-
CD)p were fabricated through amide crosslinking. The latter corresponds to the insoluble 
(precipitate) fraction separated from PpIX-CD after centrifugation. PpIX@CD was obtained 




Aim: Screen treatment combinations to determine best parameters for low fluence PDT using 
multicellular cancer spheroids. 
Objectives:  
 Select a time point during spheroid growth for PDT evaluation based on growth kinetics. 
 Determine in vitro PDT parameters for spheroids based on previously measured LC50 
concentrations and light doses. 
 Evaluate the effect of light fractionation (sequential light exposures) on spheroid damage. 
 Examine PDT-induced morphological changes in spheroids using light sheet fluorescence 




All reagents were used as received unless stated otherwise. Deionized water was used for all 
buffers and samples in experiments. 
Materials 
2-hydroxyethylagarose, formaldehyde, and dimethyl sulfoxide (DMSO) were acquired from 
Sigma Aldrich (United Kingdom). Dulbecco’s modified Eagle’s medium (DMEM, high 
glucose), Dulbecco’s modified Eagle’s medium (DMEM, high glucose, without phenol red), 
foetal bovine serum (FBS), Quant-iT Picogreen dsDNA quantification kit, Pierce LDH 
cytotoxicity assay kit, LIVE/DEAD Viability/Cytotoxicity Kit for mammalian cells, and 
trypsin-EDTA were obtained from Thermo Fisher (United Kingdom). Syringe filters with a 0.2 
μm pore size were acquired from Sarstedt (United Kingdom). 1 KDa MWCO, 6.4 ml/cm 
dialysis tubing was acquired from Spectrum Labs (United States of America).  
Sample preparation 
CD-PS conjugates were prepared according to a previously described protocol [330]. CDs were 
synthesized via the microwave pyrolysis citric acid or sucrose, with ethylenediamine as a 
passivating agent and PpIX for host-guest embedded conjugates. Amide cross-linking was used 
to bind CDs and PpIX. Conjugates were further processed utilising centrifugation and dialysis 
to remove excess reagents and waste products. 
Multicellular tumour spheroid (MCTS) culture 
Cells were donated by Dr. Helen Bryant from the Medical School, University of Sheffield. The 
cell lines C8161 (human melanoma) were cultured in phenol red-free DMEM with 10% foetal 
calf serum, 1% penicillin and streptomycin, and 1% L-glutamine. Cells were cultured in a T75 
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plate at 37°C, 5% CO2 until around 80% confluence.  Multicellular tumour spheroids were 
produced utilising agar coating to prevent cell adhesion. A 1.5% agarose solution was prepared 
with 2-hydroxyethylagarose and standard cell culture media (DMEM). This solution was 
sterilised by autoclave and stored at 4°C. Agar-coated plates were prepared by adding 100 μl 
of the agarose solution into each well and left to set at room temperature for at least 1 hour. 
Plates were seeded with 100 μl phenol red-free media containing 6 x 103 cells per well and 
returned to the incubator until spheroids reached approximately 500 μm diameter. Growth 
media was changed every third day by adding 100 μl to each well and removing an equal 
volume.  
Photoactivation with multicellular tumour spheroids 
Spheroids were subjected to single and double light exposure periods with a mounted LED. 
Conjugates were subjected to ultrasonic processing with a Hieschler UP50H ultrasonic probe 
prior to the dilution to remove aggregates and dissolved in phenol red-free media at a 
concentration of 50 μg/ml, being kept refrigerated until used. Stock solutions were placed in 
an ultrasonic water bath for 15 minutes at 37°C. Spheroids were treated using conjugate 
dilutions to achieve concentrations of 1, 5, and 10 μg/ml in a 200 μl volume. The plates were 
then returned to the incubator for 2 hours to allow uptake.  
A M405L2 ThorLabs mounted LED with a collimator adapter (405 nm, 2.76 mW/cm2) was 
used to induce light-activated toxicity.  Single exposure samples were placed under 
illumination for 15, 30, and 60 minutes and subsequently returned to the incubator, 
corresponding to 2.5, 5, and 10 J/cm2. Sequential light exposure was carried out for spheroids 
on Day 2. LDH release and DNA quantification were measured at 24, 48 and 72-hour time 
points (post light activation). 
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LDH release assay 
LDH (lactate dehydrogenase) is an enzyme present in all cells which is used as a marker for 
plasma membrane damage. Adverse conditions cause enzyme leakage, which can be quantified 
colorimetrically as a red-coloured formazan product is formed when adding a tetrazolium salt. 
This is a rapid and inexpensive assay which can differentiate between growth inhibition and 
cell death [331]. While resazurin reduction is a useful tool for determining metabolic activity, 
determination of spheroid viability is more useful for PDT evaluation.  
LDH release was measured in all samples by collecting 50 μl of media and transferring it to a 
96-well plate. Spheroids with no conjugates and equal irradiation times were used as negative 
controls for spontaneous LDH release. The positive control was carried out by incubating 
spheroids with TE buffer (10 mM Tris-HCl, 1 mM EDTA, pH 7.5) for 45 minutes. An 
additional four freeze-thaw cycles were used to ensure membrane disruption and indicate 
maximum LDH release. Subsequently, 50 μl LDH working solution was added to each well 
and covered to avoid contact with light. Plates were incubated for 30 minutes and 50 μl LDH 
stop solution was added to finalise the reaction. Absorbance for each well was read at 490 nm 
(LDH) and 680 nm (background) with a with a fluorescence plate reader (Biotek Instruments 
ELx800). Viability was calculated with the following formula: 
%             =  
(                   −                        )
(                    −                        )
× 100 
%          = %                     −  %                   
dsDNA quantification (PicoGreen) assay 
Changes in cell growth are typically measured using metabolic activity assays such as MTT or 
resazurin reduction. However, they may not always accurately represent actual cell numbers, 
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leading to discrepancies between assays. In comparison, dsDNA quantification can provide a 
much more precise measurement that is independent of intracellular conditions. PicoGreen is 
a dye which increases its fluorescence after binding with DNA and can be easily quantified 
using a microplate reader. It is also well-suited for spheroid analysis as it does not suffer from 
false readings due to high ECM content. However, samples require complete lysis to release 
all dsDNA for measurement.  
Picogreen working solution was prepared by dissolving the reagent in TE buffer (10 mM Tris-
HCl, 1 mM EDTA, pH 7.5) according to the instructions from the manufacturer. Spheroids 
were removed from each well and placed in a 96-well plate and carefully washed three times 
with 50 μl sterile PBS to remove cellular debris. Cell lysis was performed by adding 50 μl TE 
buffer to each well and freeze-thawed four times. An equivalent volume of 100 μl Picogreen 
working solution was added. Plates were covered from light and incubated for 10 minutes at 
room temperature. Fluorescence was read at 485 nm excitation and 528 nm emission with a 
fluorescence plate reader (Biotek Instruments FLx800). A blank was prepared by adding 
deionised water and Picogreen in equal volumes.  
Live/dead Staining 
Cells were stained with 2 μM calcein AM and 4 μM ethidium homodimer-1 to differentiate 
live and dead cells. Staining solutions were prepared on the day of use to avoid the spontaneous 
hydrolysis of calcein AM due to moisture. Spheroids were moved to new wells and gently 
washed with PBS before adding 100 μl of staining solution. The plates were left at room 




Images were obtained using an AE2000 inverted light microscope (Motic, United States) fitted 
with a Moticam 2.0 camera (2 MP) and a 4x objective. Images were obtained before and after 
clearing cellular debris from each well. White balance was used increase spheroid contrast 
against the background. 
Light sheet fluorescence microscopy (LSFM) 
Spheroids were embedded in 1% 2-hydroxyethyl agarose prior to imaging. LSFM was carried 
out with a Zeiss Z.1 light sheet microscope (Zeiss, United Kingdom) fitted with a W Plan-
Apochromat 10x objective. Images were obtained as Z-stacks with a 1.8 μm slice interval and 
a size of 878.09 μm × 878.09 μm. Light sheet thickness was adjusted to 6.4 μm and the pixel 
size was 0.46 μm. Image processing was carried out using Zeiss ZEN 2014 SP1 software 
version 9.2.0.0 and ImageJ. 
PpIX uptake quantification 
PpIX uptake within MCTS was confirmed through fluorescence based on its emission at 633 
nm after excitation with the 405 nm laser line. Additionally, a separate control to measure 
background fluorescence was prepared by adding growth media instead of nanoparticle 
suspension. The innermost section of each spheroid was taken to estimate total PpIX uptake. 
Live/dead microscopy 
The equipment was set up with the following: a 405/488/561/640 nm laser blocking filter, an 
SBS 560 nm long pass filter. Images were captured simultaneously: Calcein AM (live, 505-
545 nm bandpass filter) and ethidium homodimer-1 (dead, 660 nm long pass filter). A 448 nm 
laser was used at 0.6% power with 119.85 ms exposure time. Each spheroid was imaged at 0, 
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120, and 240 degrees with the same parameters. 
Drug uptake analysis 
After a 3-hour uptake period, samples were fixed with 3.7% paraformaldehyde overnight and 
kept at 4°C until used. The equipment was set up with the following: a 405/488/561/640 nm 
laser blocking filter, an SBS 560 nm long pass filter.  A 405 nm laser (5% power and 199.7 μs 
exposure time) was used to acquire images. Fluorescence intensity was measured within the 
middlemost section of the spheroid as determined by Z-stacks (2 μm interval).  
Scanning electron microscopy (SEM) 
Spheroids fixed in 3.7% paraformaldehyde were washed twice in PBS at intervals of 10 
minutes. Afterwards, they were fixed a second time in 1% aqueous osmium tetroxide for 1 hour 
at room temperature before undergoing two more PBS washes. Samples were exposed to an 
ethanol series at room temperature at 15-minute intervals (75%, 95%, 100%, 100% dried over 
anhydrous copper sulphate). Each sample was placed in 50/50 mixture of 100% ethanol / 100% 
hexamethyldisilazane for 30 minutes, followed by 30 minutes in 100% hexamethyldisilazane. 
Spheroids were air-dried overnight in a fume-hood and coated with gold in an Edwards S150B 
sputter coater. SEM micrographs were obtained using TESCAN Vega 3 LMU Scanning 
Electron Microscope at an accelerating voltage of 20 kV. 
Statistical analysis 
Experiments carried out with three independent repeats in triplicates (N=3, n=6) and results 
were normalized using untreated controls. Statistical analysis was carried out using GraphPad 
Prism version 8.3.0. A normality test was performed on each data set to confirm the use of 
ANOVA. The comparison of metabolic activity was evaluated by 2-way ANOVA analysis 
with Dunnett’s test for multiple comparisons, with adjusted P values < 0.05 considered 
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statistically significant. Data was presented as means ± SEM (standard error of the mean). 
Charts include symbols representing adjusted P values, which are shown below. 
Table 4.1 – List of symbols used to represent statistical significance. 
P value Symbol 







Results and Discussion 
Spheroid culture 
Selection of spheroid culture system 
Spheroids can be formed by covering tissue culture plates with a material which prevents 
specific and unspecific cell attachment. Although there are other alternative methods for 
spheroid production such as hanging drop and rotating vessels, the use of non-adherent surfaces 
does not require additional equipment and can be adapted for use with biological assays. 
However, there is no effective control of spheroid size and variations are common between 
plates, even considering the use of ultra-low attachment microplates.  
The agar coating method with 2-hydroxyethylagarose has been previously used to successfully 
produce MCTS from various cell lines, such as NCI-ADR-RES (ovarian adenocarcinoma) and 
HUH7 (hepatocellular carcinoma) [84,332]. This is a simple, low-cost, and reliable method for 
cultivating spheroids which makes use of agarose dissolved in serum-free media. A total of 
100 μl agar allowed cells to remain in suspension and form three-dimensional aggregates, 
leaving approximately 100 μl extra volume for growth media.  
Spheroid growth kinetics can be used to select the best time point for experiments 
First, a preliminary study was carried out to determine the growth kinetics of C8161 with 
different cell seeding densities. MCTS can begin forming with as low as 100 cells per well and 
quickly develop different zones. Spheroids under 200 μm typically have proliferating and 
quiescent cells, while those around 300 μm begin to show signs of hypoxia in their centres. 
Furthermore, the diffusion limit of molecules such as oxygen is 150 – 200 μm, leading to the 
formation of a necrotic core in spheroids larger than 500 μm after several days [333]. 
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Fig. 4.4 – Spheroid growth kinetics based on initial seeding density. Diameter was 
measured using images taken with an AE2000 inverted light microscope and ImageJ. Growth 
reached a slowed after spheroids passed 600 µm. 
  
The manipulation of low cell densities for spheroid formation is challenging as there is an 
increasingly greater variation in diameter and the experiment time greatly increases. A seeding 
density of 12,500 cells per well was selected as it continued growth until slowing after day 13 
post-seeding (Fig. 4.4). A key advantage of large spheroids (>500 μm) have been shown to 
have a high degree of similarity to murine xenografts in cell cycle and apoptosis [334]. They 
have also shown increased drug resistance in comparison to smaller aggregates (<300 μm), 
likely due to a combination of necrosis and hypoxia [335].  
In the following experiments, a series of morphometric parameters were acquired using 
automatic image processing software (AnaSP). Spheroids were preselected before PDT based 
on their sphericity, ensuring drug uptake and diffusion variations are minimised. This 
methodology will be expanded upon in Chapter 6. 























Assays for estimating of drug-induced toxicity vary in 3D cell models 
MCTS are compatible with many of the commonly used cytotoxicity assays for monolayers, 
including MTT and resazurin reduction. The combination of multiple assays can be used to 
elucidate more information regarding treatment effectiveness. However, there are key 
limitations to their use with spheroids. These assays are indirect measurements of cell viability 
which are affected by variables such as cell culture conditions, incubation time, and lack of 
supplied standards, which need to be standardised previously. Nonetheless, they are widely 
used as initial tests for nanoparticle cytotoxicity evaluations. This has led to increasingly 
greater discrepancies as the estimation of cell proliferation after exposure to unknown 
compounds is not optimal [336].  
However, it has been shown that the higher cell density within 3D cell models, including cancer 
spheroids, results in great inconsistencies in comparison to traditional cell monolayers. Firstly, 
metabolism drastically changes in spheroids, particularly due to cell-cell interactions and the 
presence of cell layers (proliferating, quiescent, and necrotic). In comparison to cell 
monolayers, which keep expanding until they take up all available space, spheroids typically 
reach a maximum size and maintaining their state for several days before dying. Secondly, the 
diffusion of reagents through a 3D environment is inconsistent and leads to poor 
reproducibility. Therefore, the selection of an appropriate assay is essential to evaluate MCTS 
drug response [337]. 
LDH release was chosen to monitor the relative damage to cell membranes in each spheroid. 
While other assays such as MTT or ATP quantification are well-known and low-cost, repeated 
measurements are impossible as spheroid disruption is required to analyse the contents. Alamar 
blue (resazurin reduction) assay can be used without affecting the sample but is difficult to 
standardise as spheroids are suspended on agar, which absorbs part of the solution and is 
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difficult to wash away. In contrast, the LDH assay only requires a small aliquot of growth 
media to analyse each sample, reducing the risk of spheroid disruption as samples which have 
been heavily damaged by PDT are often very structurally weak and readily break apart if not 
handled carefully.  
DNA quantification is another parameter which can be compared when evaluating PDT effect 
and its subsequent cytotoxicity. However, it is heavily reliant on complete cell membrane 
disruption in order to accurately quantify total DNA in each sample. Although the 
manufacturer’s guidelines suggested the use of a lysis buffer (TE, Tris-EDTA), it was observed 
that it was not enough to cause total spheroid disruption even after incubation for 4 hours. 
Therefore, the protocol was changed to use TE buffer in combination with a total of 4 freeze-
thaw cycles, ensuring each sample was completely lysed prior to analysis. 
It is important to take note that LDH release should not be considered directly proportional to 
total DNA content. As previously mentioned, LDH release is caused by damage to cell 
membranes, which causes leakage of intracellular components to the media. The half-life of 
LDH is approximately 9 hours, though it varies according to the enzyme isoform. Therefore, it 
is best used as a representation of the total damage sustained by cells at a specific timepoint 
[338]. In comparison, DNA quantification is a much more sensitive detection method based on 
the specific binding of the Picogreen dye to dsDNA as it can detect as few as 50 cells, taking 
advantage of its >1000 fold increase in fluorescence when bound to dsDNA [339]. 
  
 222
Light microscopy (LM) 
Monitoring spheroid growth and hypoxic core formation 
Light microscopy was used to monitor spheroid growth throughout several days, observing 
morphology to determine variations between wells. Hypoxic core formation has been reported 
to occur within 4 – 10 days, depending on cell type and initial seeding density. Oxygen 
deficiency has been shown to be a crucial part of cancer drug resistance and is linked to the 
overexpression of VEGF (angiogenesis) and CD44 (adhesion receptor) [323]. The appearance 
of the hypoxic core can be seen in Fig. 4.5, with the inner section of the spheroid becoming 
more pronounced as cell compaction separates the layers into proliferating, quiescent, and 
necrotic [340]. 
 
Fig. 4.5 – Progression of spheroid growth after initial aggregation. Spheroids reach a 
maximum diameter (~600 μm) and maintain their morphology until decaying. 
 
The workflow of screening PDT parameters with spheroids requires frequent observation of 
individual samples to reduce the effect of cellular debris on biological assays (Fig. 4.6). Though 
PDT required spheroids to be outside of normal incubation conditions, prolonged exposure to 
stress caused a slight disruption in the outer layers. Spheroids of 450 – 500 μm were selected 
as they showed the presence of hypoxia in the core region while having outer layers of 
proliferating cells. Though larger spheroids could have been used (600 μm) these would have 
variations in drug response as cells pass from proliferation to quiescence. 




Fig. 4.6 – Multicellular tumour spheroids react differently to PDT. Spheroids were 
selected for use in PDT after reaching ~450 μm (A). Prolonged exposure to environmental 
stress in addition to conjugate dark toxicity caused slight damage to the outer cell layer (B). 
PDT caused significantly more damage, resulting in large seen as debris surrounding the 
spheroid (C). Debris can be removed to reveal the spheroid (D).  
 
Dark toxicity 
Spheroids show increased resistance to dark toxicity compared to cell monolayers 
Dark toxicity in MCTS was re-evaluated to observe differences from monolayers and select an 
appropriate PpIX concentration range for PDT. PpIX showed a steady drop in spheroid 
viability as evidenced by the elevated LDH release. Nonetheless, the highest concentration of 
10 μg/ml did not drop viability below 50%. In comparison, PpIX-CD and PpIX@CD 
consistently showed a decreased impact at all timepoints with concentrations over 1 μg/ml (Fig. 




Fig. 4.7 – LDH release varies according to sample type and dose (μg/ml). PpIX-adjusted 
values show samples have similar dark toxicity in spheroids. Each sample was compared to 
the positive control PpIX. (n=6, N=3) 
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Fig. 4.8 – Total dsDNA concentration shows less variability between samples and 
concentrations. PpIX-adjusted concentrations show similar behaviour to LDH release, with 
no significant difference between conjugates and PpIX. Each sample was compared to the 




However, PpIX-adjusted values indicate there is no significant drop in viability based on total 
drug content, with the highest dose (10 μg/ml) only reducing around 20% of the spheroid 
viability. PpIX@CD initially showed slightly improved cytocompatibility at 24 hours post-
exposure, though the difference ceased at later time points. These results are consistent with 
those found through the initial cytotoxicity evaluation of CD-PS conjugates in the previous 
chapter. Likewise, the slight recovery of viability after treatment (48-hour timepoint) was 
previously observed in cell monolayers. 
DNA quantification showed a similar behaviour, with concentrations over 1 μg/ml showing 
significant difference between samples and control (Fig. 4.8). PpIX-CD once again showed 
very similar behaviour to the control with PpIX-adjusted concentrations at most timepoints. 
Interestingly, PpIX@CD continued to slightly outperform PpIX-CD with higher viability at 5 
and 10 μg/ml. Spheroids began recovering after 48 hours post-PDT, as shown in Fig. 7, 
particularly at 10 μg/ml.  
In summary, results appear to indicate doses of 1 – 5 μg/ml are ideal, though conjugates could 
be used up to >10 μg/ml. While PpIX showed a significantly improved PDT effect in 2D, the 
variability induced by high dark toxicity makes lower concentrations easier to evaluate. 
Spheroid DNA content and membrane damage are very near the values for control spheroids 
in this concentration range.  
Variation between 2D and 3D cell culture is due to morphophysiological cues 
Previously, results from 2D cell culture showed conjugates reduced metabolic activity by 50% 
at higher concentrations than PpIX (88.5 μg/ml PpIX-CD, 95.4 μg/ml PpIX@CD, 14.6 μg/ml 
PpIX). In comparison, spheroids demonstrated higher drug resistance than monolayers with all 
samples, particularly at the highest tested concentration of 10 μg/ml. LDH release and DNA 
quantification showed a similar trend, slightly decreasing as drug concentration increased.  
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Though a direct comparison between resazurin reduction and LDH or Picogreen is not ideal 
due to the characteristic differences in measured variables, there was one key difference that 
could be observed between 2D and 3D models. PpIX showed a significant difference in dark 
toxicity from 5 μg/ml compared to the conjugates in cell monolayers. This difference was not 
observed with MCTS, which only showed significant differences for PpIX@CD at PpIX-
adjusted concentrations over 2.5 μg/ml on days 1 and 2 post-PDT for both LDH and Picogreen. 
Contrariwise, PpIX-CD showed very similar behaviour to PpIX at all timepoints with PpIX-
adjusted concentrations.  
There are different proposed mechanisms for increased drug resistance in spheroids which have 
been explored in the literature. The three-dimensional structure of spheroids has been 
previously shown to influence drug uptake depending on a multitude of factors such as 
spheroids size, cell type, and phase of cell cycle [341]. While the stroma and other cellular 
components are typically the focus of research, extracellular matrix and the interstitial fluid 
surrounding the main tumour mass have also been found to be an important factor in drug 
response. Normal tissue typically has 14-34% of its total volume occupied by interstitial fluid, 
while tumour tissue exhibits a much higher range of 36-53% [342]. This significantly affects 
drug and nanoparticle distribution as they typically rely on concentration gradients. Therefore, 




Ultra-low fluence rates can be used to determine light toxicity thresholds 
Initial light treatment (LT) tests showed a significantly different response from spheroids in 
comparison to cell monolayers after 5 minutes of exposure (0.83 J/cm2). This was expected as 
MCTS showed consistently higher drug resistance during dark toxicity evaluation. Therefore, 
the total light exposure (irradiance) was adjusted to higher values (2.5 – 10 J/cm2) where greater 
phototoxicity could be observed. While it is a 3 to 12-fold increase, total light exposure is still 
within the ultra-low fluence range [344].  
Values for total light exposure in the literature range from 25 J/cm2 in the low end to >350 
J/cm2 with high dose conditions, delivered through a laser light source instead of an LED [345]. 
Laser setups has the advantage of delivering a large amount of energy in less time without 
power loss due to light scattering and controlling laser power by adjusting the beam. However, 
high power output has also been shown to cause photobleaching and tissue damage. LEDs are 
a low-cost reliable alternative that has shown clinical success with PDT at various fluence rates 
[346]. Damage distribution to tumours also varies according to irradiance, with scar formation 
and other symptoms appearing after high fluence PDT [347]. 
In this chapter, fluence was adjusted to the ultra-low range (>10 J/cm2). This range was 
previously utilised by Matthews et al. (2009) to deliver sub-lethal light doses to human glioma 
spheroids with 5-aminolevulenic acid at 1.5 – 6 J/cm2 [297]. Additionally, photobleaching rates 
have been shown to vary according to light intensity (mW/cm2) and refer to the point at which 
~37% of fluorescence signal strength is lost. PpIX bleaching rates vary from 3.5 J/cm2 at 5 
mW/cm2 to 6 J/cm2 at 150 mW/cm2 [298]. This intensity value is well below the 2.76 mW/cm2 
output of the mounted LED, which should circumvent PpIX photobleaching in the experiments. 
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Fractionated treatments were also carried out, in which the total light dose was separated by a 
24-hour time interval. This is represented by the abbreviation “LT”, which is short for light 
treatments. For example: 5 J/cm2 (2LT) would correspond to a 30-minute (5 J) exposure on day 
1, a 24-hour interval between doses, and a second exposure on day 2. Other abbreviations and 
explanations for PDT parameters can be found in Table 4.2. Fractionation in PDT has been 
proposed as a method for improving treatment outcome without requiring the use of longer 
timescales for irradiation or higher drug doses. This method has shown positive results in pre-
clinical trials, with 2-fold illumination treatments showing a markedly improved complete 
response rate compared to the control [348].  
Table 4.2.  Explanation of PDT parameters screened with spheroids. 
Parameter Range Summary 
Fluence  
(J/cm2) 
2.5 / 5 / 10 
Total energy delivered per area. Most 








1 or 2 




24 / 48 / 72 




1 / 5 / 10 
Concentration based on previously obtained 
results in Chapter 4. 
 
Spheroids react to stressful environmental conditions after prolonged exposure 
A separate experiment was carried out using spheroids without PS in order to determine 
potential drops in viability due to prolonged time outside standard incubation conditions. The 
effect of 405 nm light exposure was also investigated using the same methodology. Spheroids 
placed outside the incubator for 2 hours began to show some signs of stress as their morphology 
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changed, with some cells on the outer layers becoming detached. This happened regardless of 
light exposure duration. However, there was no significant difference after returning spheroids 
to the incubator for 24 hours (Fig. 4.9). Therefore, total light irradiation time had to be adjusted 
to a maximum of 60 minutes, corresponding to 10 J/cm2. This ensured more light could be 
delivered without significantly altering results due to sample variability. 
 
 
Fig. 4.9 – Effect of prolonged exposure to environmental stress on spheroid viability. 
Spheroids showed no significant difference in LDH release and total DNA content after a 2-
hour period outside the incubator. Each sample was compared to spheroids left within 
incubation conditions. (n=3, N=3) 
 
Light toxicity in spheroids caused varying degrees of cell death 
Spheroids showed a significant increase in resistance to light-activated toxicity in comparison 
to 2D cell culture. Cell death can be seen easily through light microscopy (LM) as a halo of 
debris surrounding the spheroid. The quantity of debris changes depending on experimental 
conditions and sample used; typically, higher light and drug doses induce greater PDT effect 
(Fig. 4.10). Spheroids with extensive damage undergo changes in their morphology, losing 
their spherical shape and becoming deformed as lysis occurs [349]. Media changes can be used 
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to slowly remove debris from each well, though this becomes more difficult with increasing 
damage. Spheroids with the highest parameters (10 μg/ml, 10 J/cm2, 2LT) were prone to 
complete disruption after trying to rinse out their well. All spheroids used in light toxicity 
experiments were washed to lessen variability due to remaining dsDNA or LDH within debris. 
 
Fig. 4.10 – PDT-induced phototoxicity in spheroids after 24 hrs (PpIX-CD 5 μg/ml, 5 
J/cm2, 1LT). Cell debris precipitates to the bottom of the well, obscuring the spheroid. 
Removal must be done with care to avoid spheroid disruption. 
 
All evaluated conditions showed a decrease in both viability and total DNA content after PDT. 
As expected, low drug doses (1 μg/ml) combined with low irradiance (2.5 J/cm2) did not show 
a strong PDT effect. The increase of both dose and irradiance significantly increased treatment 
effectiveness. Double light treatments showed significant difference from single treatments at 
most experimental conditions, which is consistent with the literature [350].  
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Fig. 4.11 – Light fractionation improves PDT outcome. Fractionated treatments (2LT) 
showed significant differences from single treatments (1LT) at concentrations >5 μg/ml. 
Higher irradiance and drug concentration significantly increased damage to spheroids 
regardless of sample type. (N=3, n=6) 
 
There was a significant difference in observed values between LDH release and DNA 
concentration at low light doses and drug concentrations. As can be seen in Fig. 4.11, LDH 
values (% viability) consistently show significant difference between 1LT and 2LT, regardless 
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of sample or conditions. In contrast, total dsDNA has no significant change, particularly at 2.5 
J/cm2 and 1-5 μg/ml.  1LT was unable to consistently reduce spheroid viability and DNA 
content below the 50% threshold, though high drug/light combinations (1LT with >5 μg/ml 
and 5 J/cm2) were shown to be significantly more effective compared to low doses. 
Low-fluence as an alternative to high-fluence PDT 
Clinically, PDT treatments tend to have high fluence values. These are generally preferred due 
to their increased and proven effectiveness as more power leads to increased O21 production. 
Photofrin, also known as the FDA-approved 5-aminolevulenic acid, has standard clinical 
treatment parameters of 1 mg/kg (body weight), 630 nm light, and 150 mW/cm2 specific power 
(215 J/cm2 in total). Interestingly, it has been found that the tissue microenvironment undergoes 
a rapid depletion of oxygen during at least 40% of the total treatment duration, making it highly 
inefficient.  
In comparison, a lower power of 30 mW/cm2 has been previously shown to be as effective at 
disrupting tumour growth [351]. However, oxygen depletion and subsequent hypoxia in the 
treated area may limit further PS activation as the concentration of immediately available O2 
is rapidly diminished after irradiation. In particular, cells with low PS concentration or 
insufficient light exposure have been shown to have minimal PDT-induced death, even with 
high fluence (360 J/cm2, 200 mW/cm2) [352]. 
There are several factors that may intervene in these similar outcomes between high and low 
power intensities. Endothelial and cancerous cells within the tumour periphery are more likely 
to have a normal blood supply and oxygen partial pressure values compared to those found 
within the tumour core [353]. While PDT focused on destroying tumour vasculature may be 
highly effective, it will not be enough to cause total tumour ablation. It is also highly likely that 
high-fluence light irradiation causes oxygen depletion in the area and, more importantly, rapid 
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PS photobleaching [354]. This can explain the discrepancies in treatment effectiveness. 
Photochemical consumption of oxygen and the subsequent production of singlet oxygen are 
directly linked to PS concentration, oxygen availability, and light fluence. Thus, PS excited 
with a high-intensity light source would be steadily bleached, effectively reducing its 
concentration until oxygen consumption could keep up with available molecules in the tumour 
microenvironment. The spacing of light doses is meant to enable reoxygenation in affected 
tissue while maintaining PS function [355]. 
Fractionated PDT varies in effectiveness according to compounds and light activation 
Fractionated PDT showed a slight variation between light doses, as seen in Fig. 4.12. While 
LDH release is significantly higher in fractionated treatments, this is not always observed with 
dsDNA quantification. Some variations can be seen at higher concentrations (> 5ug/ml) or light 
exposure (>5 J/cm2), though they vary between samples.  
There are conflicting reports regarding the usefulness of fractionated light doses. Babilas et al. 
(2003) stated that fractionated PDT using PpIX with different specific power ranges (25 – 100 
mW/cm2) were not as effective in comparison to single high-dose treatments [350]. There are 
some key differences in their methodology from other protocols. Their method of light 
fractionation consisted in an initial 20 J dose, followed by a 15-minute interval to allow 
oxygenation, and finished with a final 80 J dose. Irradiation was also carried out using a non-
coherent light source (580 – 740 nm) as opposed to a monochromatic light source with a 
specific wavelength. Similar results were found by de Bruijn et al. (2007) using methyl-5-
aminolevulinate (MAL) in a mouse skin model [356]. Their results suggest PS localisation 
prior to PDT is a key factor in not only treatment effectiveness, but in determining differences 
between single and multiple light doses. Compounds which do not reach their targets can 
greatly diminish PDT effectiveness, regardless of the total energy applied. 
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Fig. 4.12 – Fractionation of light exposure increases PDT effectiveness. Treatments with 
1LT show slightly decreased damage to spheroids in comparison to 2LT, even with lower 




However, the experiments that were carried out using PpIX and its CD-based conjugates 
greatly differ in methodology. The use of a 405 nm LED with a low bandwidth (405 ± 13 nm) 
ensured more efficient absorption at the PpIX maxima. Most importantly, the time between 
light doses was greatly increased from 15-minute intervals to a 24-hour period. As was 
previously mentioned in Chapter 4, PpIX sensitizes cancer cells to PDT by interaction with 
p53, tumour suppression protein. They showed that cells treated with 2 J/cm2 and 1 μg/ml PpIX 
caused a significant increase in p53-mediated and independent apoptosis. Fluorescence-
activated cell sorting confirmed PDT induced apoptosis through the activation of the HDM2-
p53 complex [312]. In comparison to necrosis, apoptosis is an ordered sequence of events 
leading to cell death. It is generally thought to occur within a period of 12 to 24 hours after 
signalling, though the exact duration is hard to determine as it depends on the activation 
pathway [357]. The experimental conditions which were used in the present study are like those 
reported by Ouyang et al. (2018). They selected a treatment based on the percentage of early 
apoptotic cells in comparison to necrosis, which corresponded to 4 μg/ml PpIX and a 5 J/cm2 
light dose [358].  
Concentration adjustment show equivalent PDT effect between samples 
PpIX-adjusted concentrations reveal a similar trend to that found previously with 2D cell 
culture. PpIX-CD consistently outperformed other samples at most conditions, particularly at 
10 μg/ml, though this was only observed at 24 and 48 hrs post PDT. PpIX@CD showed poor 
effectiveness at 1 μg/ml for LDH release, but consistently demonstrated an equal effect to both 
PpIX-CD and PpIX during DNA quantification. In general, PpIX-loaded conjugates appeared 
to be like PpIX in both assays (Fig. 4.13). 
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Fig. 4.13 – PpIX-adjusted values show similar behaviour between PpIX and conjugates. 
This trend can be seen in LDH release and total DNA content in samples treated with single 
(top) and double (bottom) light treatments. (N=3, n=6) 
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Summary of PDT parameter screening 
In total, 54 parameter combinations were evaluated using MCTS at three distinct timepoints. 
Fig. 4.14 shows the variation in spheroid viability according to treatments. Single light 
treatments (1LT) proved to be unreliable unless higher drug concentrations were added, which 
adds additional variation due to innate dark toxicity from samples. 2LT was shown to be 
slightly more effective at lower drug concentrations. Therefore, ideal PDT conditions would 
require 2LT with a drug concentration of around 5 μg/ml, which is enough to cause 
considerable damage without substantial dark toxicity. 
 
Fig. 4.14– Heatmap of all treatment combinations. Values correspond to % viability (LDH 
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High fluence PDT using a laser 
A 405 nm laser (Vortran Laser Technology, USA) was used to evaluate the effect of increased 
power output on the PDT effect in spheroids. The laser power was measured at the point of 
contact with the 96-well plate using a power meter, ensuring output was consistent. In 
comparison to the previously used LED, the 405 nm laser has the capability of providing up to 
200 mW of stable output. The positioning of the laser spot was difficult as the adjacent mirror 
had to be adjusted for light to reflect onto the complete area of each well (Fig. 1.15c and 1.15d). 
The irradiance was adjusted to values considered standard (25 J/cm2) and high (100 J/cm2). 
PDT effect was evaluated using LDH release as a marker for damage and cell death. 
 
Fig. 4.15 – Schematic of 405 nm laser setup. The laser was controlled through software (a) 






Results demonstrate high irradiance does not cause significantly higher cell membrane damage 
compared to the standard treatment. PpIX and PpIX-CD both showed decreased effectiveness 
after a 100 J/cm2 dose at 5 μg/ml. In contrast, PpIX@CD did not show a significant change 
between treatments. Nonetheless, all high irradiance treatments resulted in much higher sample 
variability, which can be seen in Fig 4.16. This discrepancy has been previously reported in 
the literature as high fluence rates (>100 mW/cm2) were shown to significantly reduce oxygen 
levels in carcinomas, with depletion occurring during approximately 40% of the total light 
exposure duration [359]. 
 
Fig. 4.16 – PDT effect does not scale with high irradiance. The increase of irradiance does 
not lead to significantly different treatment outcomes in multicellular tumour spheroids using 
a 405 nm laser (25 and 100 J/cm2). (N=3, n=6) 
 
Drug/light product has a lower threshold for effective PDT  
PDT is composed of a drug and a light dose, which can be expressed as drug/light product. 
This can be reciprocal in some cases: for example, 1 mg/kg PpIX (150 J) and 3 mg/kg PpIX 
(50 J). In ideal conditions (i.e. no oxygen depletion), tumour destruction has been found to be 
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strongly linked to this parameter. However, the drug and light doses have been found to have 
a specific threshold below which reciprocity does not occur [360]. This effect was later 
confirmed by Seshadri et al. (2008) as they evaluated the effectiveness of PDT with high (100 
mW) and low (7 mW) laser power regimens while adjusting PS concentrations. They did not 
observe a significant change in the total area of necrosis after PDT, observing intermittent 
hypoxia in the 100 mW ultimately leading to reduced effectiveness compared to 7 mW [361]. 
This indicates that light delivery over longer periods of time with lower power enhances the 
effectiveness of PDT.  
Light sheet fluorescence microscopy (LSFM) 
PpIX uptake can be observed throughout the inner layers of spheroids 
Light sheet fluorescence microscopy was carried out using fixed spheroids incubated with all 
samples for 3 hours to estimate drug uptake. LSFM has been shown to be a much more efficient 
method for evaluating drug uptake in MCTS. While confocal laser scanning microscopy has 
been widely used to observe spheroids, it lacks enough imaging depth (~100 μm maximum) to 
accurately monitor drug distribution. In contrast, LSFM was capable of analysing spheroids up 
to 1 mm in diameter and determine drug penetration [362]. 
Spheroids typically exhibit some autofluorescence at 405 nm excitation, but the use of the long 
pass filter ensured the control did not show any appreciable fluorescence emission after 600 
nm. Conversely, spheroids incubated with all samples and doses (1 – 10 μg/ml) for 3 hours 
showed emission peaks. Low sample concentrations (1 μg/ml) showed the presence of PpIX 
on the spheroid periphery, with slightly increased fluorescence in the control and PpIX-CD 
(Fig. 4.17). PpIX@CD showed aggregation within one side of the outermost layer of the 
spheroid, with low emission in other areas. 
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Fig. 4.17 – Conjugate uptake in spheroids at 1 μg/ml. Drug uptake with 1 μg/ml is an 
insufficient dose for PDT as uptake is limited to outer spheroid layers. 
 
The increase of dosage to 5 μg/ml corresponds to a sizeable increase of fluorescence from all 
samples (Fig. 4.18). PpIX-CD displayed markedly higher emission in comparison to the control 
PpIX, with approximately 28% more uptake. PpIX-CD also showed similar values along the 
innermost part of the spheroid. In comparison, PpIX@CD continued to show much lower PpIX 
accumulation, with only 49 – 60 % emission in comparison to PpIX and PpIX-CD, 
respectively. The embedded conjugate once again showed higher uptake in one side of the 
spheroid, with drastically reduced emissions in the opposite sides.  









































































































































Fig. 4.18 – Conjugate uptake in spheroids at 5 μg/ml Drug uptake and signal emission are 
significantly improved after increasing dose to 5 μg/ml. PpIX@CD shows signs of 
aggregation or quenching. 
 
 
This behaviour continued as conjugate concentration increased to 10 μg/ml. PpIX-CD 
continued to show significantly higher PpIX accumulation, with approximately 31% more drug 
in comparison to the control at equal nanoparticle concentrations (Fig. 4.19). Interestingly, 
PpIX-CD shows increased accumulation within the spheroid core at around 150 – 200 μm 
depth while PpIX shows a steady decrease after the initial 50 μm. PpIX@CD showed an even 
greater decline in PpIX uptake, with only around 37% accumulation of the PpIX control. 
Spheroids showed an initial high uptake until ~50 μm, after which it steadily dropped. 







































































































Fig. 4.18 – Conjugate uptake in spheroids at 10 μg/ml. PpIX-based emissions with 10 
μg/ml show drug uptake throughout the spheroid diameter and within the hypoxic core. 
  
The fluorescence intensity found from PpIX and PpIX-CD was very similar at all 
concentrations while PpIX@CD reached a maximum around 5 μg/ml. In comparison, 
PpIX@CD showed a significant difference in fluorescence over 5 μg/ml. Nonetheless, it is also 
possible that PpIX@CD suffers from self-quenching, as previously detailed in Chapter 3. The 
embedding of PpIX on its surface can both obstruct surface traps (CD fluorescence) and limit 
PpIX fluorescence. 
  







































































































Live/dead staining shows spatially directed PDT damage in spheroids 
The observation of PDT-induced damage to spheroids is difficult due to their growth 
conditions. Spheroids rest within the bottom of a 96-well plate with agar, which aids in the 
formation of spherical aggregates. Typically, light microscopy (LM) or fluorescence 
microscopy used to observe spheroids, especially in high-throughput screening as they are fast, 
reliable, and inexpensive. Imaging shows treated spheroids have reduced size and slightly 
irregular morphology, but generally keep their roundness regardless of light treatment as shown 
previously. However, only inverted microscopes can observe the bottom of the plates – 
spheroids would lose sterility if the cover is removed and the focal length is inadequate as the 
objective cannot approach samples.  
In comparison, light sheet fluorescence microscopy (LSFM) can be used to observe the 3D 
structure of samples. Samples are placed within a glass capillary and embedded in agarose, 
which allows the equipment to rotate spheroids along the X axis. Imaging of spheroids can 
reveal more information about physical changes to their structure after PDT (Fig. 4.20). LSFM 
of PDT-treated spheroids can be improved by live/dead staining to observe damage at various 
time points. This stain uses two components to differentiate between live (calcein AM, green) 
and dead (ethidium homodimer-1, red). Calcein AM is a cell-permeant compound that is 
transformed into the fluorescent calcein after uptake, showing a characteristic green colour, 




Fig. 4.20 – Sample rotation within LSFM permits more detailed evaluation of spheroid 
morphology. Live (green) and dead(red) cells can be seen throughout the spheroid at all 
angles (top). PDT damage can be seen in some samples, with spheroids showing sloughing 
and loss of sphericity after treatment (bottom). Image at 0° corresponds to the point of view 
seen with light microscopy.  
 
The distribution of live/dead cells within MCTS was observed using LSFM. Spheroids were 
washed to remove cellular debris, fixed, and stained 24 and 48 hours after delivering final light 
dose. While spheroid morphology appeared to remain intact from initial viewing angles, with 
some irregularities being apparent on their surface. Changes in viewing angles demonstrate the 
extent of PDT-induced damage. A test was done using a small quantity of Tris-EDTA buffer 
to induce cell lysis within the sample chamber. After 30 minutes of incubation, a weak signal 
was obtained from the red channel, corresponding to ethidium homodimer-1 entering the nuclei 
of dead cells, seen in Fig. 4.21. Spheroids did not show significant changes in morphology. 
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While it is possible to use LSFM to image live samples, image quality differed between 
spheroids. Live imaging was not used for further work and fixed samples were obtained for all 
timepoints.  
 
Fig. 4.21 – Live LSFM imaging of spheroid treated with lysis buffer. Images were 
separated by channel (calcein-AM, ethidium homodimer-1, and the merged image). 
 
Images were obtained from three separate angles to observe morphology after PDT with 5 
J/cm2, which was a light dose which produced significant damage to spheroids while reducing 
time spent outside the incubator. Drug doses (1 – 10 μg/ml) and fractionated light exposures 
(1LT and 2LT) were left unchanged from the previous methodology. An additional light 
treatment (3LT) was added to observe continuous light activation and spheroid response to 
PpIX-triggered sensitization to PDT [363]. Samples using 1 μg/ml did not show significant 
changes to roundness, with only small sections being affected, regardless of light dose. 
Nonetheless, sample rotation revealed changes in spheroid thickness, which was reduced from 
~450 μm to ~400 μm as a result of PDT-induced cell death. 
PDT with a concentration of 5 μg/ml significantly increased damage to spheroids and caused 
disruption in their spherical shape, shown in Fig. 4.22. PpIX and PpIX-CD show damage 
throughout the spheroid surface, appearing as large grooves that run across its diameter and 
missing sections corresponding to the area which was in contact by light. The core area of all 
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spheroids showed a high number of dead cells, which corresponds to the hypoxic region formed 
during initial growth and compaction. Spheroid shape was also influenced by sample 
manipulation during fixing and mounting: samples frequently needed to be swapped as too 
much force caused the spheroid to begin falling apart.  
In comparison, spheroids treated with 10 μg/ml show more pronounced damage and a similar 
loss of shape and roundness, as can be seen in Fig. 4.23. However, it should be noted that not 
all spheroids within the same conditions show the same degree of damage. This is likely 
because of the variability within groups, which is present even with close monitoring of 
spheroid growth kinetics and preselection of suitable spheroids prior to drug uptake. Das et al. 
(2016) determined that these variations occur in part due to edge effects from uneven agarose 
surfaces within individual wells and evaporation-induced liquid media loss at the plate 
periphery [364]. Nonetheless, spheroid morphology cannot be completely observed through 
widefield microscopy. The structural changes that spheroids undergo after PDT suggest that 
low-fluence PDT is capable of tumour ablation at nontoxic PS doses. 
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Fig. 4.22 – Spheroids show directional ablation after PDT. Post-PDT morphology varies 




Fig. 4.23 – Drug dose increases damage to spheroids. Increased drug doses destabilise 





Light fractionation caused significant damage after 48 hrs  
Spheroids treated with 2LT showed a much more pronounced reduction in size and higher 
degree of cell death than those with 1LT. This was expected as both LDH release and DNA 
content indicate lower sample viability with repeat light exposure. Prolonged damage to 
spheroids was also observed in all conditions, reflecting results found previously, where 
toxicity reduced spheroid viability for up to 72 hours after PDT, shown in Fig. 4.23. This is 
likely caused by the aforementioned mechanism of PpIX-induced cell death, which promotes 
apoptosis through the activation of the p53 pathway [312].  
 
Fig. 4.23 – Spheroids showed prolonged response to phototoxicity. Continuous cell death 
could be observed up to 48 hours after the final light treatment. Initial damage was similar to 




Fig. 4.24 – 3LT causes significant PDT damage compared to 1LT and 2LT. Live imaging 
of 3LT PDT (24 hrs) shows significantly increased cell death and localised damage on the top 




As expected, 3LT showed a significant increase in spheroid damage as can be seen in Fig. 24. 
However, the PDT effect was not as consistent as with previous conditions (Fig. 4.24). While 
some spheroids suffered complete disruption and were unable to be imaged, others retained 
their morphology and showed similar morphology to that seen with 2LT (5 or 10 μg). However, 
the dead or damaged cells on the top section of spheroids were much more prominent in 
spheroids treated with PpIX-CD in comparison to PpIX and PpIX@CD. 
In summary, LSFM was used to observe the morphology of PDT-treated spheroids, showing 
varied morphological changes occurred after light activation. Spheroid thickness was 
consistently reduced with all samples and concentration, though differential drug uptake may 
cause variation between samples with identical treatment conditions. Live imaging was also 
used to observe in situ PDT damage without compromising spheroid viability. 
Scanning electron microscopy (SEM) 
SEM imaging has been previously used to observe fine details in spheroid morphology. The 
surface roughness can indicate the amount of produced extracellular matrix [365]. It can also 
be used to observe cell-cell interactions and growth progression with higher magnifications. 
Most importantly, the surface morphology can be used to observe morphological changes 
which are not immediately apparent with LM. However, it requires the use of glutaraldehyde 




Fig. 4.25 – Standard C8161 melanoma spheroid imaged using SEM. Slight damage 
visible in the top right corner due to manipulation during fixation. 
 
Control spheroids show a clear round morphology which is reminiscent of images obtained 
with LM, seen in Fig. 4.25. However, PDT-treated spheroids show key differences as ablation 
deforms spheroid morphology (Fig. 4.26). The outer layers of spheroids appear to have been 
sloughed off due to extensive cell death and have not been reformed after 48 hours post light 
exposure. This shedding of layers has been previously observed in spheroids which have passed 
their stationary phase as a sign of entering their death phase [366]. In summary, the 
combination of LSFM and SEM was used to observe subtle changes in spheroid morphology, 
which is summarised in Fig. 4.27. 
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Fig. 4.26 – PDT-induced damage is visible using SEM. In comparison to the previously 
shown untreated spheroid (Fig. 4.25), treated spheroids show a significantly reduced size and 
loss of sphericity. PDT caused sloughing of outer layers as damage increased due to 
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Currently, the gold standard for cancer drug testing is the in vivo tumour xenograft mouse 
model. Cell line and patient-derived xenografts have been shown to accurately replicate tumour 
morphophysiological characteristics. However, the use of animal models is not suitable for 
exploring the effect of individual treatment parameters due to their intrinsic complexity. 
Furthermore, large-scale screening experiments are costly, time-consuming, and face issues 
with ethical concerns.  
In this study, a total of 18 combinations of different PDT parameters (drug concentration, 
fluence, and light fractionation) were tested with PpIX, PpIX-CD, and PpIX@CD, totalling 54 
combinations. These treatment conditions were evaluated using two different assays to 
determine viability after PDT (LDH release and dsDNA quantification) and monitored at 3 
time points (24, 48, and 72 hours post-PDT). This led to the pre-screening of unsuccessful PDT 
conditions such as 1 μg/ml drug doses or 1LT, which would not have been apparent with only 
2D cell culture. Furthermore, light sheet microscopy was used to obtain information regarding 
drug penetration into spheroids, with PpIX and PpIX-CD showing higher uptake compared to 
PpIX@CD. Spheroid morphology was also shown to be irregular due to varying response to 
PDT-induced damage resulting in the shedding of the outer proliferating cell layer.  
In conclusion, PDT parameter pre-screening was able to rule out multiple conditions previously 
thought to be successful with cell monolayers. The results presented here highlight the 
importance for custom models tailored for PDT. As research continues, high-throughput 
analysis of experimental conditions will be needed in order to adequately assess the efficiency 
of novel PDT agents such as CD-based conjugates. 
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Chapter 5 – Automated parameter acquisition and comparison to metabolic 
activity data 
Introduction 
3D cell culture models can replicate in vivo conditions such as hypoxia, dormancy, and cell-
cell interactions more accurately than 2D models. In the previous chapter, spheroids were 
shown to be a better screening tool for optimising PDT parameters. However, this model is 
highly variable, being affected by parameters such as partial oxygen pressure, compactness, 
diffusion, and nutrient gradients [367]. In some cases, conventional methods for evaluating 2D 
cell cultures have been shown to be unsuitable for 3D cell cultures, further increasing 
variability [368]. This has caused some to question the validity and reproducibility of acquired 
data. Thus, there is a lack of standardized, easily accessible methods to provide quantification 
of drug-responsiveness tailored for use with MCTS [369]. Moving forward, this may place 
limitations for the extended use of spheroids; there is a special interest in high-content 
screening, where thousands of chemical compounds are tested with standardized conditions.  
Spheroid morphology has been found to be a key parameter in experimental standardisation, 
ensuring other factors like microenvironment to be more similar between samples. These 
morphological parameters (i.e. diameter, volume, sphericity, etc.) can be obtained through 
imaging with various types of microscopy, such as light, fluorescence, and light sheet 
microscopies [370]. They can then be used to observe variations in growth kinetics, improving 
experimental reproducibility [335]. Image-processing software such as AnaSP (open-source) 
or ImageXpress Micro XLS (proprietary) can also be utilised to automatically process multiple 
image sets simultaneously, allowing users to quickly obtain data regarding spheroid variability 
prior to starting experiments [371].  
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Furthermore, the same morphological parameters have been shown to be related to drug-
responsiveness. Thakuri et al. (2019) demonstrated that size-based analysis closely matched 
traditional assay-based analysis in evaluating drug responsiveness. They also observed that 
spheroid growth could be linked to resazurin reduction [372]. A similar trend was also observed 
by Ivanov et al. (2014) with the acid phosphatase assay, though it can only be performed as an 
endpoint assay due to requiring cell lysis [373]. However, there has not been any attempt to 
determine correlation between drug response and spheroid morphology using assays such as 
LDH release and DNA quantification. 
As previously mentioned, most software is centred on high-throughput screening, which relies 
on costly automated equipment, limiting its use by non-specialised users. The development of 
open-source alternatives is a key step in the introduction of reliable computer-assisted image 
analysis to researchers working with MCTS. Piccinini (2015) developed a MATLAB-based 
suite for analysing various spheroid parameters: AnaSP (ANAlyse SPheroids) [371]. Likewise, 
the visualization and estimation of spheroid volume has seen advances and has been shown to 
be possible to recreate based on a projection from a 2D image using ReViSP (Reconstruction 
and Visualization from a Single Projection) [374]. In comparison to other methods of volume 
assessment, reconstruction from a simple light microscopy image is less labour and time 
intensive. 
In this chapter, MCTS morphological parameters with LDH release and DNA content will be 
compared to determine a possible correlation. Furthermore, the use of automated image 




Aim: Demonstrate a link between spheroid morphometric parameters and PDT-induced cell 
death in previously evaluated treatment combinations. 
Objectives:  
 Reduce spheroid variability in groups by pre-screening samples based on morphology. 
 Select best morphometric parameters to differentiate between damage and control 
spheroids. 
 Investigate the relationship between morphometric parameters and previously obtained 
biological assay data. 






Materials used for spheroid culture, LDH assay, Picogreen DNA quantification, live/dead 
staining, and microscopy were identical to those previously mentioned in Chapter 5. 
Automated parameter acquisition 
Images were obtained using an AE2000 inverted light microscope (Motic, United States) fitted 
with a Moticam 2.0 camera with a 4× objective. Images were obtained before and after clearing 
cellular debris from each well. White balance was used increase spheroid contrast against the 
background. AnaSP version 1.2 (https://sourceforge.net/projects/anasp/) was downloaded from 
the source webpage. The scripts were loaded onto MATLAB R2019b (Version 9.7) with Image 
Processing Toolbox. Spheroid images were only utilised in data analysis if image segmentation 
was performed automatically. The standard morphological parameters were extracted: Area, 
Convexity, Equivalent Diameter, Length of Major Diameter Through Centroid, Length of 
Minor Diameter Through Centroid, Perimeter, Solidity, Sphericity, and Volume. 
Statistical analysis 
Experiments carried out with three independent repeats in triplicates (N=3, n=6) and results 
were normalized using untreated controls. Statistical analysis was carried out using GraphPad 
Prism version 8.3.0. A normality test was performed on each data set to confirm the use of 
ANOVA. The comparison of metabolic activity was evaluated by 2-way ANOVA analysis 
with Dunnett’s test for multiple comparisons, with adjusted P values < 0.05 were considered 
statistically significant. Data was presented as means ± SD (standard deviation). Charts include 
symbols representing adjusted P values, which are shown below. 
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Table 5.1 – List of symbols used to represent statistical significance. 
P value Symbol 








Results and Discussion 
3LT was added to PDT evaluation 
Spheroids were grown as previously described in Chapter 5, using agar-coated 96-well plates 
to prevent cell adhesion. PDT was carried out using PpIX and PpIX-CD based on results 
obtained in the previous chapter. Drug concentration was adjusted to >5 μg/ml and 5 J/cm2. 
This was based on the previously observed drug response and subsequent reduction in spheroid 
viability with all samples in these conditions. An additional 3-step light dose was performed in 
addition to 1LT and 2LT. Fig. 5.1 shows the workflow for a typical spheroid PDT experiment 
with automated parameter acquisition. 
 
Fig. 5.1 – Automated parameter acquisition using multicellular tumour spheroids. 
Spheroids were cultured, pre-screened, and treated with various PDT combinations. Image 
acquisition was done using widefield microscopy and automatic segmentation with AnaSP 




Automatic image processing and parameter acquisition with AnaSP 
The open-source software AnaSP can extract morphological parameters from spheroids by pre-
processing suitable images and identifying the area of interest based on histogram intensity and 
automatic triangle segmentation. There are several parameters that are calculated by default, 
which are listed below in Table 5.2. Although new parameters can be programmed, it was 
determined that predetermined values were enough for analysis. 
Table 5.2. List of morphological parameters extracted from multicellular tumour spheroids 
using AnaSP. 
Parameter Explanation 
Area (A) Total number of pixels in foreground 
Volume (V) 
Volume estimated from segmented image 
projection (ReViSP) [374] 
 LMajorDTC 
Maximum length of axis through centre of 
spheroid mass 
LMinorDTC 
Minimum length of axis through centre of 
spheroid mass 
Convexity Degree of spheroid curvature 
Equivalent 
Diameter 
Diameter corresponding to a circle with 
equivalent area 
Perimeter (P) Total number of pixels in outer border 
Solidity 
Degree of spheroid compaction after growth 
(Area/Convexity*Area) 
Sphericity 
Degree of similitude to a perfect sphere               




Modification to AnaSP workflow due to image processing errors 
Initially, AnaSP was unable to convert images to binary format: this process changes colour 
values to binary values. Instead, image pre-processing returned greyscale images, which were 
not able to be successfully segmented. It is unclear what caused this issue as the command for 
binary image conversion was correct in the source files. In order to continue with automatic 
segmentation, an extra step was introduced to obtain binary images. The following script was 
run within the folder containing the images (Input) and converted images were manually 
moved to the “mask” folder: 
% Run START SEGMENTATION 
% This script will convert .jpg "mask" images to true binary in .tif format 
% Change Spheroid to image filename in Output folder 
% Script has to be in the same folder as masks in order to work 
% Must move images from Output folder to Mask folder 




imwrite(im2,[file_name '.tif'])  
 
Early variations in spheroid growth significantly change morphology 
Spheroid morphology was monitored throughout their initial growth period to determine 
differences between samples before undergoing PDT. In general, high sphericity (how close 
an object approximates a perfect sphere) is a desirable parameter for pre-screening spheroids. 
Diffusion kinetics of nutrients, oxygen, and drugs within spheroids are significantly changed 
by both shape and cell compaction, with irregular/elongated shapes being generally undesirable 
[375]. Furthermore, oxygen consumption drastically changes as cells begin compacting, 
resulting in an approximately 8-fold increase as spheroid size stabilizes. In turn, this increases 
the size of the hypoxic zone, a key factor of in vivo tumour microenvironments. Leung et al. 
(2014) determined sphericity and compactness are highly linked to a uniform solute gradient 
within MCTS [376]. Therefore, the evaluation of PDT response and parameter screening 
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should be performed with samples presenting low variation in morphology, with sphericity 
being closely monitored as the main parameter for selection, as shown in Fig. 5.2. 
 
Fig. 5.2 – Spheroid growth and morphology depends on agarose coating quality. 
Spheroids initially may show irregular morphology as cells begin to aggregate in Day 1. 
Steady growth eventually leads to a more spherical shape with no irregularities by Day 3. 
Defects in the agarose coating or incubation conditions led to irregular morphology. 
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Automatic segmentation versus manual (freehand) segmentation 
Image pre-processing is an essential step in parameter acquisition as it influences all obtained 
data. Manual segmentation done through free-hand drawing using a stylus or mouse cursor can 
be attempted instead of the automatic segmentation, though results are significantly different. 
Fig. 5.3. shows a comparison between manual and automatic image processing and its impact 
on extracted parameters. Initially, parameters like sphericity and convexity appear to increase 
in manual segmentation, which conflicts with the reduction of other data with manual 
segmentation. However, this is caused by the lack of jagged edges seen in the automatic 
processing that cannot be replicated with freehand contouring. In contrast, the parameters area 
(-28.25%), perimeter (-30.95%), and volume (-39.87%) were reduced by as a result of 
imprecise outlines. Furthermore, the use of manually segmented spheroids within experiments 
increased variability within groups. Therefore, only automatically segmented images were 
used in analysis. 
 
 
Fig. 5.3 – Automatic segmentation reduces variability during image pre-processing. 
Manual segmentation results for area, perimeter, and volume showed high variation after 
multiple segmentation attempts with the same image. 
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Parameter extraction requires clearer images to avoid errors 
As previously mentioned, PDT-induced cell death could be observed by the formation of a 
debris halo surrounding each spheroid. In addition to possible variability in biological assays, 
the presence of this cellular debris significantly impacts parameter acquisition as segmentation 
does not adequately detect spheroid contours. This was confirmed after comparing acquired 
images from spheroids after PDT (2.5 μg/ml PpIX, 5 J/cm2, 1LT) before and after debris 
removal (Fig. 5.4). Parameters based on spheroid sphericity showed an increase of 
approximately 32-59%, while those based on area were reduced by over 27-46%. Additionally, 
automatic segmentation in AnaSP did not produce consistent image outputs for extraction as 
debris was counted as part of the main spheroid mass. Therefore, clearing cell debris is a crucial 
step in successful parameter acquisition. 
 
Fig. 5.4 – Parameter extraction improves as debris is cleared from the well. Automatic 
segmentation depends on initial binary conversion and accuracy decreases as more opaque 
objects are present in the foreground alongside spheroids. 
Parameter
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Extracted parameters vary depending in spheroids after PDT damage 
Pre-screened spheroids show no significant difference between replicates 
A significant challenge in spheroid-based platforms for drug screening is the inherent 
variability found between samples, regardless of consistency in growth conditions. Recent 
advances in culture techniques include spinner flasks, rotary culture vessels, and microfluidic 
devices, which aim to tightly control spheroid growth. However, the maintenance of these 
systems is both expensive and time-consuming [326]. The use of non-adherent surfaces like 
agarose typically leads to heterogeneous spheroid morphology. However, the selection of 
homogeneous spheroid groups before PDT improved the consistency of results. Fig. 5.5 shows 
the variation in total area between groups of treated spheroids.  
 
Fig. 5.5 – Group variability was lowered with spheroid pre-screening. Area values from 
extracted morphological data did not show significant variability between spheroid and 





































































Parameters show variable response to PDT-induced damage 
Spheroids showed increasingly more LDH release and lower dsDNA concentrations as PDT 
damage increased. Parameters such as area and volume showed significant changes exhibiting 
a similar trend to results from biological assays. This is expected as spheroid size is strongly 
linked to cell number, which is reduced with more effective treatments [324]. In contrast, 
parameters related to spheroid roundness (sphericity, convexity, solidity) did not show 
significant difference between treatments, as shown in Fig. 5.6. 
  
The variation in morphological parameters was also observed by Mittler et al. (2017). They 
used lipid vesicles carrying doxorubicin, docetaxel, etoposide, and ARN-509 to treat prostate 
cancer spheroids. Interestingly, they determined automated image analysis was inconclusive 
for determining drug-induced chemotoxicity as growth was arrested without affecting 
sphericity. Furthermore, they observed that size or roundness-based analysis was not enough 
to distinguish between drug doses (50 and 500 nM) [377]. However, their results suggest that 
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Morphological parameters can be linked to LDH release and dsDNA content 
LDH release and dsDNA quantification were repeated using PpIX and PpIX-CD with the best-
performing conditions (5-10 μg/ml, 5 J/cm2, 1-3 LT). The data was then plotted against the 
spheroid area, showing the variation in size after PDT based on total area of control spheroids 
not exposed to drug or light irradiation. Fig. 5.8 shows 1LT can be clearly separated from 2LT 
and 3LT-based treatments using only area as the primary indicator of PDT-induced damage. 
However, distinguishing between two very similar treatments, such as 2LT (10 μg) and 3LT 
(5 μg) proved to be very difficult due to the variability of acquired data. 
Results show variation between experimental groups in the same conditions. Although 
spheroids were preselected based on their area and sphericity, variations occurred in similar 
treatment conditions. However, most of the variability was shown to be statistically 
insignificant, with some exceptions. PpIX showed greater variance in both LDH release and 




Fig. 5.7 – PpIX and PpIX-CD show similar reductions to viability and area with 
equivalent treatment conditions (a, b). Light fractionated treatments caused very similar 




Fig. 5.8 – Spheroid area can be used to predict viability and DNA content. Each point on 
the graph corresponds to an independent repeat; the same spheroid was monitored through 
imaging (parameter acquisition) and biological assays (LDH release and total dsDNA 
content).  (N=3, n=6) 
 
Previously, sphericity was shown to be an important parameter to determine spheroid 
population homogeneity as it influences oxygen and drug diffusion. However, PDT-induced 
damage was not able to be estimated by spheroid roundness or other parameters such as 
LMinDTC, as shown in Fig. 5.9. This is caused by variations in size and the fragility of 
remaining aggregates; the acquisition of images from heavily damaged spheroids resulted in 
many samples being lost due to complete disaggregation during of debris removal. It is also 
possible that image quality plays an important factor. Although images were captured using a 
2.0 MP Moticam 2.0 camera, they lack the detail found in other microscopy techniques.  














































































Fig. 5.9 – Spheroid curvature is not linked to viability. Morphological parameters based 
on spheroid curvature (sphericity) and diameter (LMinDTC) showed significant variability 
compared to area or volume. 
 
In summary, morphology-based analysis has been shown to be unsuitable as a complete 
alternative to replace of biological assays as it is unable to reliably distinguish between similar 
drug treatments with the same level of accuracy. Nonetheless, its speed, cost-effectiveness, and 
capability of processing large groups of samples make it ideal for its use within PDT parameter 
screening.  
Automated image analysis with alternative image sources 
Light sheet microscopy significantly increases acquired image detail 
Light sheet fluorescence microscopy (LSFM) has been shown to be a reliable tool for imaging 
cancer spheroids. Schmitz et al. (2017) demonstrated LSFM could be used to produce three-
dimensional high-quality spheroid models for analysing growth kinetics and inner 
morphological features [378]. Image analysis using LSFM is complex due to the amount of 
data that is generated; each stack can contain anywhere from 250 – 400 individual images 
depending on the slice interval. Volume estimation can greatly vary depending on the type of 








































staining that is performed, sample quality (fixing and staining), and signal intensity. This 
requires an optimization for each spheroid type and staining protocol, further increasing 
complexity, as shown by Smyrek and Steltzer (2017) [379]. The analysis of individual 
spheroids can also be changed by the type of 3D projection that is used as finer features become 
visible, as shown in Fig. 5.11. 
 
Fig. 5.11 – Variations in surface roughness based on different models for 3D projection: 
(a) roughness and (b) mixed from Zeiss ZEN 2014 software. Data such as total fluorescence 
intensity, size, and volume can be extracted from each Z-stack. 
 
A similar approach was used by Barbier et al. (2016), analysing light-attenuated image stacks 
obtained by confocal laser scanning microscopy (CSLM) [380]. Though these tools produce 
detailed images, they are unsuitable for larger-scale experiments requiring hundreds of 
spheroids analysed at specific time points as image processing is severely limited due to 
hardware constraints. Recently, high-throughput confocal imaging has become available and 
has been used for morphological analysis of 3D cell cultures. Boutin et al. (2018) demonstrated 
high-content imaging with U87 spheroids could be achieved within lower timescales (1 hour 
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per 384 well plate) [381]. However, their protocol required an increase in slice interval (5 μm 
compared to 1.8 μm for confocal/light sheet within Chapters 4 and 5), resulting in reduced 
detail. Therefore, more precise microscopy tools are ideal for observing small changes in 
morphology and can be used to more accurately measure morphological parameters. As was 
observed in the previous chapter, spheroids subjected to PDT often present significant damage 
to their outer layers, shedding them after repeated light treatments and leading to irregular 
shapes. Nonetheless, it is not clear if this is an effect of spheroid manipulation during fixing: 
repeated light treatments have been shown to reduce spheroid solidity, making them prone to 




In the previous chapter, spheroids were shown to be a better screening model for PDT 
parameters due to their more relevant morphophysiological conditions such as hypoxia, cell-
cell interactions, and increased drug resistance. However, the inherent variability between 
individual spheroids in groups needs to be reduced in order to properly determine the effect of 
treatment parameters, as spheroid shape and size influence drug diffusion and ultimately PDT 
response. 
Computer-assisted analysis is a valuable tool for drug discovery in combination with cancer 
spheroids. Morphological parameters like volume and sphericity can be automatically obtained 
through imaging with multiple systems ranging from widefield microscopy to light sheet 
fluorescence microscopy. Automated segmentation and subsequent image processing allow 
accurate parameter extraction from a single image, leading to significantly more information 
being obtained for each condition. Additionally, single spheroid variability can be slightly 
diminished by pre-screening samples with high sphericity and low variation in area or volume. 
In this chapter, automatic image analysis was used to determine results obtained from in vitro 
assays (LDH release and dsDNA concentration) have a connection with some extracted 
morphometric parameters. Measurements based on spheroid curvature were not found to be 
significantly linked to treatment response. In contrast, area and volume demonstrated a link 
with these values and were shown to be capable of differentiating most PDT treatment 
combinations. The continuation of this work would focus on the improvement of spheroid 
segmentation, reduction of variability due to cellular debris, and the use of additional 




Currently, in vivo tumour xenograft mouse models are the gold standard for PDT evaluation. 
However, they are limited by high costs and strict regulatory controls. Furthermore, evaluating 
multiple PDT parameters and treatment combinations becomes increasingly more difficult due 
to the number of animals required. Thus, there is an urgent need for better models of PDT for 
PS evaluation prior to in vivo testing.  
Based on the data obtained in this dissertation, future work should be focused on four key areas: 
2.1. Expand and refine the current spheroid protocol for estimating spheroid viability post-
light exposure. 
2.2. Improve automated image processing to handle larger image sets and additional source 
images from other various microscopy techniques. 
2.3. Develop a protocol for ex ovo PDT evaluation using cancer xenografts within CAM 
assay to observe the effect of tumour vascularisation. 
2.4. Validate previous results using a mouse cancer xenograft model for PDT. 
Protocol for evaluating PDT with spheroids 
The expansion of the spheroid PDT protocol would be highly beneficial for the improvement 
of PDT parameter screening. Spheroids are rapidly grown, cost-effective, and can be imaged 
in high-content microscopes. Likewise, they do not need specialised equipment and can be 
readily used with a wide variety of well-known assays. Currently, there are several areas of 
opportunity within the previously established protocol. 
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1. Expansion of PDT evaluation 
Although the combination of LDH release and dsDNA concentration showed interesting 
variations during PDT, the addition of other assays will lead to better understanding of spheroid 
response to PDT. There are several assays which could be included, such as intracellular 
oxygen content (Intracellular Oxygen Concentration Assay), intracellular ROS generation 
(observed by 2,7-DCF-diacetate hydrolysis), and extracellular matrix staining (observing 
collagen deposition). These could be easily integrated into the spheroid workflow to provide 
more information about spheroid response post-PDT. Likewise, gene and protein expression 
can be used to further standardise produced MCTS and monitor heterogeneity while observing 
key differences during PDT. Finally, the use of light sheet microscopy to observe spheroid 
response to PDT has been highly beneficial. Live imaging, either through LSFM or widefield 
microscopy, can provide additional information about spheroid response to nanoparticles and 
PDT during the initial 24 hours. 
2. Mass density evaluation in collaboration with CellDynamics  
In addition, the new physical parameter of spheroid mass density can be evaluated as a possible 
marker for treatment effectiveness. This parameter varies according to the degree of cell 
compaction found in spheroids: “younger” spheroids are aggregated more loosely than “older” 
spheroids, which have produced more ECM. This work could be done in collaboration with 
CellDynamics, a company specialised in the fabrication of equipment for 3D cell biology. The 
use of mass density could reveal small variations in similar conditions such as equal drug 
dosage or irradiance with different compounds (e.g. PpIX-CD vs PpIX@CD, 5 µg/ml, 2LT, 5 
J/cm2). However, spheroid culture would have to be readjusted as the maximum size for 
measurement is 250 µm. In turn, this change will require a re-evaluation of previously 
measured LDH and dsDNA content values for the smaller spheroids. 
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3. Adaptations to spheroid protocol for PDT 
The conditions used for spheroid culture in this project were standard incubation conditions. 
However, they can be further adjusted to reflect in vivo tumour microenvironment. The change 
in oxygen content would be extremely important to improve the relevance of obtained data, as 
20% (160 mmHg) is extremely high, even compared to arterial blood (9.5%, 70 mmHg). In 
comparison, physiological hypoxia found in tumours is much lower and typically ranges from 
2-0.4%, depending on the type of tissue: melanoma tumours have been shown to possess 
approximately 1.5% oxygen (11.6 mmHg). This is around 13-fold less oxygen than what is 
currently used in cell culture and could significantly impact spheroid growth. Likewise, PDT 
response is linked to oxygen availability within cells, making this an extremely important 
parameter that needs to be adjusted. This could be achieved by using a separate incubator for 
spheroid growth and performing PDT within incubation conditions. 
Improvement of automated parameter acquisition 
Improving automated image processing will lead to better turnaround time for large datasets. 
Currently, there is a high degree of manual input needed in between sections, which slows the 
comparison of multiple PDT parameters. Currently, graphs and statistics were manually input 
and created using Microsoft Excel after obtaining morphometric parameters from AnaSP. 
However, it is possible to perform these tasks using MATLAB. Although this is an area of 
opportunity, it requires programming knowledge in order to integrate all steps in the workflow 
(image acquisition, naming of widefield images, parameter extraction, comparison of 
conditions). 
Automated parameter acquisition can also be expanded upon by making use of other imaging 
tools such as high content microscopes (widefield, fluorescence, and confocal images) and 
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LSFM. Although widefield fluorescence images could likely be processed with AnaSP, other 
images require different software for processing, such as ReViMS for LSFM and confocal 
images. The advantage of acquiring image stacks in comparison to single images is the 
possibility of reconstructing the true 3D morphology and extracting morphometric parameters 
for comparison. This could further improve the correlation between biological assays with 
PDT-treated spheroids.  
Ex ovo CAM assay for evaluation of cancer xenograft tumours 
Chick Chorioallantoic Membrane (CAM) Assay is another model based on the use of fertilised 
chicken eggs. Drug delivery evaluation with CAM assay coupled with cancer xenografts is a 
highly reproducible and cost-effective alternative to traditional animal models. Implanted 
tumours develop additional characteristics such as angiogenesis and vascularization, which are 
key areas of early tumour development. Tumour xenografts on CAM can proliferate after 
implantation using MCTS or cell suspensions and can become vascularised within the 4-day 
window for growth after implantation. CAM experiments must take place within the 14-day 
period before chick termination. An ex ovo model for cancer xenografts has already been 
established within the Biomaterials group. This model is more advantageous than the standard 
in ovo model due to the ease of implantation and image acquisition. 
A modified waterproof mounted LED system within the incubator could be used to ensure less 
stress within the CAM from temperature changes and improve chick survival rate before PDT. 
Once standardised, this model could test multiple conditions simultaneously in a two-week 
period. An experienced user can manage 12-48 eggs with 1-3 implantation sites. The use of an 
aggressive melanoma xenograft in combination with PDT will enable a closer observation of 
tumour neoangiogenesis inhibition by PDT. Additionally, CAM tissue samples can be further 
analysed through microscopy and histology to compare results with MCTS. Furthermore, 
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xenografts can be made using both cell lines (such as C8161) or patient-derived tissue. This 
assay is an ideal step up from spheroids instead of choosing CSC or CTOS organoids. 
Validation of PpIX-CD conjugates using an in vivo mouse model 
The validation of the screening would be the final step in the evaluation of PpIX-loaded CDs. 
In addition to PDT parameters obtained from the literature, newly obtained ultra-low fluence 
conditions could be evaluated in vivo. BALB/c nude mice with GFP-expressing tumour 
xenografts can be used to monitor cancer progression through fluorescence microscopy and 
determine PS localisation, uptake, and circulation lifetime. The experiments can use standard 
conditions: 5-week old mice are subcutaneously injected with a cell suspension containing 
~5×106 cells. The progression of tumour growth can be seen through optical and in vivo 
fluorescence imaging in a 3 to 8-day period,  with tumours growing to ~100 mm3 in size prior 
to PDT. Pharmacokinetic studies can be carried out using blood drawn at various time intervals 
after administration. Finally, ex vivo imaging and histological analysis of tissue will yield more 
information regarding photosensitiser uptake and circulation lifetimes. Validation in a small 
study with mice would greatly benefit our understanding of PpIX conjugate pharmacokinetics 
and in vivo efficiency. 
In summary, the combination of in vitro (MCTS), ex ovo (CAM assay), and automated image 
analysis (widefield/LSFM) will enable the determination of better treatment conditions prior 
to in vivo trials. The evaluation of low-fluence and fractionated PDT is an area of research 
opportunity which can be exploited using a combination of in vitro/ex ovo models. 
Furthermore, this model could be used to observe treatment efficiency of various parameters 
in treatments such as chemotherapy, photothermal therapy, or nitric oxide production. Finally, 
it is also possible to build on previous work by evaluating novel nanoparticle and other PDT 
agents, such as transition metal-compounds.  
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Final remarks 
Current research is focused on the improvement of existing PS through chemical modifications 
or using carriers like nanoparticles. CD-based conjugates are becoming increasingly more 
accepted in biomedical applications but are not usually compared between each other due to 
difficulties in replicating experimental methodologies. Furthermore, testing these novel agents 
is more complex than for many non-light activated small molecules by the requirement for 
light and oxygen for activity, hence the need custom models of PDT. However, the complex 
interaction between tissue oxygenation, vascularisation, light absorption, and drug 
biodistribution makes selecting ranges for PDT parameters difficult.  
In this work, protoporphyrin IX and CD-based conjugates were successfully produced via two 
distinct loading strategies. Characterisation revealed crucial differences in water solubility and 
drug loading efficiency, with conjugates showing similar behaviour to PpIX. In vitro PDT 
evaluation with cell monolayers revealed conjugates significantly improved PpIX efficiency 
through the decrease of dark toxicity.  
Cancer spheroids showed localised cell death and differential drug uptake to cell monolayers, 
demonstrating the requirement and validation of complex in vitro models. Preliminary studies 
also demonstrated the feasibility of multiple parameter testing - multiple combinations were 
carried out, evaluating the impact of drug dose, colloidal stability, light intensity, and 
sequential irradiation. A combination of biological assays, microscopy, and automated image 
analysis was used to establish a link between treatment response and morphological 
parameters, with a total of 54 conditions were evaluated at three distinct timepoints. This 
represents a substantial increase in screening speed and capability in comparison to in vivo 
mouse cancer xenograft models. In conclusion, this work showed the importance of 
intermediate models for PDT with novel compounds before in vivo trials.   
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Table A2.1 Cytocompatibility studies of carbon dots in cell monolayers 
Cell line Surface passivation CD synthesis Concentration 
Protocol used 
for cytotoxicity 









~ 300 μg/ml 
(A549) 









Branched PEI Microwave 2 – 48 μg/ml MTT assay 24 hours 
24 μg/ml 
(CD-PEI-A) 
to > 48 
μg/ml (CD-
PEI-C) 
Liu et al. 
(2012) 
[50] 
HEK 293 and 
A549 
None Combustion 0 – 250 μg/ml XTT assay 24 hours 










None Hydrothermal 0 – 320 μg/ml CCK-8 
24 and 48 
hours 
> 320 μg/ml 
Zhang et al. 
(2013) 
[48] 
293T  None Acid reflux 16 – 500 μg/ml CellTiter96 24 hours > 500 μg/ml 
Tao et al. 
(2012) 
[37] 
AD-293  None Microwave 50 – 200 μg/ml MTT assay 
4 and 24 
hours 
> 2 mg/ml 






0 – 100 μg/ml MTT assay 24 hours > 100 μg/ml 
Zhou et al. 
(2014) 
[54] 
HeLa None Hydrothermal 0 – 2 mg/ml CCK-8 24 hours > 2 mg/ml 






PEI, conjugates with 
transferrin 
Hydrothermal 




24 hours ? (Unclear) 








Microwave 0.5 – 10 mg/ml MTT assay 
Not 
mentioned 
> 10 mg/ml 






Acid reflux 0 – 400 μg/ml 












A549 and 4T1 None Hydrothermal 0 – 200 μg/ml MTS assay 24 hours > 200 μg/ml 
Zhang et al. 
(2015) 
[49] 
EAC None Acid reflux 0.1 – 1 mg/ml 
MTT and trypan 
blue staining 
24 hours > 1 mg/ml 
Ray et al. 
(2009) 
[41] 
HepG2 KH2PO4 Hydrothermal 0 – 600 μg/ml MTS assay 72 hours > 625 μg/ml 
Yang et al. 
(2011) 
[44] 
MCF-7  None Hydrothermal 0 – 50 μg/ml MTT assay 24 hours > 50 μg/ml 





PEG1500N Laser ablation 0 – 200 μg/ml MTT assay 24 hours ~ 200 μg/ml 










1, 3, and 7 
days 
> 250 μg/ml 






Microwave 0 – 100 μg/ml MTT assay 24 hours > 100 μg/ml 
Xu et al. 
(2016) 
[39] 













CD synthesis Concentration 
Protocol used for 
toxicity 
Exposure Author 




mg/ml (30 μl 
volume) 
 
Extremities: 1 mg/ml 
(10 μl volume)  
 
Intravenous: 2.2 
mg/ml (200 μl 
volume) 
In vivo/ex vivo 
fluorescence imaging 
and organ dissection 














Intravenous (0.2 – 51 
mg/kg body weight 
depending on the 
animal) 
Blood sample analysis, 
histology (all major 
organs), bone marrow 
micronucleus test, body 
weight, genotoxicity 
1, 3, 7, and 
28 days 
Wang et 
al. (2013)  
[64] 
Mouse BALB/c None Acid reflux 
Subcutaneous (2 
mg/ml, 20 μl volume) 
In vivo fluorescence 
imaging, radiolabelling, 
blood sample analysis, 
histology (all major 
organs)  
1, 7, 20, 40, 
and 90 days 
Tao et al. 
(2012) 
[37] 
Mouse CD-1 PEG1500N 
Laser 
ablation 
Intravenous (8 and 40 
mg/kg body weight) 
ALT and AST release, 
blood sample analysis, 
histology (liver, spleen, 
and kidneys) 






Chicken CAM assay None Combustion 
Intravenous (100 μg, 
unknown volume) 
Photomicrographic 
analysis of vasculature, 


















mg/kg, 50 μl volume) 
Blood sample analysis, 
NIR fluorescence 
imaging, histology (all 
major organs) 
















mg/kg, 1 ml volume) 
Blood sample analysis, 
histology (heart, liver, 
spleen, and kidney), in 
vivo fluorescence 
imaging 
1, 3, and 7 
days 














(400 mg/ml with 50 
μl volume) 
Confocal laser scanning 
microscopy, in vivo 
spectral imaging 






Wild-type (6 days 
old) 
None Acid reflux 
Microinjection of 
heart or abdominal 
cavity (0.5 – 5 μg/ml, 
total volume 5 nL) 
In vivo fluorescence 




– 2 days 
Li et al. 
(2016) 
[72] 
Rat Sprague Dawley None Hydrothermal 
Intravenous (20 - 40 
mg/kg, 1 ml volume) 
In vivo computerized 
tomography, blood 
sample chemistry, 
histology (all major 
organs) 










mg/kg body weight) 
In vivo fluorescence 
imaging,  









Soaking embryo in 
solution (2.5 mg/ml, 
5 ml volume) and 
microinjections (0.5 
– 2.5 mg/ml, 2 μl 
volume) 
Confocal laser scanning 
microscopy, brightfield 
microscopy 












mg/ml, 200 μl 
volume) 
In vivo and ex vivo 
fluorescence imaging 
24 hours 






Table A2.3 CD conjugates for drug delivery 












Lauryl betaine Antimicrobial 
Crosslinking 
(EDC/NHS) 
Multicolour fluorescence, enhanced and selective toxicity 
in Gram-negative bacteria 
Yang et al. (2016) 
[104] 
Citric acid and ethylenediamine Ampicillin Antimicrobial 
Crosslinking  
(EDC/NHS) 
Enhanced antimicrobial activity 
Jijie et al. (2018) 
[111] 
Gum arabic Ciproflaxin Antimicrobial 
Electrostatic 
interactions 
High loading capacity and controlled drug release 
Thakur et al. (2014) 
[228] 
L-arginine Silver nitrate Antimicrobial 
Host-guest 
chemistry 
Enhanced antimicrobial activity 
Fang et al. (2019) 
[107] 




Sustained drug release over several days and high loading 
capacity 







pH-dependent drug release and NIR-activated 
photothermal effect 
Kang et al. (2019) 
[114] 
Chitosan Tetracycline Antimicrobial 
Electrostatic 
interactions 




Carbon nanopowder and EDA None Antimicrobial None 
Intrinsic ROS production and A-PDT with ambient light 
illumination 
Meziani et al. (2016) 
[110] 
Ethanol and sodium hydroxide 







pH-dependent drug release with real-time monitoring, 
increased stability 
Tang et al. (2013) 
[130] 
Beer Doxorubicin Chemotherapy 
Electrostatic 
interactions 
Controlled drug release 
Wang et al. (2015) 
[121] 
Sorbitol 





High loading efficiency and therapeutic efficiency 
Mewada et al. (2014) 
[131] 
Hydroxybutyric acid Doxorubicin Chemotherapy 
Hydrazone-
based bonding 
Nucleus-targeting and increased efficiency (in vitro and in 
vivo) 
















Synergistic effect between drugs and improved 
accumulation 
Hettiarachchi et al. 
(2019) [125] 
Citric acid and ethylenediamine Doxorubicin Chemotherapy 
Electrostatic 
interactions 
High loading efficiency and increased cytotoxicity 
Kong et al. (2018) 
[120] 
Citric acid and 
diethylenetriamine 
Cisplatin(IV)  Chemotherapy 
Crosslinking  
(EDC/NHS) 
Charge-convertible behaviour, improved efficiency, 
prolonged blood circulation, controlled release 
Feng et al. (2016) 
[118] 
Gum arabic 







High loading efficiency and rapid burst release under NIR 
irradiation 
Pandey et al. (2013) 
[124] 
Polyethyleneimine and ethanol Doxorubicin Chemotherapy 
Hydrophobic 
interactions 
Controlled drug release and nucleus targeting 
Wang et al. (2017) 
[87] 
Milk Doxorubicin Chemotherapy 
Hydrophobic 
interactions 
pH-sensitive drug release, lower cytotoxicity to non-cancer 
cells, increased uptake 
Yuan et al. (2017) 
[123] 





Simultaneous imaging and therapeutic effect, real-time 
monitoring of distribution 
Zheng et al. (2014) 
[132] 





pH-dependent drug release profiles and increased stability 
Zhang et al. (2017) 
[382] 
Bovine serum albumin Doxorubicin Chemotherapy 
Hydrophobic 
interactions 
pH-dependent drug release and rapid cellular uptake 
Wang et al. (2013) 
[134] 
Citric acid and urea Doxorubicin Chemotherapy 
Electrostatic 
interactions 
pH-dependent drug release, increased stability and cellular 
uptake 
Zeng et al. (2016) 
[119] 






Intranuclear delivery, high drug loading capacity, pH-
dependent release 
Gong et al. (2016) 
[135] 













pH-dependent drug release and functionality as MRI and 
fluorescence contrast agents 
Fahmi et al. (2015) 
[139] 




pH-dependent drug release, high loading capacity and 
colloidal stability 
Wang et al. (2017) 
[136] 
Citric acid and 
diethylenetriamine 






Enhanced intracellular uptake and therapeutic efficiency 
Feng et al. (2016) 
[133] 
Hydrazine Aspirin Drug delivery 
Host-guest 
chemistry 
In vitro and in vivo anti-inflammatory effect Xu et al. (2016) [39] 
Lignosulfonate lignin powder Curcumin Drug delivery 
Hydrophobic 
interactions  
Increased solubility, high drug loading and rapid uptake Rai et al. (2017) [383] 
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PEG, and folic 
acid 
Zinc phthalocyanine PDT 
π–π stacking 
interactions 
Targeted delivery, increased efficiency and 
distribution 
Choi et al. 
(2014) [152] 
Citric acid or 
sucrose and 
ethylenediamine 





Decreased dark toxicity, increased efficiency 
at lower drug concentrations, increased 
solubility 
Aguilar Cosme 




Protoporphyrin IX PDT 
Crosslinking 
(EDC/NHS) 
PDT under two-photon excitation, high 
loading efficiency 
Fowley et al. 
(2013) [144] 
Chitosan Diketopyrrolopyrrole PDT 
Host-guest 
chemistry 
Maintains photostability under laser 
irradiation and high biocompatibility 









Increased transdermal delivery and efficiency 
Beack et al. 
(2015) [153] 
Soot and PEG 
2000N 
Chlorin e6 PDT 
Crosslinking 
(EDC/NHS) 
Improved singlet oxygen generation, water 
stability, and efficiency 
Huang et al. 
(2012) [155] 







Improved singlet oxygen generation, cellular 
uptake, and efficiency 
Wu et al. (2018) 
[145] 
PEG800 CyOH PTT 
Host-guest 
chemistry 
Improved accumulation in target site and 
tumour inhibition 
Zheng et al. 
(2016) [67] 








Two-photon triggered drug release, low 
compound toxicity 
Wu et al. (2015) 
[146] 







Improved efficiency in hypoxic environment, 
water-splitting effect, and targeted delivery 
Zheng et al. 
(2016) [158] 
Citric acid and 
polyethyleneimine 
Chlorin e6 PDT/PTT 
Crosslinking 
(DMT/MM) 
High efficiency with low loading ratios and 
dual PDT/PTT effect with NIR excitation 





None PDT None 
In situ oxygen generation and enhanced 
efficiency in hypoxic environment 








Intrinsic singlet oxygen generation and heat 
conversion 








Intrinsic singlet oxygen generation and 
efficient in vivo distribution 









Two-photon excitation and nitric oxide 
production in hypoxic environment 











Magnetic responsive properties, detection by 
magnetic resonance imaging, heat conversion 
and NIR-triggered drug release 
Wang et al. 
(2014) [159] 
EDTA·2Na Copper chloride PDT/PTT Doping 
NIR absorption, high biocompatibility, dual 
effect  
Guo et al. (2018) 
[160] 







NIR absorption, high photothermal efficiency, 
stable heat production 
Peng et al. 
(2018) [161] 
Chitosan Triphenylporphyrin PDT 
Host-guest 
chemistry 
Increased photostability and rapid cellular 
uptake leading to efficient PDT effect 







Rose Bengal PDT 
Crosslinking 
(DCC/HOBt) 
Mitochondria targeting capability, rapid 
cellular uptake, decreased cytotoxicity 





Protoporphyrin IX PDT 
Crosslinking 
(DCC/HOBt) 
Nucleus targeting capability, enhanced PDT 
effect, increased blood circulation time 









Targeted PTT effect under NIR irradiation and 
multicolour fluorescence imaging 





Table A2.5 CD conjugates in gene delivery 











Decreased protein adsorption, superior stability in 
blood, higher transfection efficiency with serum 
Cheng et al. (2015) 
[175] 





Decreased cytotoxicity and increased transfection 
efficiency 
Liu et al. (2012) [50] 
PEI 600 
pUC19, pEGFP-




Increased transfection and gene silencing efficiency 





SRC, or GFP) 
Electrostatic 
interactions 
Effective gene silencing and high pH stability Das et al. (2015) [176] 
Glycerol and PEI 




Selective targeting for lung cancer and increased gene 
silencing efficiency 
Wu et al. (2016) [179] 





Significantly lower cytotoxicity after transgene 
expression 
Pierrat et al. (2015) 
[181] 





Decreased protein adsorption, GSH-triggered release 
Zhao et al. (2018) 
[174] 
Citric acid and 
branched PEI 




Enhanced intracellular uptake, decreased immune 
response to siRNA delivery in vivo  
Kim et al. (2017) 
[172] 
Arginine and glucose pSOX9 
Electrostatic 
interactions 
Intracellular tracking, high transfection efficiency Cao et al. (2018) [169] 






Rapid intracellular uptake and improved gene silencing 
efficiency 
Wang et al. (2014) 
[227] 
PEI EGFP (plasmid) 
Electrostatic 
interactions 




Strong DNA condensation ability, low toxicity, and 
high transfection efficiency 
Zhou et al. (2016) 
[170] 





High transfection efficiency Dou et al. (2015) [171] 
Tetrafluoroterephthalic 




Maintained transfection efficiency at high serum 
concentrations and low DNA dose 






High biocompatibility and rapid intracellular uptake Noh et al. (2013) [183] 
Unspecified siRNA (Tnfα) 
Crosslinking 
(sulfo-SMCC) 







High pH stability and enhanced gene silencing 
Wang et al. (2018) 
[185] 
Folic acid (CDs loaded 






High transfection efficiency in ovo 







XPS C 1s scan of PpIX. 
 
 
XPS survey scan of PpIX. 
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XPS C 1s scan of PpIX-CD. 
 
XPS survey scan of PpIX-CD. 
 321
 
XPS C 1s scan of (PpIX-CD)p 
 
XPS survey scan of (PpIX-CD)p 
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XPS C 1s scan of PpIX@CD 
 
XPS survey scan of PpIX@CD 
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Synthesis of Eu-doped CDs with microwave pyrolysis. Europium was used to crosslink 
alginic acid at 10 mM. Hydrogel pyrolysis resulted in CD formation. 
 
Acetone did not produce efficient PpIX crosslinking with EDC/NHS, causing precipitation 
and sample aggregation. 
 325
 
Discover SP microwave reactor setup. 
 
PpIX shows significantly lower stability in water. Precipitation can be seen at 4 hours in 




Table A4.1 – Light activated toxicity at 48 hours post irradiation.  
ug/ml 
PpIX PpIX-CD (PpIX-CD)p PpIX@CD No light 
Average SEM Average SEM Average SEM Average SEM Average SEM 
0.5 78.76 2.33 72.30 3.91 89.54 2.03 78.95 5.57 100.00 0.57 
1 59.85 4.64 64.21 4.80 67.86 2.03 68.89 5.08 100.00 0.57 
2.5 46.27 1.12 49.72 3.57 64.17 0.83 42.35 2.09 100.00 0.57 
5 42.56 0.94 41.80 3.67 62.58 1.84 40.21 1.71 100.00 0.57 
10 41.32 0.97 39.81 1.71 56.64 3.41 39.96 1.37 100.00 0.57 
 
Table A4.2 – Light activated toxicity at 48 hours post irradiation.  
ug/ml 
PpIX PpIX-CD (PpIX-CD)p PpIX@CD No light 
Average SEM Average SEM Average SEM Average SEM Average SEM 
0.5 103.17 3.92 96.97 1.44 98.34 1.93 102.60 1.57 100.00 0.57 
1 66.57 6.09 89.33 2.57 100.26 0.74 89.64 2.05 100.00 0.57 
2.5 43.43 1.53 50.07 2.83 92.14 3.89 42.47 0.65 100.00 0.57 
5 41.49 1.94 40.93 2.30 85.51 3.96 39.88 0.48 100.00 0.57 








CSLM imaging of PpIX-CD and PpIX@CD with 250 μg/mL. 
 





Initial tests with resazurin reduction with spheroids. Standardisation was difficult due as the 
assay could not be done within agar-coated wells, which absorbed resazurin. Spheroid 
movement into microcentrifuge plates proved difficult and time-consuming. 
  
Monolayer PDT parameters (single 3-minute exposure at 0.87 mW.cm2) do not cause 




Spheroid damage (2LT, PpIX-CD 5 μg/ml) caused deformation and required care during 
manipulation. 
 
Live/dead staining required optimisation and LSFM filter adjustment  
(left – before, right – after).  
 330
 
Spheroids show limited autofluorescence without staining in LSFM. 
 
 
Selection of LSFM z-slice for control spheroid during drug uptake evaluation. 
 331
 
Selection of LSFM z-slice for 10 μg/ml PpIX spheroid during drug uptake evaluation. 
 




Transmission image obtained in LSFM showing PpIX aggregation on the spheroid surface at 
10 μg/ml. 
 
Spheroid treated with 5 μg/mL PpIX@CD rendered using mixed 3D projection in LSFM. 




Control spheroids showed low frequency of cell death. Dead cells were concentrated in the 








5 μg/ml 10 μg/ml
1LT













Control spheroids do not show significant changes to morphological parameters area and 




Treated spheroids do show significant changes to morphological parameters area and 
diameter after debris clearing. 
 
